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VOORWOORD 
Elk jaar worden in België duizenden patiënten gehospitaliseerd. Telkens weer stelt zich 
de vraag naar de continuïteit van de medicamenteuze behandeling bij opname en bij 
ontslag. De lijst met geneesmiddelen kan immers lang en complex zijn, en is bij opname 
soms niet eens beschikbaar. Op het ogenblik dat de patiënt terugkeert naar huis kunnen 
er problemen ontstaan als de behandeling niet duidelijk wordt uitgelegd of 
geïnterpreteerd door de patiënt en de zorgverleners. De gevaren bij de overgang van de 
ene zorgomgeving naar de andere zijn reeds lang gekend; het gaat bijvoorbeeld om 
ongewenste onderbrekingen van de behandeling, interacties, overdoseringen of niet-
geïdentificeerde contra-indicaties. Men schat dat minstens één op vier patiënten bij een 
dergelijke overgang het slachtoffer worden van problemen met de continuïteit van hun 
behandeling. 
Dit onderzoeksonderwerp werd voorgesteld door de  « Task Force Seamless Care » 
van de Algemene Pharmaceutische Bond, een wetenschappelijke groepering die zich met 
deze problematiek en de mogelijke oplossingen ervoor bezighoudt. Ook de Federale 
Overheidsdienst Volksgezondheid toonde zijn belangstelling voor dit thema, met name 
door de financiering van tientallen initiatieven met betrekking tot de overgang tussen 
zorgomgevingen, zij het zonder specifieke aandacht voor de medicatie-aspecten.  
Mirakeloplossingen werden niet gevonden, zoveel is zeker, maar door het combineren 
van verschillende onderzoeksmethoden kon dit project toch een aantal maatregelen 
naar voren schuiven die wellicht de continuïteit van de medicamenteuze behandeling ten 
goede zouden kunnen komen. 
Dit onderzoek kon bogen op de buitengewone samenwerking tussen apothekers en 
artsen van de UCL en de K.U.Leuven. Wij houden eraan om hen te danken voor hun 
professionalisme en uitstekende wetenschappelijke samenwerking.  
 
 
 
 
 
Jean Pierre CLOSON     Raf MERTENS 
Adjunct Algemeen Directeur     Algemeen Directeur 
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Samenvatting en toelichtingen 
INLEIDING 
De continuïteit van de medicamenteuze behandeling is van enorm belang wanneer de  
patiënt van de ene zorgomgeving naar de andere overstapt, en in het bijzonder bij de 
overgang tussen het ziekenhuis en de thuissituatie. De problemen die zich bij deze 
overgang voordoen, kunnen in vijf categorieën worden onderverdeeld (overeenkomstig 
de resultaten van de kwalitatieve studie die hierna wordt beschreven):  
• Problemen bij de opname, zoals : een onvolledige geneesmiddelenlijst; het 
ontbreken van informatie bij een urgentie; 
• Problemen bij ontslag uit het ziekenhuis, zoals : een slecht of niet 
geïnformeerde patiënt; een gebrekkige communicatie met de huisarts; 
onvoldoende geneesmiddelenvoorraad voor het weekend ; 
• Problemen die betrekking hebben op de zorgverstrekkers, zoals: een 
verschillend advies van huisarts en specialist; een onvoldoende begeleiding van 
de patiënt bij het nemen van de medicatie; 
• Problemen die betrekking hebben op de patiënten en hun familie, zoals: het 
niet begrijpen van de behandeling, of het niet naleven er van ; 
• Problemen die betrekking hebben op het zorgproces: onleesbare 
documenten; substitutie door de zorgverstrekkers 
Uit onderzoek blijkt dat bij de terugkeer naar huis 20 tot 60% van de patiënten te 
maken krijgen met problemen rond de continuïteit van hun medicamenteuze 
behandeling.  
DOELSTELLINGEN 
Het doel van dit project is om oplossingen aan te reiken om de continuïteit van de 
medicamenteuze behandeling bij de opname in het ziekenhuis en bij de terugkeer naar 
huis zo optimaal mogelijk te laten verlopen.   
De term "seamless care’ die in dit project wordt gebruikt, betreft alleen de 
medicamenteuze behandeling,  en wel bij de overgang tussen verschillende 
zorgverleners of zorgomgevingen. De zorgomgevingen waarop dit project betrekking 
heeft zijn meer specifiek de thuissituatie (woning of residentiële setting) en het 
ziekenhuis.   
De specifieke doelstellingen van het project zijn het realiseren van: 
• Een systematische review van de internationale literatuur met betrekking tot 
de impact en de kosteneffectiviteit van initiatieven die bedoeld zijn om de 
continuïteit van de medicamenteuze behandeling te verbeteren; 
• Een analyse van geïmplementeerde nationale en/of regionale initiatieven in 
zeven landen (Australië, Canada, Denemarken, Verenigde Staten, Frankrijk, 
Nederland en Verenigd Koninkrijk);  
• Een analyse van de Belgische gegevens zowel met betrekking tot de 
problemen bij de overgang van en naar het ziekenhuis, als met betrekking tot 
uitgewerkte oplossingen om de continuïteit van de medicamenteuze 
behandeling te verbeteren; 
• Een kwantitatieve analyse van de wijzigingen in medicatie gekoppeld aan een 
verblijf in het ziekenhuis in België, wijzigingen die mogelijk risico’s inhouden 
op het vlak van de continuïteit van de behandeling; 
• Een kwalitatief onderzoek bij Belgische zorgverstrekkers naar hun perceptie 
van verschillende benaderingen bedoeld om de continuïteit van de 
medicamenteuze behandeling te verbeteren.  
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LITERATUUROVERZICHT 
De systematische review van de geïndexeerde literatuur bracht geen enkele meta-
analyse of systematische reviews aan het licht over de impact van interventies voor het 
verbeteren van de continuïteit van de medicamenteuze behandeling. Er werden 
achtentwintig studies met controlegroep gevonden, waarvan er, op basis van de 
kwaliteit, vijftien werden geselecteerd voor verdere analyse. Door de heterogeniteit van 
de populaties, van de interventies en van de kwaliteit van de studies konden echter geen 
definitieve conclusies worden getrokken wat betreft de doeltreffendheid van de 
voorgestelde interventies.   
KLINISCHE IMPACT VAN DE INTERVENTIES 
De meeste interventies hebben betrekking op het ontslag uit het ziekenhuis. Sommige 
studies analyseerden de communicatie met de huisarts en de apotheker (bijvoorbeeld, 
via het overmaken van het behandelingsplan), andere bekeken de voorlichting van de 
patiënt voor en/of na het verlaten van het ziekenhuis door een zorgverstrekker 
(meestal een klinisch apotheker). De patiëntenpopulaties zijn uiteenlopend (4 
onderzoeken in de geriatrie) maar (een aantal van) de meest kwetsbare patiënten 
worden meestal uitgesloten (bijv. psychiatrische patiënten, dementerenden, 
analfabeten). De meeste interventies werden ingevoerd door klinisch apothekers in een 
multidisciplinaire context. Er was slechts één studie van voldoende kwaliteit die de 
impact naging van een informaticaondersteuning voor het zorgproces 
Er worden vooral conclusies getrokken op basis van proces-indicatoren (bijv. 
tegenstrijdigheden in medicatielijsten). Toch waren er ook een aantal studies die keken 
naar de impact, zoals de kans op heropname. Interventies met een positief resultaat 
bleken meestal maatregelen zowel bij als na het verlaten van het ziekenhuis te 
combineren, en waren zowel gericht op de patiënt als op de zorgverstrekkers in de 
eerste lijn. Toch kan men uit deze onderzoeken geen definitieve conclusies trekken 
over de impact van de interventies op de klinische indicatoren of de levenskwaliteit van 
de patiënt. De resultaten van studies uit andere landen (VS, Australië, Canada) kunnen 
bovendien niet zonder meer worden overgedragen op de Belgische situatie. 
KOSTENEFFECTIVITEIT VAN DE INTERVENTIES 
Er werden zes kosteneffectiviteitsonderzoeken en één kosten-utiliteitsonderzoek 
geanalyseerd. De gegevens met betrekking tot de effectiviteit zijn meestal gebaseerd op 
een patiëntenbevraging, gecombineerd met andere informatiebronnen (dossier...). De 
kosten waarmee rekening wordt gehouden, verschillen sterk al naargelang de 
onderzoeken. De meeste van deze onderzoeken besluiten dat er een positieve impact is 
op gebied van therapietrouw en het percentage heropnames. De heterogeniteit van de 
interventies, van de populaties en van de beschouwde parameters laat echter niet toe 
om de kosteneffectiviteit van de voorgestelde interventies te evalueren.  
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INITIATIEVEN IN HET BUITENLAND 
De analyse van nationale en regionale initiatieven had betrekking op volgende landen: 
Australië, Canada, Denemarken, Verenigde Staten, Frankrijk, Nederland en Verenigd 
Koninkrijk.  
De voornaamste initiatieven omvatten : 
• het opstellen van praktijkaanbevelingen voor zorgverstrekkers; 
• nationale informatiecampagnes; 
• vorming van zorgverstrekkers; 
• de ontwikkeling van communicatietechnologieën voor het uitwisselen van 
informatie uit patiëntendossiers en van voorschrijfgegevens 
Al deze initiatieven veronderstellen inzet en verantwoordelijkheid van alle betrokken 
actoren, intramuraal en ambulant. Het ontstaan van deze initiatieven dateert van een 
tiental jaar terug, maar ze evolueren nog voortdurend. Volgens de geconsulteerde 
publicaties en de betrokken internationale deskundigen zijn de succesfactoren het 
bestaan van incentives voor de implementatie (systemen van accreditering, financiële 
sancties), een aanpassing van de initiatieven aan de lokale context, de motivatie van de 
actoren, het bestaan van “leadership” om de nationale en lokale krachten te mobiliseren 
en informatica-ondersteuning. Negatieve factoren, daarentegen, zijn het gebrek aan 
menselijke en financiële middelen, het niet opnemen van verantwoordelijkheden door 
zorgverstrekkers, een gebrek aan vorming en  interesse, en moeilijkheden rond de 
veiligheid en vertrouwelijkheid van de gegevens.   
De evaluatie van deze initiatieven gaat, behalve op lokaal niveau, meestal niet verder dan 
een becijfering van hun gebruik in de praktijk.  
Ook al zijn deze initiatieven niet zonder meer overzetbaar naar de situatie in België, 
toch bevatten ze een heel aantal elementen die waardevol zijn voor het uitwerken van 
Belgische oplossingen voor het verbeteren van de continuïteit van de medicamenteuze 
behandeling. 
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STAND VAN ZAKEN IN BELGIE 
De analyse van de stand van zaken in België bestaat uit drie delen: een samenvatting van 
documenten die de Belgische initiatieven beschrijven, een analyse van de 
voorschrijfgegevens en een kwalitatieve analyse van de standpunten van 
zorgverstrekkers, patiënten en sleutel-actoren van het Belgische 
gezondheidszorgsysteem. 
PUBLICATIES MET BETREKKING TOT BELGISCHE INITIATIEVEN 
In totaal werden 66 initiatieven geanalyseerd, waarvan 43 onderzoeksprojecten 
(resultaten beschikbaar) en 23 andere initiatieven.  
Het gaat meestal om lokale projecten met eerder beperkte patiëntenaantallen. Negen 
projecten analyseerden de meerwaarde, bij opname, van een medicatie-anamnese door 
een klinisch apotheker. Zes projecten onderzochten het effect van een advies aan de 
patiënt bij ontslag, hetzij door een klinisch apotheker, hetzij door een verpleegkundige. 
Andere interventies bestudeerden de impact van procedures voor het verbeteren van 
de kwaliteit van de zorgverlening bij de opname of bij ontslag (bijvoorbeeld het effect 
van een brief aan de officina-apotheker).  
Enkele projecten peilden naar de mening en de ervaringen van zorgverstrekkers en 
patiënten.  
Het grote aantal en de verscheidenheid van de projecten getuigen van de belangstelling 
die er heerst voor de problematiek, evenals voor de betrokkenheid van diverse 
zorgverstrekkers uit verschillende sectoren bij het zoeken naar geschikte oplossingen. 
De evaluatie van de projecten toont een positieve impact op een aantal proces-
parameters (kennis van de patiënt, afstemming tussen voorgeschreven en gevolgde 
behandeling). Net zoals in de internationale literatuur, werd geen klinische of 
economische impact aangetoond. Uit deze projecten kunnen dus momenteel slechts 
zeer weinig kwaliteitsvolle wetenschappelijke gegevens worden gehaald met betrekking 
tot de doeltreffendheid van deze interventies in België. Ze geven echter wel informatie 
met betrekking tot de hinderpalen en faciliterende elementen waarmee rekening moet 
worden gehouden bij het implementeren van dit soort innovaties.  
ANALYSE VAN DE VOORSCHRIJFGEGEVENS  
De voorschriftgegevens werden geanalyseerd op eventuele wijzigingen in chronische 
medicatie als gevolg van een hospitalisatie. Uit de literatuur blijkt dat deze wijzigingen 
een veel voorkomende oorzaak zijn van een breuk in de continuïteit van de behandeling. 
De analyses hadden betrekking op respectievelijk statines en protonpompinhibitoren 
(PPI), en waren beperkt tot patiënten waarbij deze geneesmiddelen zowel in de drie 
maanden voor als de drie maanden na een opname werden afgeleverd (gegevens van het 
Intermutualistisch Agentschap). Er werd gekeken naar alle mogelijke wijzigingen binnen 
eenzelfde chemische groep (ATC niveau 4), bijvoorbeeld: overstap van het ene 
molecule naar een andere (bijv. : Simvastatine EG® naar Lipitor®); overstap van een 
generisch product naar het originele (of vice versa);overstap naar een andere specialiteit 
voor dezelfde molecule (bijv.: Cholemed® naar Docsimvastatine®); wijziging in de 
dosering van de tabletten. 
Er werd een wijziging opgetekend in 17% van de chronische behandelingen met statines 
en 29% van deze met PPIs. De data lieten echter niet toe uit te maken welke de reden 
hiervoor was, noch of dit al dan niet een nefast gevolg had voor de patiënt.  
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KWALITATIEVE STUDIE 
Een kwalitatieve studie sloot dit onderzoek af : ze had tot doel de mogelijke oplossingen 
te identificeren, en hun graad van prioriteit en haalbaarheid in België na te gaan. Er 
werden elf focusgroepen georganiseerd: 9 groepen met zorgverstrekkers (en patiënten), 
en 2 groepen met vertegenwoordigers van de organisaties die betrokken zijn bij het 
implementeren van oplossingen.  Bij de aanvang van de gesprekken vermeldden de 
deelnemers een lange lijst met problemen. Deze werd in vijf categorieën opgedeeld (zie 
inleiding).  
De deelnemers stelden ook talrijke denkpistes voor oplossingen voor, met name: 
• Een sensibilisatie van patiënten en zorgverstrekkers rond de problemen 
verbonden aan de transitie tussen verschillende zorgomgevingen en rond de 
gedeelde verantwoordelijkheid van alle actoren om de kwaliteit te 
verbeteren, o.m. via een nationale sensibilisatiecampagne ; 
•  Een standaardisering van de procedures: o.a. een gestandaardiseerde 
ontslagbrief; de permanente beschikbaarheid  - elektronisch of op papier – 
van de geactualiseerde lijst medicatielijst van de patiënt; 
• De ontwikkeling van aangepaste informatica-oplossingen: o.a. het elektronisch 
voorschrift, een elektronisch medisch en farmaceutisch dossier, toegankelijk 
(mits toestemming van de patiënt) voor de verschillende verstrekkers, vanuit 
hun eigen setting; 
• Nieuwe nomenclatuurcodes om bepaalde groepen patiënten thuis te helpen 
bij het organiseren van de inname van hun geneesmiddelen; 
• Een verbetering van het overgangsproces: ondersteuning van een klinisch 
apotheker, contact met de eerstelijnszorgverstrekkers vóór het ontslag uit 
het ziekenhuis.  
Een belangrijke factor die in de meeste focusgroepen naar boven kwam, is de noodzaak 
dat de verschillende betrokken zorgverstrekkers hun verantwoordelijkheid nemen. 
Indien coördinatie wenselijk is, wordt de huisarts vaak vernoemd als de meest 
aangewezen zorgverlener hiervoor.  
De deelnemers aan de focusgroepen waren het er ook over eens dat continuïteit van de 
medicamenteuze behandeling elke patiënt aanbelangt. Bepaalde, meer kwetsbare 
groepen, vereisen echter bijzondere aandacht, zoals geriatrische patiënten, patiënten 
met een psychiatrisch profiel, patiënten onder polymedicatie.  
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BASISELEMENTEN VOOR EEN VERBETERING VAN 
DE CONTINUITEIT VAN DE MEDICAMENTEUZE 
BEHANDELING 
Het doel van dit laatste deel was het identificeren van de basiselementen voor een 
systeem voor het optimaliseren van de continuïteit van de medicamenteuze behandeling. 
De resultaten van de verschillende delen van het onderzoek werden transversaal 
onderzocht en gecombineerd met interviews van personen die gespecialiseerd zijn in de 
uitwisseling van elektronische gegevens in België. De elementen die uit deze analyse 
naar voren kwamen zijn de volgende :  
Op het niveau van het gezondheidsbeleid: 
• Nationale richtlijnen voor de zorgverstrekkers, die vervolgens aan het lokale 
niveau moeten worden aangepast; 
• Een coördinerende structuur op regionaal niveau om de aanbevelingen op 
lokaal niveau te implementeren;  
• Een nationale campagne om zorgverstrekkers en patiënten te sensibiliseren 
voor het probleem en eenieders verantwoordelijkheid in deze; 
• Financiële stimuli of reglementaire bepalingen (zoals accrediteringssystemen) 
om de implementatie van de richtlijnen te ondersteunen; 
•  Een adequate vergoeding voor de tijd die besteed wordt aan het verbeteren 
van de continuïteit van de zorg, vooral net vóór en na het ontslag uit het 
ziekenhuis; 
• Een elektronische infrastructuur die de continuïteit van de zorgverlening 
vergemakkelijkt, vooral bij transitiesituaties: 
• De regels en maatregelen die van kracht zijn in de verschillende 
zorgomgevingen moeten beter gekend zijn en men moet er meer rekening 
mee houden (bijvoorbeeld de stimuli voor het voorschrijven van generische 
geneesmiddelen in de huisartsenpraktijk); 
• Bijzondere aandacht voor kwetsbare patiëntengroepen, waarvan de definitie 
kan afhangen van de lokale context; 
• Onderzoek om objectief de klinische, menselijke en economische impact na 
te gaan van de lopende initiatieven; 
Op het niveau van de zorgverstrekkers zelf: 
• Het versterken van de betrokkenheid en de verantwoordelijkheid van de 
zorgverstrekkers (artsen en apothekers, op niveau van het ziekenhuis en in 
de eerste lijn); 
• Lokaal overleg (ziekenhuis en eerste lijn) om de samenwerking tussen 
zorgverstrekkers van de verschillende zorgomgevingen te verbeteren; 
Op het niveau van de patiënt: 
• Bij opname in het ziekenhuis, verschillende informatiebronnen combineren en 
standaardprocedures gebruiken voor de medicamenteuze anamnese; 
• Bij ontslag uit het ziekenhuis, zorgen voor een tijdige, gestructureerde en 
volledige informatie aan patiënten en zorgverstrekkers van de eerste lijn; 
• Bij ontslag uit het ziekenhuis, zorgen voor een voldoende voorraad 
geneesmiddelen om de periode vóór de mogelijke aankoop van 
geneesmiddelen te overbruggen;  
• Na ontslag uit het ziekenhuis, het versterken van de  informatie, en het 
toepassen van een procedure voor het op elkaar afstemmen van de 
theoretische behandeling en wat de patiënt effectief neemt;  
• De beschikbaarheid, voor elke patiënt, van een geneesmiddelenlijst (bij 
voorkeur ook in elektronisch formaat), toegankelijk voor de betrokken 
zorgverstrekkers; 
viii Continuïteit van de medicamenteuze behandeling KCE Reports 131A 
 
KCE  AANBEVELINGENa 
Uit het rapport komen geen echte wetenschappelijke bewijzen naar voor. Toch lijken 
de volgende maatregelen de situatie te kunnen verbeteren : 
• Men zou een richtlijn voor de goede praktijk moeten opstellen, publiceren 
en verspreiden met betrekking tot de continuïteit van de medicamenteuze 
behandeling. Dit  zou moeten gebeuren op basis van de internationale 
richtlijnen en op basis van de resultaten van dit onderzoek (onder andere de 
procedures met betrekking tot de opname en het ontslag uit het ziekenhuis 
die in het laatste hoofdstuk worden beschreven). Voor het opstellen van 
deze richtlijn zou samenwerking vereist zijn tussen apothekers, artsen en 
ander zorgverstrekkers, zowel in de ziekenhuisomgeving als in de eerste lijn; 
• Bij de sensibilisatie van zorgverstrekkers en patiënten zou vooral de 
aandacht moeten worden gevestigd op het belang van de continuïteit van de 
medicamenteuze behandeling bij de overgang tussen zorgomgevingen en op 
de verantwoordelijkheid van alle betrokkenen in deze; 
• Er zou verder werk gemaakt moeten worden van het operationaliseren van 
elektronische systemen voor het delen van patiëntengegevens zodat 
medische gegevens, waaronder een geactualiseerde geneesmiddelenlijst, 
beschikbaar zouden zijn voor de patiënt en de betrokken zorgverstrekkers, 
waarbij uiteraard de regels van veiligheid en vertrouwelijkheid dienen 
gerespecteerd te worden; 
• De continuïteit van de medicamenteuze behandeling bij opname en ontslag 
zou moeten worden geformaliseerd in duidelijke procedures. 
•  De erkenning van ziekenhuisstructuren zou criteria moeten omvatten die 
betrekking hebben op de continuïteit van de medicamenteuze behandeling 
bij opname en ontslag uit het ziekenhuis; 
• De opleiding van zorgverstrekkers (zowel voor de ambulante sector als voor 
het ziekenhuis) zou een onderdeel moeten bevatten met betrekking tot de 
continuïteit van de medicamenteuze behandeling bij overgang tussen 
zorgomgevingen;   
• De eventuele financiering van initiatieven met betrekking tot de continuïteit 
van de zorgverlening tussen thuis en ziekenhuis zou moeten afhankelijk 
worden gemaakt van een geloofwaardige evaluatie die tot doel heeft de 
klinische en eventueel daaropvolgende economische impact ervan, aan te 
tonen. 
 
                                                     
a  Alleen het KCE is verantwoordelijk voor de aanbevelingen aan de overheid 
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1 INTRODUCTION 
1.1 DEFINITION OF SEAMLESS CARE 
Several definitions of seamless care (or continuity of care between settings) have been 
published in the literature. In 2000, a review of continuity of care across all medical 
disciplines concluded that the concept of continuity of care was broad and frequently 
led to misunderstanding. This review proposed a multi-element definition1:   
1. The experience of a co-ordinated and smooth progression of care from the 
patients’ point of view (experienced continuity); 
2. Excellent information transfer following the patient (continuity of information; 
continuity and coherence of medical record); 
3. Effective communication between professionals and services and with patients 
(cross-boundary and team continuity); 
4. To be flexible and adjust to the needs of the individual over time (flexible 
continuity); 
5. Care from as few professionals as possible, consistent with other needs 
(longitudinal continuity); 
6. To provide one or more named professionals with whom the patient can 
develop a therapeutic and interpersonal relationship (relational or interpersonal 
continuity). 
This work focuses on seamless care with regard to medications and the authors 
searched for a more specific definition: they found three definitions of seamless care or 
continuity of care that included the medication component.  
In 1998, the Canadian Society of Hospital Pharmacists and the Canadian Pharmacists 
Association defined seamless care as “the desirable continuity of care delivered to 
patient in the health care system across the spectrum of caregivers and environments”2. 
“Spectrum of caregivers” refers to multidisciplinary care and how members of different 
health care professions interact to provide total patient care. “Environments” refer to 
different health care settings and transition between them 3. 
The same year, the Australian Pharmaceutical Advisory Council developed continuity of 
care guidelines focusing on medication management. They defined seven principles to 
ensure continuity of care in medication management: (1) identifying a person to 
coordinate the medication discharge plan, (2) obtaining an accurate medication history, 
(3) evaluating the complete medication list for appropriateness, (4) developing a 
treatment plan that is part of the overall care plan, (5) dispensing an adequate amount 
of medication at discharge, (6) ensuring the patient has been educated about the 
discharge treatment plan, and (7) communicating to follow-up health care4. 
In 2003, the American Society of Health-System Pharmacists5 developed a definition of 
continuity of care in medication management based on a consensus-building approach 
using a modified Delphi process: “Continuity of care is a longitudinal process that is 
coordinated and provided among practitioners and organizations over time, consistent 
with the ongoing needs of the individual patient. Medication management is an essential 
component of continuity of care. All entities responsible for an individual’s health care, 
including practitioners from multiple professions, health care organizations, and the 
individuals themselves, should strive for cohesive care across a continuum of sites (from 
intensive care to self-care) that is responsive to changes in needs over time”.  
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For the purpose of this work, the authors combined the ‘general’ Canadian definition 
with the ‘specific’ medication component of the Australian definition. For the latter they 
made a few modifications in order to increase sensitivity and specificity and also 
specified a transition between the hospital setting and another non-hospital setting. This 
choice was made for homogeneity purposes and because this is a frequent transition, 
which has been the most researched, and has been shown to be a high-risk situation. 
Therefore the authors define continuity of care or seamless care (used synonymously in 
this report) with regard to medications as: 
“The desirable continuity of care delivered to patient in the health care system across 
the spectrum of caregivers and environments2. “Spectrum of caregivers” refers to 
multidisciplinary care and how members of different health care professions interact to 
provide total patient care. “Environments” refer to different health care settings (one of 
them being the hospital, the other being community care [home, rehabilitation care 
facilities and long term care facilities]), and transition between them3. The most 
important principles to ensure continuity of care in medication management include: (1) 
having well-defined processes of care and responsibilities across the spectrum of 
caregivers, (2) obtaining an accurate medication history, (3) developing a treatment plan 
on admission as well as at discharge that is part of the overall care plan, (4) dispensing 
an adequate amount of medication at discharge, (5) ensuring the patient has been 
educated about the discharge treatment plan, and (6) communicating to follow-up 
health care 4. 
This report focuses on the bidirectional transition between hospital and community.  
It is important to highlight that optimising seamless care is just one component of 
quality improvement focusing on the use of medicines. Other important quality 
improvement measures, such as assessing the quality of prescriptions,  are not the focus 
of this research.  
1.2 PROBLEMS ASSOCIATED WITH DISCONTINUITY OF 
CARE IN RELATION TO MEDICATIONS 
Medication management is an essential component of continuity of care5. Despite the 
desirability of such continuity, patients often experience drug-related problems (DRPs) 
as a result of discontinuity of care. DRPs are events or circumstances involving drug 
therapy that potentially or actually interfere with the patient achieving an optimal 
outcome6. The risk for DRPs increases in case of transfer of the patient from a setting 
of care to another one. On admission to hospital, a recent literature review outlined 
that there was at least one error in medication history for 27%–54% of patients and that 
19%–75% of the discrepancies were unintentional 7. International research estimated 
that about 63,7% of the patients discharged from the hospital experience drug related 
problems8. Two prospective9, 10 studies in North America (Canada and US) found that 
19 to 23% general medicine patients experienced adverse events after discharge from 
hospital. Adverse drug events (ADEs) were the most common type of adverse events: 
more than half of them could be prevented and were improvable (duration or severity 
could have been decreased). More specifically, about 60 % of unplanned re-admissions 
of elderly people could be avoided by a more efficient intervention at discharge from 
the hospital11.  
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2 OBJECTIVES AND RESEARCH QUESTIONS 
Several initiatives to improve continuity of care have already been developed, in Belgium 
or abroad, as for example transmission of discharge plan to primary care providers, 
medication reconciliation process on admission and at discharge, patient medication 
counselling at discharge, nationwide on-line prescription records and post discharge 
telephone follow-up.  
This project aims at proposing a system to improve continuity of care with regard to 
medications, on admission as well as at discharge from the hospital. Since several 
countries have expertise in this matter, the existing know-how and information will be 
drawn-up, compared, evaluated and tested for usefulness in Belgium. 
More specifically, the objectives of this project are: 
1. to systematically review the international literature on the impact of initiatives 
aiming at improving continuity of care between settings with regard to 
medications ; in a separate chapter, to review the international literature on the 
cost-effectiveness of initiatives aiming at improving continuity of care between 
settings with regard to the use of medications;  
2. to review the grey literature on seamless care initiatives or recommendations 
that have been developed in 6 selected countries; 
3. to summarise Belgian data on drug related problems related to discontinuity of 
care, as well as initiatives to improve continuity of care focusing on medications; 
4. to quantify the extent of drug substitution as a result of a hospital stay in Belgium 
(as one cause of changes in medication therapy and a potential source of drug-
related problems); 
5. based on data from the first three objectives, to conduct focus groups with 
Belgian healthcare professionals, patients and stakeholders to evaluate the 
usefulness and feasibility of systems to improve continuity of care in Belgium. 
6. based on Belgian and international findings, to highlight lessons learned for a 
quality improvement system and to discuss practical considerations for their 
implementation in Belgium. 
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3 EFFECT OF INTERVENTIONS TO IMPROVE 
CONTINUITY OF CARE WITH REGARD TO 
MEDICATION: SYSTEMATIC REVIEW OF THE 
INTERNATIONAL LITERATURE 
3.1 RESEARCH QUESTIONS 
The objective of this chapter is to systematically review the international literature on 
the impact of initiatives aiming at improving continuity of care between settings with 
regard to medications. The research questions are as follows: 
• Setting: Transition between ambulatory care (including nursing homes) and 
hospital care worldwide; 
• Perspective: patients admitted and/or discharged from hospital; health care 
professionals caring for these patients in the outpatient and inpatient settings; 
• Intervention: Seamless care interventions with a focus on medications; 
• Comparison: usual care; 
• Evaluation: Process measures (eg medication discrepancies, medication 
related problems); clinical and humanistic outcome measures (economic 
outcome measures are reported separately in the next chapter). 
3.2 METHODOLOGY 
3.2.1 Search strategy  
3.2.1.1 Databases 
The indexed literature search was conducted within the following databases: Medline 
(OVID), EMBASE, the Cochrane Database of Systematic Reviews, Cumulative Index of 
Nursing and Allied Health Literature (CINAHL), International Pharmaceutical Abstracts 
(IPA). The different databases were searched in June and July 2009. All details are 
provided in appendix 1. The search strategy relative to economic studies is detailed in 
the next chapter.  
3.2.1.2 Selection criteria 
The following inclusion criteria were applied: 
• Date of publication: from 1995 onwards; 
• Language: English or French or Dutch; 
• Sample: Patients admitted to hospital and/or patients discharged from hospital 
(no age or other limitations regarding the patients); health care professionals 
caring for these patients in the outpatient and inpatient settings; 
• Intervention: Seamless care interventions focusing on medications; 
• Study design: Experimental and quasi-experimental studies (parallel group 
studies), systematic reviews and meta-analyses.  
The exclusion criteria are detailed in appendix 1. 
3.2.2 Critical appraisal of the evidence selected 
All studies were appraised using a grid including 14 different items 12 used in another 
KCE project. The tool and procedure are detailed in appendix 1. 
Systematic reviews and meta-analysis were appraised using the Dutch Cochrane grid 
also displayed in appendix 1. 
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3.2.3 Data extraction 
A data extraction form was developed and pilot tested on a small number of studies 
before the final form was decided upon. This form was also used for the extraction of 
data from the projects conducted in Belgium (see chapter 6). This form summarized 
specific information i.e. the research setting, study population, focus of transition, study 
design, objectives of the study, type and characteristics of intervention, outcome 
measures, main findings, comments. Data extraction was performed by one member of 
the research team (PC) and checked by a second member (AS). Disagreements were 
resolved by consensus. 
3.3 RESULTS 
3.3.1 Search results  
The detailed search results are provided in appendix 1 and summarized in the figure 
below. 
Figure 1: Selection process for the inclusion of the studies 
 
No systematic review/meta-analysis exclusively focused on seamless care in relation 
with medications. However, several of them had included individual studies that possibly 
fitted the inclusion criteria and were consulted for this purpose 13 , 14 , 15 , 16 , 17 , 18 , 19.  
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3.3.2 Characteristics of the included studies 
Two studies focused on the admission component only, and investigated the impact of a 
structured and comprehensive medication history done by a pharmacist on admission. 
In contrast, the vast majority of studies (n=21) focused on the discharge component. 
These interventions were delivered before discharge, shortly after discharge, or before 
and after discharge. Finally, in five studies, the interventions were delivered both on 
admission and at discharge: three of them involved computer-based interventions. The 
interventions often targeted the patients, sometimes the primary care providers (GPs 
and/or community pharmacists), or both. 
The studies were conducted in the United States of America (n=9), the United Kingdom 
(n=7), Canada (n=4), Australia (n=3), The Netherlands (n=2), Germany, Spain, and 
Northern Ireland (1 for each). 
The majority of studies were randomised controlled studies, several of them at a cluster 
level. When the intervention was provided by a health care professional, pharmacists 
were mostly involved, followed by nurses. The characteristics and main results of these 
28 studies are summarised in the table below. Their full details are in a separate 
document available upon request.  
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Table 1: characteristics of studies included in the review: quality appraisal score and summary of the main results 
1A. Studies focusing on admission 
Ref Sample Design Intervention Control Effect of the intervention QS 
Nester 
2002 20 
100 patients admitted to a 
tertiary-care referral hospital 
USA 
CT Structured pharmacist medication 
history (if needed, the pharmacist 
contacted the patient’s community 
pharmacy to clarify the medication 
regimen) 
Standard care: nurse-
conducted medication 
histories  
P: more clinical interventions performed by 
pharmacists (p<0.05); more patients  indentified 
as taking herbal preparations, non prescription 
medications (p<0.001) 
6* 
Kwan 
2007 21 
464 patients with 
preadmission clinic 
appointment before surgical 
procedures in one tertiary-
care teaching hospital 
Canada 
RCT Structured pharmacist medication 
history interview (if needed contact 
with community pharmacy or GP) and 
generation of a postoperative 
medication order form 
Standard care: nurse-
conducted medication 
histories and surgeon-
generated medication 
orders 
P: less patients with at least 1 postoperative 
medication discrepancy related to home 
medications (p<0.001), including for discrepancies 
with the potential to cause possible or probable 
harm (p<0.001) 
9* 
Abbreviations: *: publication selected for the synthesis of evidence (QS≥6); CT: controlled trial; GP: general practitioner; P: process measure; QS: quality score (/14); RCT: 
randomised controlled trial.  
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1B Studies focusing on discharge 
Ref Sample Design Intervention Control Time of f-up Effect of the intervention QS 
Communication of discharge information to primary care providers  
Kunz 
2007 22 
178 primary care practices, 
patients prescribed new 
medications at discharge 
Germany 
Cluster 
RCT 
One-sentence evidence 
summaries appended to discharge 
letters for GPs 
Discharge letter 
without evidence 
summary 
≥100 days P: decrease in non adherence to discharge 
medication (p=0.039)  
H: most GPs enthusiastic but few felt the 
summary provided new information 
5 
Duggan 
1998 23 
501 general medical patients in 
one teaching hospital 
UK 
CT Copy of the discharge drug 
information given to the patient 
for the community pharmacist 
Usual care (no letter 
for the community 
pharmacist) 
10 weeks P: lower rate of unintentional drug 
discrepancies (p<0.001), including 
discrepancies judged to have a definite 
adverse effect (p<0.01)  
0 
Gutschi 
1998 24 
135 postcardiac surgery 
patients at a University 
Institute 
Canada 
RCT (a) Discharge letter given to the 
patient for the community 
pharmacist 
(b) Discharge letter given to the 
patient for the community 
pharmacist and the GP 
Hospital pharmacist 
counselling 
3 months P: no statistically significant difference in 
pneumococcal or influenza vaccination 
rates 3 months after discharge 
1 
Lalonde 
2008 25 
83 patients discharged from a 
geriatric, family medicine, or 
psychiatric ward (urban 
hospital) with ≥ 2 
pharmacotherapeutic changes 
Canada 
RCT Medication discharge plan (MDP) 
sent to community pharmacist 
and GP 
Usual care (routine 
pharmaceutical care): 
MDP completed but 
not sent and not given 
to patients 
1 week P: no difference in the rate of medication 
discrepancies 
9* 
Patient education and counselling  
Provided before discharge       
Hayes 
1998 26 
60 elderly (≥ 60 yrs) patients 
discharged home from 3 rural 
ED 
USA 
RCT Individualized computer-
generated discharge instructions 
designed within a geragogy 
framework 
Usual preprinted 
discharge instructions 
with handwritten 
medication 
information 
2-3 days P: greater knowledge of medication 
(p=0.016) 
12* 
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Ref Sample Design Intervention Control Time of f-up Effect of the intervention QS 
Al 
Rashed 
2002 27 
83 elderly patients on 2 care 
of the elderly wards and 
discharged home on ≥4 drugs, 
with medication problems,  
UK 
Cluster 
RCT 
Predischarge pharmaceutical 
counselling 
Usual care: medication 
and information 
discharge summary 
given at discharge, and 
explanations by a 
nurse 
3 months P: better medication knowledge  
(p<0.01)and compliance (p<0.001) 
C: fewer unplanned visits to GP and 
hospital readmissions (p<0.05) 
2 
Voirol 
2004 28 
291 patients admitted to a 
general academic pediatric  
ward and discharged on ≥1 
new medication 
USA 
 
RCT Proactive program of discharge 
planning by the pharmacy team 
Usual care (assistance 
from the pharmacy 
team only upon 
request) 
Median 12 days P: increased caregivers’ probability to 
obtain prescribed medications within 24 
hours (p=0.027; but not significance in the 
final MV model); no difference in 
caregivers’ knowledge of how to 
correctly administer medications 
9* 
Manning 
2007 29 
337 patients discharged from 4 
medical units in one teaching 
hospital with > 3 discharge 
medications and returning to 
self-care at home 
USA 
RCT 3D: durable display at discharge Medication list and 
schedule generated 
electronically by the 
nurse and given to the 
patient 
7-14 days P: greater understanding of prescribed 
medication (p<0.05);  
C: no significant difference in self-
reported medication errors 
H: no significant difference in patient 
satisfaction 
7* 
Lowe 
1995 30 
88 patients discharged home 
from 2 pairs of medical wards 
at a general hospital 
UK 
Cluster 
RCT  
Hospital self medication program 
in which patients are educated 
about their medicines and given 
increasing responsibility for taking 
them in hospital 
Discharge information 
given by a nurse 
10 days P: better compliance score (p<0.02) and 
knowledge of the purpose of their 
medicines (p<0.001)  
5 
Pereles 
1996 31 
107 patients admitted to 
geriatric assessment and 
rehabilitation program in 2 
geriatric units and discharged 
home 
Canada 
RCT Three-stage self-medication 
program  
 
Standard care: 
medications 
administered by the 
nursing staff 
40 days P: no significant difference in ability to 
self-medicate and medication knowledge, 
better medication compliance 1 month 
after discharge (p<0.001) 
H: no significant difference in morale 
9* 
Provided after discharge  
Dunn 
1995 32 
204 patients discharged from a 
geriatric hospital to their 
homes 
UK 
RCT  Home visit by a health visitor 72 
hours after discharge to evaluate 
and improve medication 
management 
Normal post-discharge 
care (no visit) 
28 days P: less tendency to start drugs 
C: More of the study subjects than the 
control subjects were back in the hospital 
or had moved into a nursing or residential 
home; no difference in survival, cognitive 
5 
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Ref Sample Design Intervention Control Time of f-up Effect of the intervention QS 
and physical function, services requested 
and supplied at 28 days post-discharge 
Dudas 
2001 33 
221 medical inpatients 
discharged home with 
pharmacy-facilitated discharge 
(one service, one teaching 
hospital) 
USA 
RCT Follow-up phone call by a 
pharmacist 2 days after discharge 
Usual care 
(=pharmacy-facilitated 
discharge)  – no phone 
call 
30 days H: more patients satisfied with medication 
discharge instructions 15 days after 
discharge (p=0.007) 
C: decreased rate of visits to ED 
(p=0.005) and hospital readmission 
(p=0.07) 30 days after discharge  
E: total cost savings $11,910 
P: resolution of medication-related 
problems 
1 
Vuong 
2008 34 
316 patients ≥55 yrs 
discharged home from 2 
acute-care tertiary teaching 
hospitals at risk of drug-related 
problems 
Australia  
RCT Community liaison service: home 
visit from a community liaison 
pharmacist within 5 days after 
discharge (+ report to GP and 
community pharmacist) 
Standard care 
(discharge counselling, 
provision of 
compliance aids and 
communication with 
primary healthcare 
providers when 
necessary) 
8-12 weeks P: no significant difference in number of 
medications taken; improvement in self-
perceived medication understanding in  
intervention patients (p<0.001); significant 
improvements in adherence in both 
groups 
6* 
Provided before and after discharge  
Cabezas 
2006 35 
134 patients admitted for 
heart failure in two hospitals 
and discharged home 
Spain 
RCT 
 
Pharmaceutical care program: 
discharge counselling + post-
discharge telephone calls 
(monthly for 6 months, then ev 2 
months for 6 additional months)  
Usual care 1year C: fewer hospital readmissions and days in 
hospital (significant at 2 and 6 months, 
non significant at 12 months), fewer 
deaths (p<0.05) 
P: better patient compliance  
E: saving in hospital costs 578€/patient 
H: no difference in quality of life, higher 
patient satisfaction (p<0.05) 
10* 
Schnippe
r 2006 36 
178 patients discharged home 
from the general medicine 
service at a large teaching 
hospital 
USA 
 
RCT Pharmacist: medication review, 
patient counselling at discharge, 
and follow-up telephone call 3 to 
5 days later (+ communication to 
GP) 
Usual care: routine 
review of medication 
orders by a ward-
based pharmacist and 
medication counselling 
by a nurse at the time 
of discharge 
30 days C: lower rate of preventable ADEs 
(p=0.01); lower rate of preventable, 
medication-related ED visits or hospital 
readmission (p=0.03); no difference in 
total ADEs, health care utilization 
P: no difference in medication adherence 
H: no difference in patient satisfaction 
9* 
16  Seamless care KCE Reports 131 
Ref Sample Design Intervention Control Time of f-up Effect of the intervention QS 
 
 
Complex interventions focusing on both patients and primary care providers  
Provided before discharge       
Smith 
1997 37 
66 elderly patients  discharged 
from one hospital to their own 
home, likely to experience 
difficulties with their 
medication 
UK 
RCT Normal discharge information + 
verbal counselling by a pharmacist 
+ written information about their 
pharmaceutical care plan. Copies 
of the plan given to the patients + 
instruction to show to their 
doctor and pharmacist.  
Normal discharge 
information (usual 
pharmaceutical care, 
medicine record card, 
copy of discharge 
prescriptions) 
7-10 days P: better compliance (p<0.01); less 
patients with therapeutic management not 
maintained after discharge (75% vs 96%) 
1 
Shaw 
2000 38 
97 patients from 2 adult and 1 
care of the elderly acute 
admission wards at one 
psychiatric hospital 
UK 
RCT Pharmacy discharge planning, 
patient education, discharge plan 
sent to community pharmacist 
Usual care 12 weeks C: not significant decrease in hospital 
readmission (p=0.065);  
P: no significant difference in medication 
knowledge; fewer medication problems 
and non-compliance 
5 
Provided after discharge       
Hugtenb
urg 2009 
39 
715 patients registered in 37 
community pharmacies, 
discharged from hospital to 
the community, and using ≥ 5 
prescribed medicines 
The Netherlands 
Cluster 
CT 
Comprehensive pharmaceutical 
care by community pharmacists 
at discharge (medication review 
and reconciliation, home visit, 
medication scheme, GP informed) 
Usual care 9 months P: more changes in drug therapy 
C: no difference in mortality 
E: reduced medication costs 
H: increased patient satisfaction about 
drug counselling (p<0.001) 
3 
Provided before and after discharge       
Nazareth 
2001 40 
362 patients ≥75 years 
discharged from 3 acute 
general and 1 long-stay 
hospital  on ≥ 4 medicines 
UK 
 
RCT Pharmaceutical discharge plan by 
a hospital pharmacist, given to 
the patient, carers and 
professionals; home visit by a 
community pharmacist 1-2 weeks 
after discharge 
Usual care: discharge 
letter to the general 
practitioner listing 
current medications 
6 months C: no significant difference in hospital 
readmission 3 and 6 months after 
discharge, mortality, care utilization 
P: no difference in medication knowledge 
and adherence 
H: no difference in patient general well-
being and satisfaction 
8* 
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Ref Sample Design Intervention Control Time of f-up Effect of the intervention QS 
Crotty 
2004 41 
110 older inpatients (3 
metropolitan hospitals) 
awaiting transfer to a long-
term care facility 
Australia  
RCT 
 
Pharmacist transition 
coordinator: medication 
management transfer summary 
for GP and community 
pharmacist, medication review by 
community pharmacist and 
multidisciplinary case conferences 
Usual care: standard 
hospital discharge 
summary 
8 weeks P: Lower scores of inappropriate 
prescribing (MAI) at follow-up (p=0·006);  
C: Better pain control (p=0.023) and 
lower hospital use (p=0.035); no 
significant difference in adverse drug 
events, falls/ 
mobility, behavior/cognition 
9* 
Jack 
2009 42 
749 medical patients admitted 
to a medical teaching service 
and discharged  to the 
community 
USA 
RCT 
 
Reengineered Hospital Discharge 
= patient education and 
comprehensive discharge planning 
by a discharge nurse, summaries 
faxed to primary care provider, 
postdischarge telephone 
reinforcement 2-4days after 
discharge by a clinical pharmacist 
(+ communication to primary 
care providers) 
Usual care 30 days C: lower rate of hospital utilization 30 
days after discharge (p 0.009) and higher 
rate of primary care follow-up visits 
(p<0.001) 
P: better self-reported preparedness for 
discharge (p=0.013)  
E: 33.9% lower observed cost 
 
 
8* 
Abbreviations: *: publication selected for the synthesis of evidence (QS≥6); ADE: adverse drug event; C: clinical outcome measure; CT: controlled trial; E: economic outcome 
measure; ED: emergency department; GP: general practitioner; H: humanistic outcome measure; MAI: medication appropriateness index; MV: multivariate; P: process outcome 
measure; QS: quality score (/14); RCT: randomised controlled trial.  
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1C. Studies focusing on both admission and discharge 
Ref Sample Design Intervention Control Time of f-up Effect of the intervention QS 
Stowasse
r 2002 43 
240 patients admitted to 8 
acute wards and 1 orthopaedic 
pre-admission clinic 
at 2 major hospitals, and 
returning to the community 
following discharge 
Australia 
RCT Medication Liaison Service: drug 
history by a clinical pharmacist on 
admission (+ confirmation by GP 
and community pharmacist) + 
discharge plan communicated to 
GP and community pharmacist 
upon discharge 
Clinical pharmacist: 
medication history on 
admission; standard 
discharge summary 
(routine clinical 
pharmacy service) 
30 days P: more clinical pharmacy interventions 
and changes in drug therapy (p<0.05) 
C: no significant effect on length of stay, 
mortality, readmission (p=0.055); fewer 
health care professional visits per patient 
(p<0.05) 
H: no significant difference in change of 
functional health status (but tendency to 
more improvements) 
7* 
Bolas 
2004 44 
243 medical inpatients ≥55 
years, taking ≥3 regular drugs, 
discharged to the community 
Northern Ireland 
RCT Community liaison pharmacist: 
comprehensive drug history on 
admission, discharge counselling, 
and information to GP and 
community pharmacist 
Standard clinical 
pharmacy service (no 
discharge counselling) 
3 months P: less discrepancies between discharge 
prescription and home medication 
(significant for drug names and dosage 
frequencies) 
P: better knowledge of drug therapy 
(p<0.001) 
4 
Computer-based interventions 
Smith 
1996 45 
348 inpatients of an acute 
medical service of a university-
affiliated medical centre 
USA 
Cluster 
RCT 
computer-generated drug list to 
cancel or renew previous 
outpatients prescriptions, or to 
prescribe new medications 
No cancelling 
outpatient drugs; 
writing all medications 
on individual 
prescriptions 
0 P: fewer prescriptions on admission and at 
discharge, but no significant difference in 
the increase from admission to discharge 
(p=0.87) 
3 
Vanderka
m 2001 
46 
139 patients admitted in one 
hospital and cared for by a 
participating GP 
The Netherlands 
Prospec
tive 
cohort 
electronic communication 
between GP and local pharmacy 
to transfer data about 
prescriptions 
Paper-based 
communication  
10 days P: better agreement between the GP and 
community pharmacist on current 
medication of the patient – but insufficient 
0 
Schnippe
r 2009 47 
322 general medical inpatients 
(14 medical teams, 2 academic 
hospitals) 
USA 
Cluster  
RCT 
Computerized medication 
reconciliation tool and process 
redesign  involving physicians, 
nurses, and pharmacists and 
supported by information  
technology 
Usual care  30 days P: significantly lower rate of unintentional 
discrepancies between preadmission 
medications and admission or discharge 
medications that had potential for harm 
C: non significant decrease in hospital 
readmission or emergency department 
visit 
10* 
Abbreviations: *: publication selected for the synthesis of evidence (QS≥6); C: clinical outcome measure; GP: general practitioner; H: humanistic outcome measure; P: process 
outcome measure; QS: quality score (/14); RCT: randomised controlled trial.  
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3.3.3 Quality of the studies 
Fifteen studies had a quality score ≥ 6/14. Five studies received a score of 5 and 8 
studies had a score between 0 and 3. The items that were most often rated as negative 
were: sample size, blinding, and confounders addressed. The full details of the scores 
are in Appendix 1.  
3.3.4 Summary of the evidence 
The summary of the impact of interventions is based on the studies (n=15) with a 
quality score of 6 and above. Due to heterogeneity between studies in terms of 
population, intervention, and measures of evaluation, a quantitative meta-analysis was 
not possible.  
3.3.4.1 Interventions focusing on admission 
Two studies evaluated the impact of medication histories conducted by pharmacists 
(including, if needed, a contact with general practitioners (GP) and community 
pharmacist) as compared to histories conducted by nurses20 , 21. The first study found 
that the intervention led to more interventions performed by clinical pharmacists during 
hospital stay, and that more patients were found to take herbal preparations and non-
prescription medications20. Kwan et al. found a significant decrease in postoperative 
medication discrepancies that had the potential to cause possible or probable harm21. 
However none of the studies evaluated the impact of history taking on clinical 
outcomes. 
3.3.4.2 Interventions focusing on discharge 
Communication of discharge information to GP and community 
pharmacist 
Several studies evaluated the effect of communicating discharge information to GP 
and/or community pharmacists, but only one of them reached a quality score of more 
than 625. This study evaluated the impact of sending a medication discharge plan to the 
community pharmacist and GP. The authors found no difference in the rate of 
medication discrepancies (in this case, any discrepancy between the medication 
discharge plan and (i) the discharge prescription, (ii) the patient’s community pharmacy 
dispensing records or (iii) the patient’s medication self-report). However, the control 
group received routine pharmaceutical care as provided in Canada, including medication 
history on admission and discharge counselling (the latter was provided to 79% of 
intervention patients and 66% of control patients), and this – together with the small 
sample size – could have diluted the effect of the intervention. 
Education and counselling of patients before discharge 
Four trials evaluated the effect of educating patients before discharge from hospital26 , 28 , 
29 , 31. The results are somewhat disappointing, and despite having a sufficient quality 
score, the studies have many weaknesses e.g., patient selection biases, insufficient power 
of the study. 
Hayes et al reported greater knowledge of medication in patients receiving discharge 
instructions specifically designed for elderly people when compared to usual discharge 
instructions26. The patients – voluntary elderly people – were taking few medications 
and complex regimens were not frequent. In addition, the adherence was not evaluated. 
This limits the value and generalisability of the results.  
Voirol et al. found mixed results on the effect of a proactive discharge program for 
caregivers of pediatric patients28. However, the baseline level of discharge management 
was high (86% of caregivers in the control group stated that they received information 
on the medications before discharge from a pharmacist, nurse or physician), and there 
was insufficient power to detect any significant difference.  
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Pereles et al evaluated the effect of a three-step self-medication program: (1) patient 
counselled by the pharmacist about his/her medications and the medication regimen, (2) 
patient given a 24-hour supply of medication to self-administer, (3) patient given several 
days supply of medication31. Patients were monitored by the nursing staff and the 
pharmacist.  Both control and intervention patients had a 20-minute counselling session 
with a pharmacist 3 days before discharge and received a 40-day supply of medications 
from the hospital pharmacy. The medication that they had previously used at home 
were stored at the hospital during the trial and returned at the follow-up visit. These 
two interventions (i.e. 40-day supply, and storing+returning at follow-up visit) are far 
from what is done in the Belgian context and therefore limit the generalisability of the 
findings.   
Manning et al. evaluated the effect of a redesigned patient education discharge tool with 
durable display (space in which a tablet or pill is to be affixed and displayed) in patients 
discharged home with at least three medications29. They reported greater understanding 
of prescribed medication, but no significant difference in self-reported medication 
errors and patient satisfaction. Limitations included a high dropout rate of 48%, and a 
lack of data on the validity of the measures used to evaluate the impact of the 
intervention. 
Education and counselling of patients after discharge 
The only trial that evaluated the effect of a pharmacy service provided a few days after 
discharge is of limited interest34. The authors aimed to evaluate the effect on 
readmission rates, but the required sample size was never reached, and the results on 
this primary outcome were not reported. Nevertheless the authors reported higher 
improvements from baseline in medication adherence in the intervention group as 
compared to the control group (secondary outcome measure).  
Education and counselling of patients at  and after discharge 
The most informative studies relative to patient education are those where the 
intervention was provided both at and after discharge. Two randomised controlled 
trials were identified and they both measured an impact on outcome measures (clinical 
and humanistic or economic measures) in addition to process measures of 
evaluation35,36. 
Schnipper et al. evaluated the effect of pharmacists who provided patient counselling at 
discharge and during the follow-up (telephone calls three to five days later). The 
population was a general patient population discharged from a teaching hospital to the 
community setting (n=178, mean 58,4 years, median n medications= 8)36. The 
pharmacists providing the intervention found at least one medication discrepancy in 49% 
of patients upon discharge, and in 71% of patients during telephone calls. The problems 
identified were communicated to the medical team or to the primary care provider. 
They found significant reductions in the rate of preventable adverse medication events 
(evaluated by blinded researchers – absolute risk reduction (ARR)=10%, unadjusted OR 
0.10, 95%CI 0.013-0.86, number needed to treat (NNT) calculated by ourselves = 10) 
as well as in the rate of preventable medication-related visits to the emergency 
department or hospital readmissions (ARR 7%, no CI provided, self-calculated 
NNT=14). This was observed despite a high rate of discrepancies in both groups 30 
days after discharge (65% of control and 61% of intervention patients). There was no 
difference for the other secondary outcomes such as total ADEs (this was due to a 
higher rate of non preventable ADEs in the intervention group), health care utilisation, 
medication adherence, and patient satisfaction.  
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A Spanish study evaluated the effect of a pharmaceutical care program involving 
discharge counselling and post-discharge telephone calls during 1 year in a population of 
patients admitted for heart failure (n=134, mean age 75 years) and discharged home35. 
The study population had a very low educational level, and the involvement of the 
caregivers was therefore essential. They found significantly fewer hospital readmissions 
and length of stay in hospital two, six and 12 months after discharge (ARR for 
readmission (%) and self-calculated NNTs were: at month 2: 13.6%- 7,3; at month 6: 
17.9% - 5,6; at month 12: 15.5% - 6,5), and significantly fewer deaths. In addition, 
significant differences in patient adherence and patient satisfaction were found, but there 
was no difference in quality of life. Savings in hospital costs were also calculated: the 
results are presented in the economic part.  
Complex interventions involving patients and health care 
professionals 
In this report, « complex » interventions are those that aim to systematically target 
both patients and health professionals in order to optimise continuity of care.  
The three randomised controlled trials with sufficient quality all investigated the effect 
of an intervention that was provided before and after discharge, and all three evaluated 
the effect of the intervention on outcome measures (clinical, economic, and/or 
humanistic) in addition to process measures 40 , 41 , 42. Two of them reported positive 
findings41 , 42. 
Nazareth et al. found no impact of a comprehensive and time-consuming intervention 
(involving pharmaceutical discharge planning, communication with carers and healthcare 
professionals, and home visit by a community pharmacist) on hospital readmission 
(primary outcome measure), mortality, care utilisation, medication knowledge and 
adherence, patient general well-being and satisfaction40. The time taken by the discharge 
pharmacist to prepare and administer each care plan was 5.5 hours per patient, which is 
far superior to the time needed by pharmacists in other studies that reported positive 
findings. The authors provide limited explanation for the absence of impact. 
The study by Crotty et al., interestingly, was the only study focusing on patients 
discharged to a long-term care setting41. The health care professionals providing the 
intervention included a pharmacist transition coordinator, the community pharmacist as 
well as a multidisciplinary team (for case conferences). However, case conferences took 
place in only 14.3% and 3.7% of intervention and control patients, respectively. Despite 
this low percentage, the authors found significant improvements in appropriateness of 
prescribing (primary outcome measure), using a validated instrument, in pain control 
and hospital use. The study was underpowered to detect differences in secondary 
outcomes. No significant differences were found in ADEs, falls and mobility, behaviour 
and cognition. 
Jack et al. evaluated the impact of a multidisciplinary approach (called the “Reengineered 
Hospital Discharge”): a discharge nurse was responsible for the patient-centred 
education before discharge, for the discharge planning, and a clinical pharmacist did 
telephone reinforcement with the patient two to four days after discharge42. In addition, 
discharge summaries were faxed to primary care providers on the day of discharge. 
Similarly to Schnipper, the research staff was blinded to treatment allocation. The 
authors found significantly lower rates of hospital utilisation 30 days after discharge 
(incidence ratio 0.695, 95% CI 0.515-0.937, p=0.009) and of primary care follow-up 
visits (ARR 18%, self-calculated NNT=5.6), better self-reported preparedness for 
discharge, and lower costs. The intervention was the most effective in the subgroup of 
patients with a preceding hospital admission in the previous six months. Two thirds 
(65%) of the intervention patients who completed their medication review with the 
pharmacist after discharge had at least one medication problem and 53% needed a 
corrective action by the pharmacist.  
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3.3.4.3 Interventions focusing on both admission and discharge 
Two out of the five studies that focused on admission and discharge were selected after 
quality appraisal43 , 47.  
The first study took place in two Australian hospitals43. It analysed the effect of a 
medication liaison service between the hospital and the GPs/ community pharmacists. 
Similarly to Nester et al., the study found that more interventions were made by clinical 
pharmacists in the intervention group, reflecting that having a comprehensive drug 
history on admission was important to better optimise drug therapy during hospital 
stay. No significant differences were found in length of stay, mortality, readmission (but 
trend to reduction in the intervention group) and functional health status. There were 
fewer health care professional visits per patient in the intervention group. The study 
probably lacked power to detect significant differences in clinical outcomes.  
The recent study from Schnipper et al. was a cluster RCT (at the level of the medical 
team) in two US hospitals47. It was the only study focusing on computer-based 
intervention, namely a computerised medication reconciliation tool and process 
redesign involving physicians, pharmacists and nurses. The NNT to prevent one 
unintentional discrepancy that had potential for harm (PADE) was 2.6 (adjusted relative 
risk of 0.72, 95%CI 0.52-0.99). Although significant, the confidence interval was wide 
and close to non significance. Subgroup analyses showed that the effect was greater in 
patients at higher risk, that the reduction in PADE was significant at discharge but not 
on admission, and that the intervention was effective in one hospital only. One 
explanation could be that hospitals differed in the extent of the integration of the 
medication reconciliation tool into computerized provider order entry applications at 
discharge. The authors also reported non-significant decreases in hospital readmission 
or ED visits, but the study did not have sufficient power to detect differences in health 
care use. 
3.4 DISCUSSION 
3.4.1 General findings 
About half of the included studies had a sufficient quality and were included in the 
synthesis of evidence. Nevertheless, the quality appraisal highlighted that these fifteen 
studies had methodological problems and several of them were underpowered to 
detect any significant improvement in clinical outcomes. There is therefore insufficient 
evidence to draw conclusions on several types of interventions, such as patient 
education and counselling that is provided either before or after discharge. This 
conclusion is similar to the one of Coleman several years ago: “The paucity of high-
quality research examining transitional care is disproportionate to the magnitude with 
which these care handoffs occur each day and the importance of this topic for ensuring 
high quality care of patients with complex care needs”48. Previous systematic reviews 
relative to continuity of care in general also highlighted the low methodological quality 
of the studies included13 , 17 , 19 , 49.  
There is recent evidence showing that patient education and counselling that are 
provided before discharge and reinforced after discharge (mostly by pharmacists, 
sometimes by nurses, in some case with involvement of primary care providers), can 
decrease the risk of (preventable) hospital readmission and/or preventable ADEs. 
However, this has to be confirmed in further multi-center randomised controlled trials 
with adequate power to detect significant differences in relevant clinical outcomes. 
A quantitative synthesis of the evidence was impossible due to the high variability 
between studies in the patient populations, outcome measures, and types of 
interventions.  
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3.4.2 Settings 
The studies of acceptable quality were mostly performed in the United States, Australia, 
and Canada. The issue of applicability of the results to the Belgian health care setting is 
discussed below. Less than 50% of studies were multi-center and they usually involved 
no more than 3 hospitals. This limits the generalisability of the findings. 
This review excluded studies where the patient was not admitted to and/or discharged 
from the hospital. Recent trials have been published about medication reconciliationa in 
outpatient care50 , 51 , 52 , 53. These studies showed that engaging the health care members 
and the patient improved the accuracy of medication lists 51 , 52 , 53. A recent systematic 
review on interventions to improve medication reconciliation in primary care concluded 
that there was no good quality evidence demonstrating the effectiveness of medication 
reconciliation in the primary care setting13.  
3.4.3 Study design 
This review excluded before-after studies53 , 54 , 55 , 56 , 57 , 58 , 59 because they convey an 
important risk of bias, including the possibility of non-comparable groups at baseline, 
and the confounding effect of secular time trends. Such studies were sometimes 
included in previous systematic reviews13 , 49. 
3.4.4 Patients populations 
Most studies included patients discharged from the hospital irrespective of the presence 
of risk factors for experiencing problems during the transition. Two studies included 
patients with pharmacotherapeutic changes25 , 28, one study targeted patients at risk of 
medication-related problems34 and two studies included patients taking at least three or 
four medications29 , 40. Four out of 15 studies specifically targeted elderly patients26 , 31 , 40 , 
41but three of them did not take into account any other risk factor for inclusion. The 
goal of risk identification is to ensure that the patients who will most likely benefit from 
these services are identified, thereby enhancing the cost effectiveness of these 
interventions48. This review shows that this is not yet the case: it could have been easier 
to demonstrate an overall significant impact of the interventions if the individual studies 
had more focused on at-risk patients. A recent study published after this search 
selected discharged patients at high risk of medication-related problems60. However 
there was no significant impact of the intervention (pharmacist-facilitated hospital 
discharge program) on readmission rates or emergency department visits. 
The majority of studies concentrated on patients discharged from medical or surgical 
wards to the community setting and managing their medications at home. These studies 
commonly excluded vulnerable patients, including those with language difficulties, unable 
to communicate, cognitively impaired, or discharged from psychiatric wards. However, 
these patients are at high risk of suffering from adverse consequences of discontinuity of 
care. Future research should, for example, evaluate the impact of involving patients’ 
caregivers (only two studies clearly reported that caregivers were involved28 , 35) or 
design interventions for individuals with cognitive impairment. 
The study by Cabezas et al. included patients with a very low educational level35. These 
patients consult more easily emergency departments (and therefore bypass the GP): the 
finding of decreased readmissions in the intervention group cannot be generalised to a 
population with a higher educational level. 
There are very limited data on patients transferred to postacute care settings, while this 
is an increasingly frequent situation. However, these transitions carry a high risk of 
problems because those settings are settings where patients’ usual physicians do not 
practice and their previous medical records are not available61. Similarly, only one study 
focused on patients newly transferred to long-term care41and this is also an area for 
further research. 
                                                     
a  Medication reconciliation is a process of identifying the most accurate list of all medications a patient is 
taking and using this list to provide correct medications for patients any-where within the health care 
system. Medication reconciliation has been widely implemented in healthcare organisations as a strategy 
to improve patient safety, but its effectiveness has been poorly studied . 
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3.4.5 Health care professionals involved 
The vast majority of interventions were implemented by (clinical) pharmacists. Only the 
two studies focusing on admission directly compared two different health care 
professionals (in this case, a pharmacist and a nurse)20 , 21, which hampers the 
generalisation of the results due to the limited scope of the intervention (i.e. admission 
to the hospital).  
Pharmacists are well trained to provide many supportive function of continuity of care. 
The chapter 6 will show that in many pilot projects on clinical pharmacy, the scope of 
the activities performed by these pharmacists includes seamless care. Murray highlighted 
one disadvantage i.e. the pharmacists are sometimes limited by a lack of prescribing 
authority and comprehensive medical training compared with physicians and by their 
distance from the frontline of care provided by nurses62. Hence, the pharmacists will be 
most effective when working closely in collaborative arrangements with physicians, 
nurses, and other healthcare team members. This was the case in the studies included in 
this review. It is also the case in the Belgian pilot projects around clinical pharmacy. 
Nothing can be concluded on the role of community pharmacists. Three studies 
evaluated their role but were not included in the synthesis of evidence due to low 
quality scores 23 , 24 , 39. In three other trials the community pharmacist played a proactive 
role but its effect was either not documented or non significant 34 , 40 , 41.  Finally, in other 
trials community pharmacists played a more passive role (i.e. they received discharge 
information) and were not the person responsible for coordinating the continuity of 
care. 
Nurses are well positioned to provide a continuity of care, but their expertise on 
medications is not similar to that of pharmacists. No trial in this review exclusively 
addressed the role of nurses. This might be explained by the fact that nurses who 
provide a continuity of care usually have a broader scope of action than only 
medications: trials involving nurses might have therefore been excluded. Controlled 
studies show evidence that management of seamless care by advanced practice nurses 
can reduce the readmission rates for patients with congestive heart failure and for older 
patients with complex care needs61. 
3.4.6 Interventions  
3.4.6.1 Limited literature on information technology 
There are limited data on the effect of information technology (IT) interventions. 
However authors underlined the fact that the implementation of technology is central 
for facilitating the transfer of information across settings48. Ideally IT should bridge the 
gap leading to discontinuity, but this requires that all HCPs working in different settings 
would use a system for coding patient information that enables sharing information 
across care settings. Many hospitals and GPs have access to an electronic health 
information system but few have a system with a connection beyond the hospital, clinic, 
or office61.  
In Belgium, such connections are mostly used for sharing information on laboratory 
results or diagnostic tests, but rarely on medications. Chapter 6 describes some 
ongoing initiatives at local or national level to that end. Kripalani et al. did a systematic 
review on communication and information transfer between hospital-based and primary 
care physicians49. They reported that the delivery and perhaps the quality of discharge 
summaries can be improved substantially through health information technology49. In 
Denmark the use of nationwide on-line prescription records has shown to improve the 
drug history in hospitalised patients 63.  
It is tempting to assume that a shared electronic medical record will solve the 
information problems inherent in transitional care but the reality shows that this is not 
the case. First, transitional care is more complex than the simple exchange of 
information. Second, although it is important for clinicians to have ready access to a 
patient’s medical record, they also must read the information carefully and act 
accordingly. Third, this information must be up to date and comprehensive. 
KCE  Reports 131 Seamless care 25 
 
3.4.6.2 HCP accountable for the transfer of adequate information 
The model whereby an accountable HCP “bridges” the transition with the patient and 
caregiver, offers a number of benefits, including the facilitation of interdisciplinary 
collaboration between the sending and receiving care teams. This single contact HCP 
will address questions or concerns of patients and caregivers before, during and 
immediately after transfer; and the reconciliation of potential medication errors or 
discrepancies before they manifest 48. 
In this review, this accountable HCP was most often a clinical pharmacist with 
appropriate knowledge and skills to provide continuity of care. In Belgium, the number 
of clinical pharmacists is still limited although rapidly increasing. 
How much time does it take for a pharmacist to “provide continuity of care”? Several 
studies included in this review provided data on the time needed to perform the 
intervention21 , 28 , 34 , 35 , 40 , 42: 20 minutes per patient to perform a structured 
comprehensive medication history21, 40 minutes per patient for education upon 
discharge 28, 50 minutes per patient for discharge counselling and postdischarge 
telephone calls35, 30 minutes for postdischarge telephone calls42. This time should be 
balanced against the time taken by GPs to clarify medication discrepancies after 
discharge (in “usual care” situations). Unfortunately, this is probably difficult to measure, 
and has never been reported in the studies reviewed here.   
The cost-effectiveness of these interventions has been evaluated in a few trials, and is 
discussed in the next chapter.  
There is no literature to inform if the HCPs responsible for the continuity of care need 
to be involved in the entire process of medication reconciliation for every patient. They 
could focus on patients at particularly high risk or when medication regimens are most 
in doubt. Similarly, patient counselling and early follow-up might be reserved for patients 
at highest risk of ADEs 36.  
3.4.7 Potential interest to combine interventions 
The selection process excluded experimental studies focusing on seamless care where 
we could not distinguish the impact on the medication component. Similarly, it excluded 
medication-specific interventions where the seamless care component could not be 
evaluated separately. Several large-scale and well-conducted studies with interesting 
results had to be excluded on this basis64 , 65. Those data could be further analyzed to 
assess the effect of complex interventions in seamless care.  
3.4.8 Outcomes under study 
All studies used process measures to assess the impact of the interventions. Some of 
them also measured clinical or humanistic outcomes.  
3.4.8.1 Process measures 
The process measures used included the following: medication discrepancies, changes in 
medication therapy (which is only an indirect measure of quality), treatment knowledge 
and compliance, number of interventions performed by pharmacists, quality of 
prescribing. Process measures are particularly well suited to measuring seamless care 
and have the advantage that they may not require formal case-mix adjustment 
techniques 61.  
Medication discrepancy is probably the most sensitive measure to evaluate interventions 
on seamless care. Ideally, it should be measured using a validated instrument, and the 
researchers should report unintentional versus intentional discrepancies separately, the 
causes of these discrepancies, and their potential for patient harm. The Medication 
Discrepancy tool, for example, enables this assessment66. This is essential to fully 
evaluate the efficacy of the intervention. 
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3.4.8.2 Outcome measures 
Clinical and humanistic outcome measures should be evaluated in parallel to process 
measures, to check if the improvements in process measures lead to relevant benefits 
for the patients. Several authors reported a positive impact on important clinical 
outcome measures (e.g. ADEs, readmission, health care use). Unfortunately, many 
studies lacked power to detect significant differences on such outcomes. Trends in 
improvement were observed, but no definite conclusions can be drawn. 
Among studies that reported humanistic outcome measures (mainly patient satisfaction 
and quality of life), very few of them found positive significant findings. These measures 
were never primary outcome measures (and sample size was therefore not calculated 
based on such measures), with many potential confounders. No conclusion can 
therefore be drawn on this point. 
3.4.9 Are the results applicable to Belgium? 
As stated in 3.4.2., the countries under study have health care systems that differ from 
the Belgian one. In particular most studies conducted in Europe took place in countries 
where patients are registered with a GP. Links between the hospital setting and the first 
line of care are therefore easier to organize in those countries.  
In Belgium the GP has mostly the responsibility for ensuring the continuity of care at 
discharge from the hospital. This role has hardly been studied in the selected literature. 
Moreover, the collaboration of the hospital team with the GP during the follow-up is 
not clear from the literature analysed in this report: interventions mainly occurred in 
the US, where the follow-up can be ensured by the hospital team and/or the specialist. 
More detailed information on the specificities of several countries will be provided in 
chapter 5.  
In most cases the control group involved usual care. However, “usual care” in the 
countries involved is often very different from what can be considered as “usual care” in 
Belgium. “Usual care” groups often received “routine clinical pharmacy services”, which 
is not yet considered as usual care in our country where clinical pharmacy is developing. 
Therefore, the impact of the interventions might be higher if they were implemented in 
Belgium rather than in countries as the US or the UK.   
Another example of differences was the provision/supply of medications for more than 
the three legally-allowed days in Belgium (up to 40 days in one study). The risk of 
discontinuity increases if the patient does not have enough medications when coming 
back home which is very likely in Belgium especially since the new legislation relative to 
“forfaitarisation” (see chapter 8). Delays in medication administrations after hospital 
discharge were found to be frequent in a recent small American study 67. 
The position of community pharmacists might also be different from one country to 
another. Only since recently, Belgian community pharmacists receive financial incentives 
to provide basic aspects of pharmaceutical care. However, no financial incentive to be 
proactively involved in continuity of care and medication reconciliation has been implied 
so far. This is a barrier to effective involvement of community pharmacists in continuity 
of care. In other countries, pharmacists can get paid for educating patients (e.g. Canada) 
or performing medication review (e.g. Australia). The transferability of tasks described 
in other countries to community pharmacists in Belgium needs to take account of this 
different role and payment system. 
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3.4.10 Limitations of this systematic review  
The search strategy was extensive but might have missed some publications, because 
there is a lack of structured and well-recognised thesauri (MeSH and EMTREE) that are 
specific to the problem of seamless care.  
As discussed earlier, several well-conducted studies had to be excluded based on the 
fact that they did not specifically evaluate the impact of a seamless care intervention on 
the medication component. For example, Coleman et al reported that coaching 
chronically ill old patients and their caregivers to ensure that their needs are met during 
care transitions reduced the rates of subsequent rehospitalizations64. Gillespie et al. 
showed that the addition of ward pharmacists to health care teams (mainly to perform 
medication reviews and to optimise continuity of care) led to important reductions in 
morbidity and health care costs for people aged 80 and over 65. The data that such 
studies convey must however be taken into account when designing complex and broad 
interventions. 
Key points 
• This chapter reviews the international literature on the impact of 
interventions to improve seamless care focusing on medication. 
• The selection of articles focused on medication interventions for hospitalised 
patients in the transition between ambulatory and hospital care. A variety of 
types of interventions and target populations have been assessed. 
• Twenty-eight studies were included in the review. Fifteen of them had 
sufficient quality scores to be included in the synthesis of evidence. These 
studies still carried important methodological weaknesses, e.g. with regard 
to sample size, outcome measured. 
• Several categories of high-risk patients were not included in the studies. This 
might have diluted the effect of interventions. 
• In most studies, the intervention was provided by clinical pharmacists, in the 
context of multidisciplinary team working. No conclusion can be drawn on 
the impact of other health professionals given the lack of studies. 
• Most studies focused on process measures (e.g. medication discrepancy) but 
there is a lack of evidence on clinical outcomes. 
• No conclusion can be drawn on the impact of patient education and 
counselling that is provided at or after discharge. 
• The interventions for which there is evidence of a positive impact on process 
measures (such as medication discrepancies), and/or clinical outcome 
measures (such as hospital readmission) were provided both at and after 
discharge. They included: patient education and counselling, and 
interventions focusing on both patients and primary care providers  
• There is very limited information on the impact of information technology 
approaches. 
• The transferability to the Belgian health care system is hampered by 
differences in the role of the clinical/community pharmacist and other 
characteristics (e.g. “forfait” for medication)  
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4 COST-EFFECTIVENESS OF INTERVENTIONS 
TO IMPROVE SEAMLESS CARE FOCUSING 
ON MEDICATION 
4.1 INTRODUCTION 
Drug-related problems related to discontinuity of care between health care settings 
have an impact on patient morbidity and mortality but they also impose an economic 
burden on patients, on the health care system and society. The health care cost of 
managing drug-related morbidity and mortality for ambulatory patients was estimated to 
amount to $76.6 billion per year in the USA in 1995 68. Hospitalisation costs constituted 
62% of this total cost, representing 8.7 million hospital admissions. An analysis updated 
the costs of morbidity and mortality arising from drug-related problems to $177.4 
billion per year for ambulatory patients in the USA in 2000 69.  
Research has indicated that the most common type of drug-related problems affecting 
patients following hospital discharge are ADEs, followed by procedure-related injuries 
10. A literature review of the economic impact of ADEs found that preventable ADEs 
made up 43.3%-80% of all adverse outcomes in the ambulatory setting leading to 
emergency visits and hospital admissions, thus increasing health care costs 70.  
In a context of spiralling healthcare costs and limited resources, policy makers and 
healthcare payers are concerned about the cost-effectiveness of approaches to improve 
seamless care focusing on medication. The need for health economics fits within an 
overall trend towards evidence-based decision making in health care 71. 
4.2 RESEARCH QUESTIONS 
The aim of this chapter is to review the international literature on the cost-effectiveness 
of approaches to improve seamless care focusing on medication. This chapter provides 
a synthesis of economic evaluations of approaches to improve seamless care focusing on 
medication. Methodological issues surrounding the evaluation of the cost-effectiveness 
of approaches to improve seamless care focusing on medication costs are also explored. 
The relevance of the findings is discussed and gaps in the evidence base are identified.   
4.3 METHODOLOGY 
4.3.1 Search strategy  
Studies were identified by searching Medline (PubMed), EMBASE, Centre for Reviews 
and Dissemination databases (Database of Abstracts of Reviews of Effects, NHS 
Economic Evaluation Database, and Health Technology Assessments Database), 
Cochrane Database of Systematic Reviews, and EconLit (OVID) up to August 2009. The 
bibliography of included studies was also checked for relevant studies. Additionally, the 
results of the literature review of the Belgian situation (see chapter 6) and the results of 
the systematic literature review (see chapter 3) were searched for relevant economic 
evaluations. All details of the search strategy are provided in appendix 2. 
4.3.2 Selecting studies 
Evidence about the cost-effectiveness of approaches to improve seamless care focusing 
on medication was derived from economic evaluations (a study contrasting an 
intervention with a comparator in terms of both costs and consequences 72). A 
summary of the main inclusion criteria is presented in the table below. 
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Table 2: Study inclusion criteria 
Population Patients in transition between ambulatory care (including nursing homes) 
and hospital care, and patients admitted to and/or discharged from 
hospital. 
Intervention Approaches to improve seamless care focusing on medication 
Comparator Usual care 
Design Full economic evaluations: studies contrasting an intervention with a 
comparator in terms of both costs and consequences 
Trial-based economic evaluations: economic evaluations based on a 
randomised controlled trial, cohort study, case-control study or before-
and-after analysis*. 
Model-based economic evaluations: economic evaluations applying a 
decision-analytic technique (e.g. decision tree, Markov model) 
* Wider criteria were agreed upon as compared to the systematic review described in chapter 3, 
to increase the chance to gather a minimum of studies 
4.3.3 Critical appraisal of the evidence 
The quality of economic evaluations was assessed by considering the perspective, study 
design (trial- or model-based economic evaluation); source of clinical and economic 
data; cost and consequence measures; allowance for uncertainty; and incremental 
analysis of costs and consequences 72. 
4.3.4 Data analysis and interpretation 
To compare costs between studies, costs were actualized to 2007 values using a rate of 
inflation based on the evolution of the Consumer Price Index. Costs were converted 
using purchasing power parities for Belgium, i.e. market exchange rates adjusted for 
differences in purchasing power between countries and Belgium. Economic evaluations 
are summarized in table 4. 
4.4 RESULTS 
4.4.1 Search results  
The detailed search results are summarized in the table below and in appendix 2. 
Table 3: Search for cost-effectiveness studies: summary 
Database References identified 
Medline 82 
EMBASE 37 
Centre for Reviews and Dissemination  
   Database of Abstracts of Reviews of Effects 28 
   NHS Economic Evaluation Database 163 
   Health Technology Assessments 16 
Cochrane Database of Systematic Reviews 22 
EconLit 65 
Total references identified 413 
Duplicates 74 
Total 339 
Few studies have investigated the cost-effectiveness of approaches to improve seamless 
care focusing on medication. Of the 339 papers identified, 11 articles were included in 
the review (see Figure 2). Seven articles specifically explored approaches to improve 
seamless care focusing on medication. In addition, there is a literature on general 
integrated health care. Four of these articles related to initiatives that, amongst other 
things, included medication management.  
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Figure 2: Flow chart of literature search for economic studies 
 
4.4.2 Evidence 
This search identified four articles on general integrated health care, including 
medication management. These articles showed that general integrated health care 
including medication management generated better compliance, fewer hospital re-
admissions, shorter length of stay, lower costs and similar clinical status than usual care 
64 , 73 , 74 , 75. However, as general integrated health care interventions consist of multiple 
components, these studies did not attribute results to individual components such as 
medication management. Therefore, these articles are not discussed further. 
The characteristics of included economic evaluations of approaches to improve 
seamless care focusing on medication are displayed in table 4 (6 cost-effectiveness 
analyses and one cost-utility analysis). No cost-benefit analyses were identified. A 
variety of intervention types and target populations have been assessed, but the body of 
evidence is limited to one economic evaluation for each particular intervention type and 
each specific target population.  
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Table 4: Characteristics of economic evaluations to improve seamless care focusing on medication 
Reference Type Sample Intervention Comparator Costs and consequences 
Smith 1997 37 Cost-effectiveness 
analysis 
53 geriatric patients 
likely to experience 
difficulties with their 
medication  
UK 
 
Patient counseling about their 
medicines and information about 
their pharmaceutical care plan. 
Patients received domiciliary visit 7-
10 days after discharge. 
 
Normal discharge 
information. Patients 
received domiciliary 
visit 7-10 days after 
discharge 
Analysis demonstrated better compliance levels and less counseling 
required for the study group. A pharmaceutical domiciliary visit was 
necessary for 75% and 96% of study and control patients, respectively. 
The domiciliary visit prevented hospital admission in 3 study patients 
(saving 250 € per patient) and in 4 control patients (saving 374 € per 
patient). 
 
Dudas 2001 33 Cost-effectiveness 
analysis 
221 patients 
discharged from 
hospital to home  
USA 
 
Pharmacist phone call 2 days after 
discharge asking patients about 
medications, such as whether they 
obtained and understood how to 
take them. 
 
Usual care More patients in the phone call than the no phone call group were 
satisfied with medication instructions (86% vs. 61%). Fewer patients in the 
phone call group returned to the emergency department within 30 days 
(10% vs. 24%). Total savings of the phone call intervention amounted to 
11,992 €. 
 
Cabezas 2006 35 Cost-effectiveness 
analysis 
134 patients with 
heart failure  
Spain 
 
Information about disease, diet and 
medication at discharge and 
telephone follow-up by pharmacist 
 
Usual care Patients in the intervention group had higher level of treatment 
compliance (85% vs. 73.9%), fewer hospital re-admissions (0.56 vs. 1.13), 
fewer days of hospital stay (5.9 vs. 9.6), higher satisfaction score (9.0 vs. 
8.2), similar quality of life, lower costs (1,206 € vs. 1,905 €). 
 
Jack 2009 42 Cost-effectiveness 
analysis 
749 English-speaking 
adults admitted to a 
general medical 
service  
USA 
 
Patient education and discharge 
planning in hospital by a nurse and 
post-discharge reinforcement by a 
pharmacist 
 
Usual care Patients in the intervention group had fewer hospital visits than patients 
receiving usual care (0.314 vs. 0.451 visit per person per month), a higher 
primary care follow-up visit rate (62% vs. 44%), were more prepared for 
discharge, and had lower hospital and outpatient costs (-348 € per 
person). 
 
Hugtenburgh 
2009 39 
Cost-effectiveness 
analysis 
715 patients using at 
least five prescribed 
medicines 
The Netherlands 
 
 
An extensive medication review 
and drug counselling at the patient’s 
home 
 
Usual care More patients in the intervention group indicated that they were (very) 
satisfied with drug counselling by the community pharmacist upon delivery 
of discharge medication (87% vs. 50%). The intervention did not influence 
discontinuation of drugs prescribed at discharge or mortality. Medication 
costs were reduced by 20.7 € per patient. 
 
Desplenter 2009 
76 
Cost-effectiveness 
analysis 
99 patients with 
major depressive 
episode 
Belgium 
Medication information 
(un)differentiated according to 
patient information desire 
 
Usual care No differences were found between study groups in terms of compliance, 
anxiety symptoms, depressive symptoms, somatic symptoms, the number 
of side-effects, or patient satisfaction. Control patients had higher costs of 
hospital medicines and more hospital readmissions than patients in the 
undifferentiated group. Control patients had higher costs of primary care 
consultations and higher productivity loss than patients in the 
differentiated group. 
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Table 4: Characteristics of economic evaluations to improve seamless care focusing on medication 
Reference Type Sample Intervention Comparator Costs and consequences 
Karnon 2009 77 Cost-utility analysis Patients admitted to 
hospital 
UK 
Pharmacist-led reconciliation; 
standardised forms, pharmacy 
technicians, hospital policy; nurses 
taking histories with standardised 
form; computerised assessment and 
feedback by pharmacist; current 
medication faxed from the general 
practice. 
 
Usual care The five interventions were extremely cost-effective when compared with 
the baseline scenario. Three interventions dominated the baseline 
scenario. Pharmacist-led reconciliation intervention has the highest 
expected net benefits, with a probability of being cost-effective of over 
60% at a value of 13,000 € per quality-adjusted life year. 
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A British cost-effectiveness analysis investigated the impact of hospital-generated 
pharmaceutical care for geriatric patients who are likely to experience difficulties with 
their medication 37. Intervention and control patients received the normal discharge 
information. In addition to this, intervention patients were counselled by a pharmacist 
on why their medication had been prescribed, when to take their medicines, the 
correct use of their medication, side effects, the importance of compliance, and how to 
arrange a new supply. This information was written in a pharmaceutical care plan and 
provided to the patient. The patient in the intervention  group was also asked to show 
this plan to their physician and pharmacist. The economic evaluation had a small sample 
size, enrolling 28 patients in the intervention group and 25 patients in the comparator 
group. Effectiveness data on compliance and the need for counselling were derived from 
patient questionnaires and expert opinion. The scope of costs was limited to savings 
arising from the prevention of hospital admissions, but did not include costs of 
medicines or consultations with primary care physicians. 
The analysis demonstrated better compliance levels (p < 0.01) and less counselling (p < 
0.01) required for the intervention group. A pharmaceutical domiciliary visit was 
necessary for 75% and 96% of intervention and control patients, respectively. The 
domiciliary visit prevented hospital admission in three intervention patients (saving 250 
€ per patient) and in four comparator patients (saving 374 € per patient). The authors 
concluded that a medication and discharge summary needs to be sent to the patient’s 
primary care physician in advance of the normal discharge letter. 
A US cost-effectiveness analysis examined the impact of providing telephone follow-up 
to patients who are discharged from hospital to home 33. Patients were randomly 
assigned to the control or to the intervention group. Pharmacists called patients two 
days following discharge with a view to counsel them on discharge medications and to 
assist them in obtaining medications (e.g. telephoning discharge prescriptions to the 
pharmacy and completing third-party insurance forms). Although the structure of the 
telephone calls was standardised, there was some variability in the actual phone call 
discussions, thus introducing the potential for performance bias. In general, the 110 
patients in the phone call group had similar characteristics to the 111 patients in the 
control group (who did not get telephone follow-up), but some differences in discharge 
diagnosis were noted between groups. 
The findings indicated that more patients in the phone call than the control group were 
satisfied with discharge medication instructions (86% vs. 61%; p = 0.007). Fewer patients 
in the phone call group returned to the emergency department within 30 days (10% vs. 
24%; p = 0.005). Comparing the costs of the pharmacist intervention with the savings 
arising from the prevention of emergency department visits, the total savings of the 
phone call intervention amounted to 11,992 € (or 109 € per patient). Other health care 
costs (e.g. costs of medication, physician consultations) were not considered.  
A Spanish cost-effectiveness analysis assessed the impact of providing information about 
the disease, medication therapy and diet education to patients with heart failure at 
hospital discharge and of carrying out a telephone follow-up 35. Pharmacists responsible 
for providing information were aware of patient allocation to intervention and control 
group. Data on treatment compliance, hospital admissions, length of hospital stay, 
quality of life and patient satisfaction were collected during follow-up visits by a 
cardiologist at 2, 6 and 12 months following discharge. It could be argued that these 
follow-up visits may have had an effect on effectiveness results (e.g. treatment 
compliance). Cost data were derived from the hospital perspective. Although 134 
patients were enrolled in the study, the sample size may have been too small to detect 
significant differences at 12 months due to drop-out over time. Patients in the 
intervention and control groups had similar characteristics, except for the fact that 
patients in the intervention group had a higher ejection fraction. It should be noted that 
patients tended to have a low educational level, thus making it difficult to administer 
instruments that measure effectiveness.  
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The analysis showed that patients in the intervention group had a higher level of 
treatment compliance (85% vs. 73.9%), fewer hospital re-admissions (0.56 vs. 1.13), 
fewer days of hospital stay (5.9 vs. 9.6), a higher satisfaction score (9.0 vs. 8.2), and 
similar quality of life than patients in the control group. Comparing intervention costs 
with the costs of hospital stay during one year following hospital discharge, the 
intervention generated savings of 699 € per patient.  
A US cost-effectiveness analysis enrolled 749 adults admitted to a general medical 
service to examine the impact of an intervention designed to minimise hospital 
utilisation within 30 days after discharge 42. The intervention involved patient education 
and discharge planning in hospital by a nurse and post-discharge reinforcement by a 
pharmacist. In this analysis based on a randomised controlled trial, patients and 
providers were not blinded to treatment assignment. Some effectiveness and cost data 
were derived from patient questionnaires, thus raising the potential for recall and other 
biases. 
Patients in the intervention group had fewer hospital visits than patients receiving usual 
care (0.314 vs. 0.451 visit per person per month; p = 0.009), a higher primary care 
follow-up visit rate (62% vs. 44%; p < 0.001), and were more prepared for discharge at 
30 days. With respect to costs of hospital and outpatient visits, the intervention saved 
an average of 348 € per person. The authors did not consider the costs of outpatient 
medication.  
A Dutch cost-effectiveness analysis evaluated an intervention targeted at patients using 
at least five prescribed medicines 39. The intervention consisted of an extensive 
medication review and drug counselling at the patient’s home. Data were derived from 
a cohort study involving 37 community pharmacies and 715 patients. As pharmacies 
were able to choose their assignment to intervention or control group, there is a risk of 
selection bias. Also, intervention and control groups were not comparable: patients in 
the intervention group were younger and had a higher number of prescribed medicines. 
The authors measured changes in medication, mortality and medication costs. Hospital 
re-admission costs were not taken into account. 
More patients in the intervention group indicated that they were (very) satisfied with 
drug counselling by the community pharmacist upon delivery of discharge medication 
(87% vs. 50%; p < 0.001). This was evaluated by sending a questionnaire to patients 6 to 
9 months after discharge. The intervention did not influence discontinuation of drugs 
prescribed at discharge or mortality. Medication costs were reduced by 20.7 € per 
patient. The authors attributed the small impact of the intervention to the unstructured 
character of the medication review (for which pharmacists had not received any specific 
training) and to the fact that the intervention consisted of only one home visit. 
A Belgian cost-effectiveness analysis explored whether the provision of differentiated 
medication information depending on the extent of patient information desire is more 
beneficial for the success of pharmacotherapy, the cost of medical care and the patient’s 
wellbeing in comparison with undifferentiated information supply 76. This hypothesis was 
studied specifically for patients with a major depressive episode at hospital discharge. 
Three interventions were compared: a) undifferentiated information, with patients 
receiving a counselling session with the pharmacist on anti-depressants; b) differentiated 
information, with patients with a high information desire receiving a counselling session 
with the pharmacist on anti-depressants and patients with a low information desire 
receiving usual care; and c) usual care. The study examined the impact of medication 
information on economic parameters (costs of medication consumption, doctor visits, 
productivity loss and hospital readmission), clinical parameters (symptoms and side-
effects), and humanistic parameters (quality of life and patient satisfaction). Some of 
these parameters were repeatedly measured post-intervention; at one month, three 
months and one year following hospital discharge. 
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The analysis failed to demonstrate any impact of medication information on clinical and 
humanistic parameters following hospital discharge. Patients receiving usual care tended 
to have higher costs for some parameters as compared to patients receiving 
(un)differentiated information. The authors acknowledged that the medication 
information intervention may have been too weak to measure changes in clinical and 
humanistic parameters. Also, as researchers contacted patients by telephone to collect 
data on parameters, the researchers in fact carried out an additional intervention, which 
may have influenced results. Finally, the authors stated that their results were in line 
with those of a literature review on the impact of educational interventions about 
medicines for psychiatric patients 78. 
A British cost-utility analysis conducted a model-based economic evaluation of five 
interventions aimed at preventing medication errors at hospital admission from the 
health care system perspective 77. The five interventions were: a) pharmacist-led 
reconciliation; b) standardised forms, pharmacy technicians, hospital policy; c) nurses 
taking histories with standardised form; d) computerised assessment and feedback by 
pharmacist; and e) current medication faxed from the general practice. Each 
intervention was compared with usual care. Data on probabilities, costs and 
consequences were derived from a variety of sources from different countries. Data on 
the reduction in medication errors occurring with an intervention were derived from a 
literature review of non-randomised studies and, thus, can be questioned. In order to 
calculate quality-adjusted life years, the authors made assumptions about utility values 
and expected duration of adverse drug events. 
The results indicated that the five interventions were very cost-effective when 
compared with the baseline scenario: the intervention based on the standardised forms 
and the intervention of nurses taking histories had additional costs of 241 € and 181 € 
per quality-adjusted life year gained, respectively. The three other interventions 
dominated the baseline scenario. The pharmacist-led reconciliation intervention had the 
highest expected net benefits, with a probability of being cost-effective of over 60% at a 
value of 13,000 € per quality-adjusted life year. 
4.4.3 Methodological quality 
Economic evaluations of approaches to improve seamless care focusing on medication 
suffered from a number of methodological limitations (see table 5).   
4.4.3.1 Perspective 
All but one economic evaluation were conducted from the hospital perspective or (part 
of) the health care system perspective. On the one hand, the hospital perspective is 
acceptable as interest in approaches to improve seamless care focusing on medication 
for patients admitted to hospital or patients discharged from hospital tends to focus on 
the impact of interventions on hospital readmissions and costs. On the other hand, the 
hospital perspective is too restrictive as approaches to improve seamless care focusing 
on medication have wider implications on other parts of the health care system, such as 
ambulatory care.  
One study employed a societal perspective and measured indirect costs of productivity 
loss incurred by patients 76. For studies enrolling geriatric patients, the omission of costs 
of productivity loss may not be relevant. However, even in this case, the productivity 
loss of informal caregivers, such as family and friends, needs to be considered.  
Who will pay for the intervention should determine the choice of the study perspective: 
a societal perspective may not be appropriate if an intervention is to be funded by a 
public health care system.  
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Table 5: Methodological quality of economic evaluations to improve seamless care focusing on medication 
Reference Perspective Design Source of data Cost measures Consequence measures Allowance 
for 
uncertainty 
Incremental 
analysis 
Smith, 199737 Health care system Evaluation based on 
prospective 
randomised controlled 
trial 
 
Effectiveness data were derived 
from patient questionnaires and 
expert opinion. Cost data were 
derived from local hospital 
 
Costs of prevented hospital 
admission 
Compliance, counseling required, 
need for pharmaceutical 
domiciliary visit 
No No 
Dudas, 2001 33 Hospital Evaluation based on 
prospective 
randomised controlled 
trial 
 
Effectiveness data were derived 
from patient questionnaires. Cost 
data were derived from hospital 
records 
 
Costs of pharmacist time and 
prevented emergency 
department visits 
Patient satisfaction No No 
Cabezas, 2006 35 Hospital Evaluation based on 
prospective 
randomised controlled 
trial 
 
Effectiveness data were derived 
from follow-up visits by a 
cardiologist at 2, 6 and 12 months 
after discharge. Cost data were 
derived from hospital records 
 
Costs of intervention and 
costs of hospital stay during 
one year after discharge 
Treatment compliance, hospital 
admissions, length of hospital stay, 
quality of life (EuroQol), patient 
satisfaction 
No No 
Jack, 2009 42 Health care system 
 
Evaluation based on 
prospective 
randomised controlled 
trial 
 
Effectiveness and cost data were 
derived from patient 
questionnaires and hospital 
records. 
 
Costs of hospital and 
outpatient visits during 30 
days following discharge 
Number of hospital visits, self-
reported preparedness for 
discharge, rate of primary care 
follow-up visits 
 
No No 
Hugtenburg, 2009 
39 
Outpatient setting Evaluation based on 
prospective cohort 
study 
 
Effectiveness and cost data were 
derived from pharmacy 
information systems and patient 
questionnaires 
 
Medication costs Medication changes, patient 
satisfaction 
 
No No 
Desplenter, 2009 76 Society Evaluation based on 
cohort study 
Hospital and patient self-report Hospital and ambulatory care 
costs, costs of productivity 
loss 
 
Compliance, anxiety symptoms, 
depressive symptoms, somatic 
symptoms, the number of side-
effects, quality of life, patient 
satisfaction 
 
No No 
Karnon, 2009 77 Health care system Evaluation based on 
decision-analytic model 
 
Effectiveness data were derived 
from systematic literature review. 
Error detection rates and cost 
data were derived from various 
sources from various countries. 
Costs of pharmacist time, 
nursing time, forms, 
computerised assessment, 
dissemination of forms. 
Medication errors prevented, 
quality-adjusted life years 
Yes Yes 
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4.4.3.2 Study design 
All but one study evaluating the cost-effectiveness of approaches to improve seamless 
care focusing on medication carried out an economic evaluation based on a randomised 
controlled trial 33 , 35 , 37 , 42 or a cohort study 39 , 76. Investigating the cost-effectiveness of 
treatment alternatives in a trial setting provides a degree of internal validity. However, it 
is challenging to carry out a randomised controlled trial in this domain, and blinding of 
patients and health care professionals is difficult to achieve. Moreover, the sample size 
of the trial included in some economic evaluations was not large enough to be able to 
find statistically significant differences in costs 35 , 37. Economic evaluations based on 
cohort studies were designed to reflect real-world practices, but may be subject to a 
number of biases. 
One study used a modelling approach to assess the cost-effectiveness of approaches to 
improve seamless care focusing on medication (i.e. a model-based economic evaluation) 
77. However, due to the lack of published data, this economic evaluation had to derive 
model inputs from a variety of sources from different countries and had to make a 
number of assumptions. To address uncertainty surrounding model inputs, the authors 
conducted extensive sensitivity analyses. 
4.4.3.3 Costs and consequences 
Economic evaluations were limited in the scope of costs considered. Studies generally 
measured health care costs associated with approaches to improve seamless care 
focusing on medication37 ,42 ,76 ,77, although some analyses were restricted to hospital 
costs only 33,35. A number of studies did not take account of the costs of the 
intervention itself when calculating overall costs (or savings) arising from approaches to 
improve seamless care focusing on medication 37 , 39 , 42 , 76.   
A variety of consequence measures were used in cost-effectiveness analyses. Some 
measures were related to intermediate consequences (e.g. appropriateness of medicine 
regimens, patient treatment compliance) rather than final consequences (e.g. mortality 
rate). As studies employed multiple consequence measures but did not combine them 
into a single index, it was not possible to get an idea of the overall cost-effectiveness of 
approaches to improve seamless care focusing on medication. Therefore, it is 
impossible to compare the cost-effectiveness of approaches to improve seamless care 
focusing on medication with the cost-effectiveness of interventions for other diseases 
that are expressed in terms of generic measures such as the cost per life-year gained. 
The exception was the cost-utility analysis which expressed results using the generic 
measure of the cost per quality-adjusted life year gained 77. 
In general, economic evaluations measured costs and consequences over a limited time 
horizon, with a maximum follow-up period of one year. 
4.4.3.4 Allowance for uncertainty and incremental analysis 
Only one economic evaluation of approaches to improve seamless care focusing on 
medication allowed for uncertainty77. Studies need to conduct a sensitivity analysis to 
account for uncertainty around key estimates and assumptions made during the 
identification, measurement and valuation of costs and consequences. Only one study 
presented results in terms of an incremental cost-effectiveness ratio of patients 
participating in an approach to improve seamless care focusing on medication as 
compared with patients who do not receive such an intervention77.  
None of the economic evaluations discussed the transferability of results to other 
settings or countries. Two economic evaluations enrolled patients who use multiple 
medications39 or are likely to experience difficulties with their medication37. Therefore, 
the transferability of their results to other populations is limited because these studies 
enrolled those patients who are most likely to benefit from an approach to improve 
seamless care focusing on medication. In multiple economic evaluations, cost estimates 
originated from a single centre 33,37,42.  
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As these costs are specific to a centre, results are unlikely to be transferable to other 
centres or countries. Similarly, results may depend on whether hospital costs are 
derived from an academic versus acute hospital or from an inner-city versus rural 
hospital. 
4.5 DISCUSSION 
This literature review has summarized the evidence about economic evaluations of 
approaches to improve seamless care focusing on medication. Three studies have 
detected higher or similar treatment compliance among intervention patients after 
hospital discharge. All but one study concluded that the intervention reduced hospital 
re-admissions. In general, patients in the intervention group were more satisfied than 
patients in the control group. In studies that analysed an effect on clinical status, no 
impact of the intervention was recorded on depressive symptoms, whereas results on 
the impact on quality of life were conflicting. Studies indicated that approaches to 
improve seamless care focusing on medication were associated with cost savings, 
although the scope of cost analyses tended to be limited. 
The international literature on the cost-effectiveness of approaches to improve 
seamless care focusing on medication was made up of studies conducted in Europe and 
the USA. The results of these studies should be interpreted with care when assessing 
their relevance to Belgium. This is because the patient population, the range of 
medicines and medicine problems are not necessarily the same in these countries. 
Moreover, the funding, organisation, regulation and content of approaches to improve 
seamless care focusing on medication vary widely between countries. 
Economic evaluations of approaches to improve seamless care focusing on medication 
suffered from a number of methodological limitations relating to the narrow 
perspective; focus on health care costs only; exclusion of costs of the intervention; use 
of intermediate consequence measures; no allowance for uncertainty; and absence of 
incremental analysis. As these limitations are not inherent to the techniques of 
economic evaluation, but arise from the sub-optimal design of existing studies, more 
attention needs to be paid by researchers to the design of their studies. Therefore, a 
number of avenues are proposed for designing future economic evaluations of 
approaches to improve seamless care focusing on medication: 
• There is a need for more, better-designed and comprehensive trial-based 
economic evaluations. Studies need to be carried out that collect primary 
data on cost-effectiveness. Additionally, this review has underlined the 
importance of considering all relevant consequences in a single index. A case 
can be made in favour of cost-utility analyses that count the number of years 
of survival and adjust life expectancy for the impact of the intervention on 
quality of life. There is a need to carry out research and collect data on 
quality adjustments in the domain of approaches to improve seamless care 
focusing on medication. Alternatively, researchers may opt to conduct a cost-
benefit analysis, although assigning monetary values to health benefits is 
controversial and further work on methods that value health benefits needs 
to be carried out. 
• Studies need to provide sufficient details of the approach to improve 
seamless care focusing on medication. There is scope to improve the 
description of the intervention by reporting in more detail information about 
the recipients of the intervention, the settings in which the intervention is 
delivered, the various activities that make up the intervention, and the 
person(s) who administer the intervention. Uniform education and training of 
health care professionals who carry out the intervention on the content of 
the care to be provided may also contribute to delivering a standardized 
intervention. Researchers also need to consider the impact of programme 
factors (e.g. level of expertise of the health care professionals delivering the 
intervention) on the cost-effectiveness of the intervention.  
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• Studies need to select their perspective in terms of who will pay for the 
approach to improve seamless care focusing on medication and identify, 
measure and value relevant costs and consequences according to this 
perspective. Also, the cost of the intervention needs to be subtracted from 
any cost savings with a view to assessing the net cost impact of the approach 
to improve seamless care focusing on medication. 
• Studies need to account for uncertainty surrounding key estimates and 
assumptions relating to costs and consequences. Economic evaluations 
drawing on patient-level data can account for uncertainty by carrying out a 
sensitivity analysis. Alternatively, the non-parametric approach of 
bootstrapping can be considered to incorporate uncertainty around the point 
estimate of the incremental cost-effectiveness ratio. Bootstrapping is a 
method that is used to obtain the empirical sampling distribution of the 
incremental cost-effectiveness ratio and construct a confidence interval 
around this ratio.   
• Studies need to discuss the transferability of their findings to other settings 
and to other countries. 
Key points 
• This chapter reviews the international literature on the cost-effectiveness of 
approaches to improve seamless care focusing on medication. 
• The selection of articles focused on medication interventions for hospitalised 
patients in the transition between ambulatory and hospital care. A variety of 
types of medication interventions and target populations have been 
assessed, but the evidence is limited to one economic evaluation for each 
particular intervention type and each specific target population. 
• Most studies demonstrated an impact of interventions on compliance and 
(re)hospitalisation rates and costs. 
• Economic evaluations suffered from methodological limitations relating to 
the narrow perspective; focus on health care costs only; exclusion of costs of 
the intervention; use of intermediate consequence measures; no allowance 
for uncertainty; and absence of incremental analysis. 
• In light of the small number of economic evaluations and their 
methodological limitations, it is not possible to recommend a specific 
approach to improve seamless care focusing on medication on health 
economic grounds. 
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5 GREY LITERATURE: FOREIGN COUNTRIES 
5.1 RESEARCH QUESTIONS 
The aim of this part is to describe and analyze seamless care initiatives that have been 
implemented in 7 selected countries (Australia, Canada, Denmark, France, The 
Netherlands, UK, US) at regional or national levels. The final outputs are: 
• an overview of implemented initiatives (at national or regional levels) that aim 
at improving continuity of care focusing on medications;  
• a synthesis of the factors contributing to the success and failure of these 
systems (critical success factors); 
• a discussion of their applicability to the Belgian setting. 
The interested reader will find a detailed description of all initiatives in appendix 3. 
5.2 METHODOLOGY 
5.2.1 Selection of countries 
The 7 countries were selected for the following reasons:  
• the systematic review of the international literature gave information on 
previous or current regional or national initiatives on seamless care; 
• and/or the authors or experts reviewing report had personal knowledge of 
one or several national initiatives; 
• and/or close location to Belgium.  
5.2.2 Data sources and methodology 
For each country the authors performed a structured search of relevant websites 
(scientific, professional and political organizations) and other sources of information 
found during the systematic literature review. 
In a first round, a list of the titles and sources of relevant information were shared with 
experts identified in each country (health care professionals or researchers involved in 
seamless care projects, see list in appendix 3). These experts were asked (a) to confirm 
that the information represented a regional or national initiative to improve seamless 
care in their country; (b) to list additional sources of information (internet or paper-
based) to be considered given the objectives of the project.  
In a second round, a structured description of the initiatives implemented in each 
country was performed based on a standardized collection form (see appendix 3). The 
native experts were asked to validate the information that had been extracted. The 
characteristics of the healthcare systems in the respective countries were first 
summarised using the respective Health System Profiles (accessible at 
http://www.euro.who.int/observatory/Hits/TopPage), except for the US VA system 
(http://www4.va.gov was used) and completed with information from the experts. 
5.3 RESULTS  
The full list of websites as well as the general descriptions of the healthcare systems of 
the countries selected can be found in appendix 3.  
For the US, many initiatives were identified, but an important proportion was similar to 
those implemented in other countries whose health care system was closer to the 
Belgian system. Therefore for the US, the authors describe only two initiatives relevant 
to the purpose of the study and not described in the other countries selected. 
Table 6 gives an overview of the characteristics of the health care systems of the 
countries in relation to seamless care.   
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5.3.1 Overview of the healthcare systems, in relation with seamless care focusing on medications 
Table 6: Overview of the healthcare systems, relative to seamless care focusing on medications 
Characteristics Australia Belgium Canada Denmark France Netherlands UK (England) US (VA system) 
Ambulatory care         
Patients bound to one GP 
practice 
No 
No 
No obligation Yes 
 
Yes Yes 
Yes  
GP acts as gatekeeper for 
access to hospital care1 
Yes 
Partially 
Yes Yes 
 
Yes Yes 
Yes  
Patients bound to one 
community pharmacy 
No 
No 
No No 
 
No No 
No 
Fee for community pharmacists 
to provide patient counselling 
Yes2 
Partially6? Yes 
(province- 
dependant) 
No 
 
Yes4 Yes4 
No 
Acute care         
Home medicines brought to 
hospital 
No obligation 
No obligation 
Yes Not routine 
 
No obligation Yes 
No 
Home medicines used in 
hospital 
No 
No 
(forbidden) 
No Not routine 
 
No Yes 
No 
Clinical pharmacy: standard 
care 
Yes3 
No 
Yes No 
No 
Yes Yes 
Yes 
Drug history taking on 
admission: who 
Pharmacist or 
doctor or nurse 
sometimes pharmacy 
technicians 
Doctors or 
nurses; clinical 
pharmacists in 
pilot projects 
Pharmacist or 
doctor 
(student) 
or nurse; 
sometimes 
pharmacy 
technicians 
Doctor or 
nurse; no 
pharmacy 
technicians 
Doctors or 
nurses 
Community 
pharmacist, 
pharmacy 
technician 
Pharmacist or 
doctor (student) 
or nurse; ; 
sometimes 
pharmacy 
technicians 
hospital staff 
(medical, nursing 
and pharmacy) 
Providing information to 
patients on medications upon 
discharge: who 
Pharmacist or 
doctor or nurse 
Doctors or 
nurses; clinical 
pharmacists in 
pilot projects 
Pharmacist 
Doctor or 
nurse 
Doctor or 
nurse Depends on 
local situation 
Hospital staff 
(included 
pharmacist)  
Providers, nurses, 
pharmacists, and 
pharmacy 
technicians 
Information relative to 
medications sent to GP at 
Yes 
Yes Sometimes 
but  
Yes 
Yes 
Yes Yes 
Yes  
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discharge not 
systematic 
Information relative to 
medications sent to community 
pharmacist at discharge 
Rarely;  
pilot programs 
No Sometimes 
but  
not 
systematic 
No 
No 
Yes Yes 
No 
Medication supply at discharge Short supply 
Supply allowed 
for a 
maximum of 3 
days 
No Not always 
 No, a 
prescription 
is sent to the 
community 
pharmacist 
Yes5 Yes 
Miscellaneous         
IT platform to exchange data 
on medications between 
settings of care 
No 
No 
Yes in some  
provinces 
Yes 
No (in 
development) 
In 
development 
In development Yes  
         
Abreviations: GP : general practitioner; IT: information technology; UK: United Kingdom; US: United States; VA: Veterans Affairs.  
1Unless in the case of some emergency admissions, or referral by community treatment team (e.g. mental health team); 2Pharmacists are paid a dispensing fee for each 
prescription they dispense. This dispensing fee is paid to cover the professional duties of a pharmacist, including providing counselling; 3Clinical pharmacy is standard care in 
large tertiary referral public hospitals, but may be limited in private and smaller hospitals; 4 only for medication usage review, 5 original pack dispensing (mostly for 1 month), 
unless duration specifically stated; 6 Since April 1, 2010 pharmacists’ fee per drug dispensed is partially based on basic pharmaceutical care activities 
 
KCE  Reports 131  Seamless care 43 
 
5.3.2 Australia  
Since 1998, Australia developed several national and regional initiatives to optimize the 
continuity of care focusing on medications. 
5.3.2.1 Guidelines of national pharmacist associations for continuity of care focusing on 
medications 
In 1998, the Australian Pharmaceutical Advisory Council developed national guidelines 
to achieve quality in the continuum of medicines’ use between hospital and community 
(1). These guiding principles, adapted in 2005 79, offer a system approach to medication 
management i.e. they advocate a consistent and standard approach across all health care 
settings and health care providers. Ten guiding principles were identified:  
1. Leadership for medication management;  
2. Responsibility for medication management;  
3. Accountability for medication management;  
4. Accurate medication history;  
5. Assessment of current medication management;  
6. Medication Action Plan;  
7. Supply of medicines information to consumers;  
8. Ongoing access to medicines;  
9. Communicating medicines information;  
10. Evaluation of medication management. 
There is an expectation that all stakeholders involved in the continuity of medication 
management should implement those principles by aligning standard operating 
procedures and assigning responsibilities according to ability, skills and competence. 
However, the implementation of the Guiding Principles is a challenge, in particular to 
define who has the responsibility to initiate, follow up and maintain the implementation. 
To our knowledge, a comprehensive analysis of the uptake of the guiding principles has 
not been performed, and recent data on their impact are missing.  
5.3.2.2 National standardized inpatient medication chart to enhance the completeness 
of information on medications 
In a system-based approach to minimize the risk of adverse drug events, the Australian 
Health Ministers stated in 2003 that all public hospitals would use a common medication 
chart by June 2006. This means that the same chart is used for a given patient, by 
doctors and nurses, in any hospital. In the same reform agenda, the recommendation 
for a process of pharmaceutical review of prescribing, dispensing, administration and 
documentation processes for medication use was also formulated for Australian public 
hospitals by December 2006 80.  
Following these statements, the National Inpatient Medication Chart (NIMC) was 
developed by a national working party of the Australian Council for Safety and Quality 
in Healthcare. The form was pilot tested in 31 hospitals, and is now implemented in 
almost all hospitals throughout the country (see Appendix 3). Although primarily 
designed for in-hospital use, the chart supports medication management at transition 
moments and has increased the awareness of medication safety issues.  
Future steps will include the development of a paperless system. 
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5.3.2.3 Transition care programs with limited focus on medications 
Currently, there seems to be a blurring of boundaries between hospital care and 
community care in Australia. Programmes as “hospital in the home” and other early 
hospital discharge strategies (e.g. having a discharge nurse) are now implemented. One 
of these programmes, the “transition care program”, is a form of flexible care provided 
to older persons at the end of an inpatient hospital episode, in order to complete the 
care recipients’ restorative process, optimize their functional capacity, and assist them 
and their families to make long term arrangements for care. Although medication 
management is one of the elements mentioned in the transition care program, there is 
limited evidence from the evaluation that medication review or medical assessment was 
part of the care program 81. 
5.3.2.4 Home Medicine Review and Patient Medication Profile: two initiatives for 
outpatients involving community pharmacists 
Home Medicine Review by community pharmacists 
Within the framework of ‘Home Medicines Review’ (HMR), GPs can refer their patients 
to their nominated community pharmacy to have an HMR performed within four weeks 
post discharge. HMR is a patient-focused, structured and collaborative health care 
service provided in the community setting, to optimise quality use of medicines and 
patients’ understanding. It involves the patient, his/her GP, his/her community 
pharmacist, and other relevant members of the health care team. Target groups of 
patients are (among others): 1) patients with at least five regular medications; 2) 
patients taking more than twelve doses of medication per day; 3) patients recently 
admitted to a facility/hospital (in the last four weeks); 4) patients with significant changes 
made to medication treatment regimen in the last three months; 5) patients on 
medication with a narrow therapeutic index or requiring therapeutic monitoring; 6) 
patients suspected of non-compliance or not managing medication-related therapeutic 
devices. 
An HMR consists of a home visit of an accreditedb pharmacist (who can be different 
from the community pharmacist) to the patient, in order to identify any medication 
related problems, including underuse, overuse, adverse events, compliance and 
knowledge problems, or hoarding. Upon analysis, the pharmacist writes a report which 
is discussed with the physician. It is therefore much more comprehensive than making a 
medication profile (see below). The physician is finally responsible for developing the 
medication management plan, communicating this to the patient and for follow-up 82. 
Australia has funded HMR services since 2001 and so far more than 230.000 
collaborative medication reviews have been provided across the country, with 
approximately 12.000 medication reviews provided per quarter 83. Unfortunately, there 
are no specific data on the number of HMRs that have been performed post discharge. 
Considering the impact of HMR post discharge, one study showed that the review 
significantly reduced the number of drug-related problems 90 days post discharge. 
Unplanned readmission rates within 90 days post-discharge were also significantly lower 
for the intervention group versus the control patients and self-reported compliance was 
significantly better in intervention patients 84. 
                                                     
b  The HMR service can only be provided be a pharmacist who is accredited. The accreditation process 
assesses competence in clinical pharmacy, therapeutics, 
 pharmaceutical care and medication review. Pharmacists must be reaccredited every three years.  
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Patient Medication Profile 
Since 2005, pharmacists in Australia also get funding when producing a Patient 
Medication Profile (PMP), a comprehensive written summary of all medications taken by 
a patient. The purpose is to help patients to manage their medications at home, and to 
ensure that all HCPs can have access to an accurate medication history. A request for a 
PMP may be made by the patient or by another member of the health care team, usually 
upon consent of the patient. When producing the PMP the community pharmacist 
makes an appointment for an interview with the patient and requests the patient to 
bring all his medications with him to the pharmacy. Apart from the medication details, 
information recorded in a PMP includes medication allergies and adverse drug reactions 
as well as patient, prescriber and pharmacy details 85.  
5.3.2.5 MediConnect and HealthConnect: e-Health initiatives to improve 
communication on medications 
Systems to improve the sharing of medication information between patients and various 
healthcare providers through a shared electronic medical record have been developed 
and funded by the Australian Government since 2002. One of these initiatives, the 
MediConnect program, aims to allow consumers to give their consent to different 
HCPs for the access and, when necessary, record of information in a shared medication 
record. A secure national electronic system was pilot tested successfully in two sites in 
Victoria and Tasmania in 2003. In 2004 the MediConnect program was incorporated 
within the wider HealthConnect program. HealthConnect is an ongoing partnership 
between the Commonwealth and State and Territory governments to facilitate sharing 
of health information electronically. HealthConnect implementation aims to leverage 
existing eHealth projects and infrastructure, and progress towards compliance with 
National e-Health Transition Authority (NEHTA) and other nationally agreed standards 
to improve the availability of information in the health sector. Systems for electronic 
sharing of patient health information, including medication information, between 
different settings are currently under development and evaluation in various states 86.  
The National eHealth Strategy (December 2008) outlines a national approach to 
electronic prescription transfers and medication management. By 2012 every Australian 
should be able to have a personal electronic health record that he/she will at all time 
own and control. When implemented, a person’s individual electronic health record will 
include a list of the current medications. This information may help to reduce adverse 
events, improve service delivery and ensure that consumers do not have to remember 
or repeat information as they navigate across the health care system. The system will 
also enable a full-scale national electronic prescribing and dispensing implementation 87.  
5.3.3 Canada 
Several national and regional initiatives around seamless care focusing on medications 
have been implemented over the last 10 years in Canada. 
5.3.3.1 Workshops and guidelines on continuous care programs by national 
pharmacists associations  
At the national level, the Canadian Society of Hospital Pharmacists and the Canadian 
Pharmacists Association have had a joint Task Force on seamless care for several years. 
This Task Force studied barriers to seamless care in Canada and searched out models 
and tools that would enhance patient care 88 , 89 , 90. 
In 2003 the Canadian Pharmacists Association published a pharmacist’s guide on 
continuous care programs. This is a comprehensive and practical source of information 
on (a) how to develop and evaluate seamless care initiatives, (b) how to overcome 
barriers to seamless care, (c) documentation and technology requirements, (d) patient 
privacy and confidentiality issues 3. It seems that this guide has been widely used, but its 
effect on practice has, to our knowledge, not been documented.  
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5.3.3.2 Safer Health Care Now! Implementation of medication reconciliation at 
national level 
The most important and comprehensive national initiative is the Safer Health Care 
Now! (SHN!) Campaign launched in April 2005. Mirrored after the Institute for 
Healthcare Improvement's 100,000 Lives campaign in the U.S., SHN! is an ambitious 
pan-Canadian patient safety campaign to implement six targeted interventions in health 
care organizations that have been proven to prevent avoidable adverse events 
(http://www.saferhealthcarenow.ca). One of these interventions focuses on medication 
reconciliationc.  
Medication reconciliation will not be achieved using a single specific model. It must be 
tailored to fit the organisation or system, considering human resources, patient 
population, current admission process, culture of staff, etc. Therefore, the campaign 
focuses on sharing Canadian experiences on the use of medication reconciliation with 
the goal of reducing potential adverse outcomes of patient care related to medication 
therapy. More than 300 acute care teams are currently enrolled in the campaign, and 
the majority of them actively report data to the Central Measurement Team (using a set 
of core measures). The results of the national data compounded by the Central 
Measurement Team show a substantial decrease in the number of medication 
discrepancies on admission to hospital 91 , 92 , 93 , 94 , 95.  
Critical success factors include national leadership and support, for example by 
connecting and sharing the work of local teams, by running teleconference national calls, 
workshops and conferences to educate teams. Also the fact that Accreditation Canada 
requires all Canadian hospitals to do medication reconciliation has boosted the 
implementation of medication reconciliation. Many teams have moved toward sustaining 
medication reconciliation on admission and are now earnestly focused on transfer 
within the hospital and hospital discharge. The Campaign is now being extended to 
medication reconciliation in ambulatory care, homecare and long-term care.  
5.3.3.3 MedsCheck and SHN!: province-wide initiative involving community pharmacists 
in medication reconciliation 
In 2008, ISMP Canada developed and delivered a pilot program in Ontario to link the 
community-based MedsCheck d  program with the SHN!-led medication reconciliation 
programs in hospitals to streamline the medication reconciliation process in the pre-
admission clinic for planned surgical admissions 96. The goal of this collaborative initiative 
between hospitals and community pharmacists was to improve the medication 
reconciliation process for elective surgery patients by asking patients to obtain a 
MedsCheck from community pharmacists prior to their pre-admission clinic 
appointment. Leadership and support were present, similarly to the SHN! Campaign. 
However, the initial results were somewhat disappointing, as the MedsCheck quality 
was not consistent and at a professional standard. An important next step for moving 
this initiative forward consists therefore of teaching community pharmacists a 
systematic process for completing MedsCheck at the highest possible level.  
                                                     
c  Medication reconciliation is a formal process of: 
 (1) obtaining a complete and accurate list of each patient’s current home medications – including name, 
dosage, frequency and route, 
 (2) using that list when writing admission, transfer and/or discharge medication orders, and 
 (3) comparing the list against the patient’s admission, transfer, and/or discharge orders, identifying and 
bringing any discrepancies to the attention of the prescriber and, if appropriate, making changes to the 
orders. Any changes in orders are documented.  
d  The MedsCheck is a one-to-one pharmacist consultation with patients taking three or more prescription 
medications for approximately 30 minutes once a year, to help them comply with their prescription 
medications and better understand how the medications interact with each other and other over-the-
counter medication they may be taking 
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5.3.3.4 Canada Health Infoway: national workforce to accelerate the use of electronic 
health records 
Canada Health Infoway is an independent, not-for-profit organization funded to 
accelerate the use of Electronic Health Records in Canada 97. It has been created by the 
federal government, in collaboration with the provinces and territories, health care 
providers and technology solution providers.  
Among ten investment programs, the Drug Information Systems (DIS) investment 
program supports jurisdictional projects that will result in interoperable systems to 
enable authorized health care providers to access, manage, share and safeguard patients’ 
medication histories. Implementation and evaluation is ongoing 97.  
5.3.4 Denmark  
5.3.4.1 National infrastructure for electronic medication profiles 
Since 2004, the Electronic Medicine Profile (EMP) has been implemented in the Danish 
health care system 98 The EMP is an electronic overview of the dispensation of 
prescription medications from community pharmacies (OTC medicines are not 
registered) 99. All items dispensed are automatically registered and gathered in an 
individual, personal medical profile for every citizen 99. The Danish Medicine Agency 
(DMA) is responsible for this secure system. Citizens can access the EMP via a common 
health public electronic portal (the National eHeatlh portal) or via the website of DMA 
100. Physicians and community pharmacists can also access the EMP, without and with 
patient consent respectively 100. EMP has been shown to improve the completeness of 
medication history at admission, but also its weaknesses as a unique source of 
information. Indeed, one study showed that on average 27% of prescribed medication 
registered in EMP during the month preceding hospital admission was not reported by 
the patient and/or in hospital files. This may be due to patient recall bias, but can also 
point towards non-adherence or discontinuation of therapy, which should be taken into 
account when designing a medication plan 63. Another weakness of the EMP is the non 
registration of medications prescribed in the hospital setting (i.e.: medication delivered 
by the hospital pharmacy for inpatients as well as outpatients, such as chemotherapy).   
A new initiative, called “The Common Medication Card” (FMK in Danish) is therefore 
being nationally implemented since the beginning of 2010 101. It aims to provide to 
patient and healthcare professionals an accurate and updated current patient medication 
list (including information e.g. on dose, time of intake) at hospital admission and at 
hospital discharge. The objective is to share the medication information between the 
hospitals’ medication systems, GP systems and personal medication profile 101.  
5.3.5 France 
Two national initiatives, still in a pilot phase, were selected.  
5.3.5.1 The pharmaceutical file  
The pharmaceutical file (“dossier pharmaceutique”) is a shared electronic file which 
allows pharmacists – after patient consent – to record and check information on 
prescribed and non-prescribed medications delivered over the last fourth months 102. 
This initiative was developed and promoted by l’Ordre des Pharmaciens Français. It has 
been nationally implemented in the primary care setting since the end of 2008. 
Perspectives are currently to extend the use of the pharmaceutical file to the hospital 
setting. The results of the first pilot phase should be available in February 2011103.  
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5.3.5.2 High 5s project 
At the end of 2009, the French National Authority for Health, an independent public 
body, decided to engage French hospitals in the international High 5s project initiated by 
the WHO. The Mission of the High 5s Project is to facilitate implementation and 
evaluation of standardized patient safety solutions within a global learning community to 
achieve measurable, significant and sustainable reductions in challenging patient safety 
problems. It is a patient safety collaboration among a group of countries and the WHO 
Collaborating Centre for Patient Safety in support of the WHO Patient Safety 
Programme 104. Several standard operating procedures (SOP) are being developed by 
these countries and one of them relates to medication reconciliation at patient 
transition developed by Canada (via the Canadian Patient Safety Institute) 105. A national 
project related to this SOP was launched in France at the end of 2009. Educational 
support will be provided at national and regional level. Ten hospitals have been 
recruited to implement this SOP over the next five years 106. 
5.3.6 The Netherlands  
One national project aims at an overall implementation of medication management 
initiatives. This project started from guidelines developed by the inspection of health, 
and is coordinated through different working groups and parties. A description of the 
different key elements and characteristics of this project is given below. 
5.3.6.1 A guideline on transfer of medication 
In the Netherlands, a national guideline about transfer of medication was developed by 
the inspection of health care in 2005. This guideline states that by 2011 a list of the 
current medications will have to be available any time at each point of prescribing. The 
medication list will have to be completed within 24 hours of admission to the 
emergency department and upon transfer between settings of care. The implementation 
of this guideline will be controlled by the inspection of healthcare from 2011 onwards.  
5.3.6.2 Management of a large national project to implement the guideline 
At the national level the implementation of the guideline is led and managed by a 
steering committee. This steering committee includes representatives of business 
organizations, professional organizations (pharmacists, hospital pharmacists, nurses, 
hospitals, nursing homes, general practitioners, specialists, home nurse care, IT 
specialists), patient organizations, and the government. Specific groups are responsible 
e.g. for the legal framework, the development of tools for medication management.  
5.3.6.3 Local projects 
Health care professionals work on specific subprojects in order to implement the 
guideline at local and regional levels. Hospital pharmacists and pharmacy technicians are 
the main driving forces of these projects. They work in collaboration with specialized 
physicians, general practitioners, dentists, community pharmacists, hospital nurses and 
home nurses, as a broad range of transitions is concerned.  One example is the 
implementation of pharmacotherapeutic consultations by the inpatient pharmacy 
department at an orthopaedic ward, where a pharmacy technician collects a list of the 
outpatient medication from the community pharmacy and discusses this with the 
patient. Having shown, in a pilot project, error rates of 72% in medication lists obtained 
in common practice, the procedure for pharmacotherapeutic consultations was 
standardized and implemented.  
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5.3.6.4 Electronic patient file enhances the implementation of the national guideline 
In 2009, the government voted in a law that regulates the obligatory use of an 
electronic patient file by health care professionals (general practitioners, pharmacists 
and specialists). If the patient consents, the aforementioned health care professionals 
will have  access to the complete list of medication,  including medications prescribed in 
the hospital, contra-indications, intolerances, allergies, reasons for prescribing, clinical 
status and lab results. On this moment, a limited number of hospitals are working with a 
computerized system and the transition of medication between community pharmacy 
and hospital pharmacies is organised by an electronic system. It is expected that the 
availability of a nationwide electronic patient file will facilitate the implementation of the 
guideline. 
5.3.6.5 Sensitisation and education 
In line with the implementation of the guideline, campaigns are organized to inform all 
stakeholders, professionals as well as patients, on the necessity and benefits of safe 
medication transfer. Specific for HCPs, there is a book published about transition of 
medication; one part of this book consists of a checklist that can be used to guide the 
implementation process. For pharmacy practitioners, e-learning modules on admission 
and discharge conversations, including video fragments, are available. 
The process of implementation is further supported through a specific website, 
www.medicatieoverdracht.nl, where all developments, successes and failures are 
discussed. More details on this large implementation project can be found in the tables 
in appendix 3.   
5.3.6.6 Results 
National data on the impact of these initiatives has not been found. A lot has been 
published, however, on local initiatives, either in internal reports or local papers. 
Overall, the results show that there is a significant reduction in errors in medication 
histories on admission by the implementation of a standardized medication 
reconciliation procedure (17-96%). The reports mention that medication management 
initiatives lead to more quality, efficiency and patient satisfaction. The most important 
barriers for implementation are the lack of manpower and the changes needed in the 
current working procedures. IT support is mentioned as a necessary tool, and the lack 
of effective systems limits the development of medication management 107. 
5.3.7 United Kingdom  
5.3.7.1 National guidelines relative to continuity of care focusing on medications 
In 2006 a group of national pharmacy organizations published the guidance “moving 
patient, moving medicines, moving safely” 108. It aimed to review medication problems 
during transfer of patients between different healthcare settings, to develop strategies 
and standards based on best practice and available evidence, and to make 
recommendations to reduce the risks of incidents with medicines for patients moving 
between different settings of care, in particular patients being discharged from acute 
hospitals. 
The National Institute of Clinical Excellence (NICE) also published two guidelines to 
improve seamless care in medication management in 2007 and 2009 109 , 110. The 2009 
guideline was on medication adherence but also addressed communication between 
HCPs. All healthcare professionals working in the NHS must apply these guidelines. 
One focuses on recommendations to develop medication reconciliation at hospital 
admission 109. The other looks at patient involvement in decisions about prescribed 
medicines 110. One section of this guidance relates to information for patients and 
healthcare professionals (HCP) when patients are transferred between services and 
settings of care.   
 
50  Seamless care KCE Reports 131 
For example, it is stated that, when patients are transferred between settings of care, 
there should be for all patients and subsequent HCPs a written report containing the 
patient's diagnosis and a list of all medications, clear identification of medicines that 
were started/stopped and reasons for this, clear information on which medicines should 
be continued and for how long, any known adverse reactions and allergies the patient 
has experienced, any potential difficulties with adherence. Other recommendations are 
more innovative and relate, for example, to patient involvement in decisions and 
establishment of the most effective way to communicate with each patient.  
5.3.7.2 National audits to identify opportunities for improvement 
The Care Quality Commission (CQC) conducts independent inspection to ensure 
quality of different aspects of the National Health Service in England/Wales, on 
medicines management in hospitals 111 , 112 , 113 , 114 and on the management of patients’ 
medicines after discharge from hospital 115.  From 2001 onwards, several reports 
identified key initiatives required to modernise medication management, of which 
several were part of the NICE guidelines. In addition, various indicators for high quality 
medicines management were developed, including some indicators that relate to 
seamless care. Examples include: the existence of joint formularies between primary and 
secondary care, use of patients’ own medicines and self-administration by patients or 
carers during hospital stay, medication review on admission by hospital staff, patient 
information on their medicines prior to discharge, quality of information received at 
discharge by GPs and community pharmacists, GPs processes for medicine 
reconciliation and medication review after discharge, availability of other processes than 
GP medication review to support patient medication adherence (ie. commissioned 
pharmacist or nurse in primary care trusts –PCTs- or medication review by an 
accredited community pharmacy)  and monitoring of processes by PCTs.  
The first report – “A spoonful of sugar” - reviewed medication management in hospitals 
in 2001 111 The audit was conducted in 197 out of 199 NHS acute trusts in England and 
Wales. Another report – “The best medicine – management of medicines in acute and 
specialist trusts” – was released in 2005/2006 114. It addressed the same topic and 
reported national findings, including a description of progresses made since 2002. All 
acute trusts received a personalized feedback from the CQC on their performance in 
the implementation of initiatives to modernise medication management, a guide to 
explain indicators and how conclusions about performance should be drown from them 
114.  
Based on this report, CQC made a set of specific recommendations, and also 
recommended that many background activities such as writing shared care agreements 
and developing information for patients are applicable across trusts and are made more 
efficient and effective through national initiatives developed by national organizations 114.  
The last CQC report was published in 2009 and addressed the assessment of the 
management of patients’ medicine after discharge by Primary Care Trust (PCT) 115.  
Twelve PCTs were followed up for this project. The CQC saw some evidence of good 
practice to ensure seamless care through the medication reviews for high risk patients 
following hospital discharge by GPs, but also identified some problem areas (for 
example poor completeness and effectiveness of information shared between primary 
and secondary care, lack of routine review of new medications by GPs with patients 
after discharge, ...) 115. 
From April 2010, all PCTs and acute trusts will be required by law to register with 
CQC and must meet a new set of standards (different for both groups). Effective 
management of medicines will be a requirement of registration, and CQC will take 
action where trusts fall short of meeting this 116. 
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5.3.7.3 The Standard Contract: legal national incentives to improve continuity of care 
Finally, the existence of a legal national incentive to improve continuity of care in 
England/Wales is an interesting initiative. Since April 2008, PCTs and other NHS 
healthcare providers (i.e. acute NHS trusts) must sign a contract that aims to improve 
the performance of healthcare 117. The Standard Contract supports the achievement of 
key standards and targets. Processes for identifying and seeking to remedy performance 
problems should be clearly defined in the Contract. Initial failures are not penalized, but 
financial sanctions are applied for failing to remedy a performance failure 117. With 
regard to seamless care, the new standard contract for NHS-funded hospital care sets 
out specific mandatory obligations to share discharge summaries with a patient’s GP 
within 72 hours of discharge, and to include a summary of diagnosis and details of any 
medication prescribed at the time of the patient’s discharge. PCTs can implement 
financial incentives within their local discharge protocol to stimulate the implementation 
of these obligations, and can fall back upon penalties if needed 115. 
5.3.7.4 NHS connecting for health initiative 
NHS Connecting for Health is an initiative developed to support the NHS in providing 
better, safer care, by delivering computer systems and services that improve how 
patient information is stored and accessed 118. Interesting parts of this initiative that 
could improve continuity of care in medication management are the progressive 
implementation of the Summary Care Records (SCR) and a personal health record 
called Healthspace. NHS is gradually introducing SCRs across England. It will be available 
to people providing patient with care anywhere in England. Patients’ SCR will contain 
important information about their health, such as details of any allergies, current 
prescriptions and whether they have had any bad reactions to medicines. Data could be 
updated by HCPs each time patients use any NHS health service. HCPs will ask patient 
permission each time they need to look at information in their SCR 119, and patients can 
discuss what is being added and how sensitive information is handled.  Patients will also 
be able to view their SCR online once their GP has created it using a secure website 
called HealthSpace 120. Healthspace also enables patient to view information on medicine 
and record information on dosage, frequency, start dates etc. They are advised to print 
out their overall health summary to take with them or show to a healthcare 
professional. 
5.3.7.5 Actions in the future 
In 2008, a White Paper called “Pharmacy in England: Building on strengths – delivering 
the future” outlined a framework of future actions, consultations and policy 
development to promote a wider role of pharmacy 121. For example, the paper 
proposes to give an access to community pharmacists to NHS summary care records 
that will contain details of any allergies, current patient prescriptions and history of bad 
reactions to medicines and that will be available to people providing care to patient 
anywhere in England. It is also suggested to reform the training of pharmacy technicians 
in order to extend their contribution to patient care at ward-level in close liaison with 
clinical pharmacists (ie medication history at admission, medication reconciliation, 
discharge planning),... 121 
5.3.8 United States  
5.3.8.1 VistA: using information technology to improve coordination of patient care 
across all settings of care 
The Veterans Health Information Systems and Technology Architecture (VistA) is a 
global initiative developed to improve the coordination of patient care for veterans, so 
that seamless care is delivered across all settings, from hospital to home 122. VistA 
includes the following components: Computerized Patient Records System (CPRS); 
VistA Imaging (to see radiography and other imagery results); Bar Code Medication 
Administration, a system for inpatient medication administration; and My HealtheVet 
(or personal health records). The CPRS and My HealtheVet are the two components of 
VistA that aim to improve continuity of care in medication management. 
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First, the CPRS allows clinicians to order lab tests, medications, diets, radiology tests, 
and procedures; to record a patient's allergies or adverse reactions to medications; to 
request and track consultations; and to enter progress notes, diagnoses, treatments for 
each encounter, and discharge summaries 122. These electronic records are available 
everywhere in the Veteran Affairs (VA) healthcare system for healthcare providers 
involved in the care of the patient 123 , 124. 
Second, Veterans have the opportunity to manage their personalized health records 
through ‘My HealtheVet’ which is accessible online 122 , 125. A section called “pharmacy” 
allows patients to refill their prescriptions, to view their prescriptions history, to record 
their non VA medications, OTC, Herbals, Supplements (name, dosage, frequency, date 
of introduction and stop) and to see their complete medication list 126. Patients can also 
search validated information on medications, using the Healthwise knowledge base 
(database with drug information developed by doctors and pharmacists, based on the 
literature or product labelling, and updated weekly 127) and print out their medication 
profile from their health journal that they manage in their “My HeatlheVet” session 126. 
Currently, patients are invited to keep an updated medication list handy – at home and 
wherever they go 128 – that can be used in case of hospital admission. In the future, 
information managed by patients could be shared (after patients’ permission) with their 
healthcare provider and patients will be able to request key portions of their CPRS 129. 
5.3.8.2 The Geisinger health care system 
The Geisinger health care system is an integrated provider network located in 31 
counties in Pennsylvania. Several initiatives improving seamless care in medication 
management were developed 130 , 131.  
First, patient involvement during hospital stay is encouraged. With regard to continuity 
of medication management, they are encouraged to (1) make sure that doctors have a 
complete list of all medications they are currently taking and are informed on any 
medication allergy or previous ADEs; (2) ask information on medication indication to 
HCP during inpatient stay; (3) ask written information at discharge on dosage, duration, 
side effects, interactions, activities to avoid while taking medication; (4) check when 
picking up their medication at the pharmacy if that is exactly the type their doctor 
prescribed and (5) ask the pharmacist any questions about the directions on medication 
labels.  
Second, electronic health records are implemented in the entire Geisinger health care 
system.  
Third, a medical home model was implemented to closely monitor patients with chronic 
conditions. High risk patients are assigned to a nurse case manager. With regard to 
continuity of care after hospital stay, case managers telephone high-risk patients 24 to 
48 hours after hospital discharge to assess their status, review their care plan and 
medications, and confirm or make follow-up appointments including a primary care visit 
four to seven days after discharge. 
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5.4 DISCUSSION: MAIN RESULTS AND APPLICABILITY TO 
THE BELGIAN SETTING 
5.4.1 Common features of seamless care initiatives  
In summary, national initiatives to improve continuity of care with regard to medications 
have been identified in all selected countries . 
These initiatives were mainly developed since the early 2000, and most of them are still 
ongoing. Several of them have been developed by national quality and safety groups, 
others by professional groups (mainly pharmacists). In all initiatives, the approach 
involved different types of HCPs working in different settings of care, and targeted all 
patients (i.e. no selection criteria relative to the types of patients were applied). The 
initiatives included national campaigns, national guidelines and recommendations on how 
to improve continuity of care with regard to medications in local settings, education of 
health care professionals, IT technologies relative to electronic health records and 
databases to share medication data between settings of care. Most initiatives initially 
focused on the hospital admission and/or discharge components, and several of these 
are being extended to other types of transitions (eg between hospital units, in long-term 
care).  
5.4.1.1 National guidelines or recommendations 
The publication of national guidelines or recommendations was often the first initiative 
(or among the first ones) at national level and was the trigger for further actions in the 
countries studied. For example, in Canada, the UK and the Netherlands, national 
recommendations were further used for national campaigns, support and education of 
healthcare professionals, development of performance indicators and implementation of 
local projects. The data suggest that these national recommendations/guidelines are an 
initial and important step. The content of the guidelines/recommendations shows that 
the problems to solve and the solutions proposed are very similar between countries 
and that there is international consensus on the priorities for implementation. In all 
cases, the recommendations clearly highlight that the different HCPs in different settings 
have to work together to optimise medication management.  
5.4.1.2 Importance of Information Technology (IT) 
Another important set of initiatives refer to the development and implementation of IT. 
IT initiatives are complementary and developed in parallel with other initiatives in most 
countries. In Canada and the US, IT initiatives relative to medications were part of the 
development of national strategies for digitalisation of the health sector. The VistA 
system in the US is a very good example of successful integration and exchange of 
health data, including data on medications, across different settings. Another interesting 
particularity of the US VA system is the role that patients can play, by accessing one 
part of the system, to improve the validity of the data on medications. Also in Australia, 
patients will have ownership and control over their electronic health record.  
In Denmark and Australia, stand-alone systems that were designed for the exchange of 
information on medication will now be integrated in larger e-health projects.    
5.4.2 Measure of impact 
Data on the impact of the initiatives at the national level are often not available. 
However, data at local or regional level have been published for some of initiatives, 
documenting the efficacy or effectiveness of the programs implemented.  
The impact and progress following the implementation of national guidelines on 
medication management in the aforementioned countries has only been thoroughly 
studied in the UK. Data show positive outcomes that can be linked with the 
implementation of key elements described in the guidelines, but also indicate that many 
opportunities for improvement remain.  
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The Canadian SHN! Campaign (the most comprehensive national initiative together 
with the Dutch one) is probably the national initiative that has been best evaluated, as 
local teams actively report data to the Central Measurement Team, using a set of 
predefined core measures relative to medication reconciliation. The results clearly show 
that implementing medication reconciliation according to the SHN! Standards results in 
a substantial decrease in the number of discrepancies in medication histories on hospital 
admission. Similar positive results have been reported for the Dutch initiative 
“medicatie overdracht” (regional data). 
In Australia as well as in Canada, community pharmacy based initiatives to enhance 
medication management were identified. Data on the Australian HMR service post 
discharge showed a significant reduction in the number of drug-related problems 90 
days post discharge, as well as a reduction in hospital admissions and an increase in 
compliance. Results for the Canadian MedsCheck program were somewhat 
disappointing, as the evaluation showed that quality was not consistent and didn’t meet 
professional standards.  
Results relative to the impact of IT initiatives are very scarce. When available, they are 
limited to results of intake in practice, but do not give information on the impact on 
clinical or economic outcomes. 
Many initiatives need more evaluation to further quantify – if possible - their impact on 
the quality, safety and cost-effectiveness of continuity of care. 
5.4.3 Critical success factors 
5.4.3.1 Leadership and commitment 
Implementing medication reconciliation at national level requires leadership and 
commitment. The Canadian and Dutch experiences are – in that respect – very similar, 
and illustrative. Both countries have had a very comprehensive and unique approach to 
quality improvement, by gathering national and local workforces, to educate health care 
professionals, to share local experiences, and to test, implement, and evaluate the intake 
of recommendations on quality of care.  
5.4.3.2 Initiatives adapted to local settings 
Another success factor in the Canadian experience was the fact that initiatives are 
tailored according to the local setting. The HCPs have flexibility to design initiatives that 
are adapted to their setting, but with the opportunity to be educated and supported by 
the national workforce. The same idea of tailoring national standards to local needs is 
also one of the key elements of the Dutch program “medicatie-overdracht”.  
5.4.3.3 Regulatory framework 
Additional measures that have been shown to improve the intake of recommendations 
into practice are the anchoring of recommendations in a legal and/or regulatory 
framework such as accreditation systems, and/or defining financial restrictions when 
recommendations are not applied. This was the case in Canada, the Netherlands and 
the UK, and such measures were described by the experts as important success factors.  
5.4.3.4 IT support 
The fact that in most countries IT systems were developed along the other initiatives 
further shows that IT support is a crucial factor for improving medication management.  
5.4.4 Disadvantages and factors contributing to failure 
Unsurprisingly, the data show that implementing medication reconciliation at national – 
but also at local – levels is complex and requires human and financial resources. The 
substantial time and money needed were mentioned in most countries as potential 
barriers. In addition, the requested involvement of many different HCPs and of patients 
further complicates the task.  
It is challenging to implement guiding principles. A big part of the challenge is whose 
responsibility it is to initiate, follow up and maintain the implementation. 
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In the UK and Australia, clinicians’ resistance and scepticism have been described, 
together with failure to reach agreements between settings of care on reallocation of 
resources (UK, original pack dispensing). The time required to get things done has 
resulted in disappointment of HCPs in several projects. Insufficient education of HCPs 
was also described as a factor contributing to failure in the Dutch and Canadian 
experiences. 
With regard to IT solutions, difficulties to establish common security solutions were 
reported in Denmark.  
5.4.5 Transferability of the results to Belgium  
5.4.5.1 Characteristics of the health care systems 
The implementation of similar initiatives to the Belgian health care system needs to take 
account of the characteristics of the health care systems of the selected countries 
(Table 6). Several characteristics are concordant with the Belgian situation (e.g. patients 
not bound to one community pharmacy). However, other factors that are different 
might have implications in terms of generalisation of the findings to the Belgian system. 
One major difference is that clinical pharmacy is part of standard care in all selected 
countries, except Denmark and France. Although the exact meaning of “clinical 
pharmacy” might differ between countries, clinical pharmacists are often responsible for 
performing medication reconciliation on admission and at discharge. In the results 
section no specific “clinical pharmacy” initiative was presented, probably because this is 
now standard care, but these pharmacists – for example in Canada - often played a 
major role in the development of guidelines and/or standardised procedures to improve 
continuity of care. Belgian clinical pharmacists are already involved in local initiatives 
around seamless care (see chapter 6), and international data call for further 
development of clinical pharmacy in Belgium, with the aim that it becomes part of 
standard care. 
Another difference is that in two countries (Canada and UK), patients bring their home 
medicines to hospital, which facilitates medication history taking on admission. This is 
not common practice in Belgium, although it has been described in some Belgian 
initiatives (see chapter 6). 
5.4.5.2 Adaptation and implementation of guidelines/recommendations 
As already mentioned, most national guidelines / recommendations have common 
grounds on problems and solutions. These guidelines could be applicable to the Belgian 
setting with only minor modifications. As an illustration, a Belgian guideline could 
include the following topics (found in the Canadian and English guidelines): how to 
develop seamless care initiatives, how to overcome barriers, documentation and 
technology requirements, performance indicators, patient privacy and confidentiality 
issues. Most of the practical tools that have been developed at national and regional 
levels to help implementing medication reconciliation are also usable in Belgium. 
An important additional point is that leadership and commitment, together with time 
and resources, are important for the effective implementation of the guidelines. This 
could be done, similarly to experiences abroad, through national existing structures 
working on quality in health care. 
The Canadian and Dutch experiences show that the implementation of guidelines, e.g. 
on medication reconciliation, will not be achieved using a single specific model. It must 
be tailored to fit the organisation or system, considering human resources, patient 
population, current processes, culture of staff, etc. 
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5.4.5.3 Regulatory framework and/or incentives  
In addition, lessons from abroad learnt the importance of regulatory and/or financial 
incentives to apply the recommendations. However, the development of incentives has 
to be coupled with a pre-existing structure to measure indicators linked with the 
implementation of the recommendations. Other countries already have those 
structures i.e. hospital accreditation (Canada), measurement of indicators (UK). Such 
structure does not exist currently in Belgium.  
5.4.5.4 Questions around IT development 
IT initiatives in the selected countries showed that many questions encountered are 
similar to the questions in Belgium i.e. identification of patient and HCP, privacy, 
responsibility. The solutions that have been found abroad could to some extent be used 
within the Belgian eHealth platform. This will be further discussed in the last chapter of 
this report. Interesting observations are: the responsibility that is given to the patient in 
some IT systems (eg US, Australia), sharing of medication dispensing information among 
HCPs (Denmark, Canada, France).  
5.4.5.5 Medication chart, medication review, medication profile 
Many local or regional initiatives have focused on the design and implementation of a 
medication chart. A medication chart was even developed at the national level in 
Australia (so far for the hospital setting only). The experience that one national form 
could be created for such a large country as Australia, with its complex mix of private 
and public funders and providers, should take away some of the barriers for the design 
and implementation of a national chart in Belgium. 
So far, community pharmacy based initiatives such as medication review (HMR in 
Australia and England, MedsCheck in Canada) do not exist in Belgium, although pilot 
projects are underway. This type of services could be developed within the new 
remuneration system for pharmacy services applied since April 2010 but, as the 
Canadian experience shows, community pharmacists might require additional training 
(eg by clinical pharmacists and/or academics experienced in drug history taking) and a 
clear definition of standards.  
Developing a patient medication profile is much more structured and formalized in the 
Australian example than it is now in Belgium. As for medication review, this could be 
another service that could be developed within the new remuneration system for 
pharmaceutical care. 
5.4.5.6 Other interesting initiatives 
The attempt to use joint forms between hospitals and ambulatory practice in the UK 
and Netherlands is interesting. In Belgium also this could decrease the number of 
problems encountered at transition moments, when switches between specialties have 
to be done to fit the hospital’s formulary and/or GP and patients’ habits. 
Several initiatives are currently not applicable to the Belgian setting for legal reasons. 
Firstly, dispensing medicines in original packs at discharge (see UK experience) is not 
possible in Belgium because in most cases this would exceed the 3-day dispensing that is 
currently allowed and because hospitals do not always have the commercial preparation 
that the patient is used to. In addition, there is currently no or limited evidence showing 
a positive impact of such initiatives. Secondly, using patients’ own medicines during 
hospital stay (see UK experience) is forbidden in Belgium, and once again, there are no 
convincing data suggesting that it has an important impact on continuity of care. 
However, the examples abroad suggest that it could be valuable to encourage patients 
to bring their home medicines to the hospital, to facilitate medication history and 
medication reconciliation on admission. 
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Key points 
• This chapter reviews national and regional initiatives that have been 
implemented in Australia, Canada, Denmark, France, The Netherlands, the 
UK and the US, in order to optimise continuity of care focusing on 
medications. 
• Initiatives have been identified in all selected countries. Most initiatives have 
been implemented since the early 2000 and are still ongoing. 
• Various kind of initiatives were reported: national guidelines and 
recommendations, national campaigns, education of healthcare 
professionals, IT technologies relative to electronic health records and 
databases to share medication data between settings of care. 
• All approaches involved different healthcare professionals from different 
settings of care. 
• Positive results have been reported in terms, for example, of intake into 
practice, or number of medication discrepancies. However, additional data 
are needed to confirm their impact on relevant clinical, economic and 
humanistic outcome measures.  
• Critical success factors identified are: requirement of leadership and 
commitment, the adaptation of initiatives to local settings, the development 
of a regulatory framework, and IT support. 
• Contributing failure factors identified are: lack of human and financial 
resources, questions relative to responsibility and accountability, lack of 
training of HCPs, lack of agreement for security solutions. 
• Although not all initiatives are applicable as such to the Belgian setting, 
most of them convey very interesting data that should be used when 
drawing recommendations for optimising continuity of care in Belgium. 
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6 REVIEW OF THE SITUATION IN BELGIUM 
6.1 RESEARCH QUESTIONS 
The aim of this part is to summarise Belgian data on drug related problems related to 
discontinuity of care, as well as initiatives to improve continuity of care focusing on 
medications. 
The research questions addressed in this part of the study are: 
• What are the most frequent drug related problems on admission and at/after 
discharge and are specifically related to transition? 
• What are the potential causes of these drug related problems? 
• Which initiatives have been tested in Belgium to avoid these errors and what 
is their impact? 
Setting Transition between ambulatory care (including nursing homes) and hospital care in 
Belgium 
Perspective Patients admitted and/or discharged from hospital  
Health care professionals caring for these patients in the outpatient and inpatient 
settings 
Intervention* Seamless care initiatives 
Comparison* Usual care 
Evaluation Drug-related problems: characteristics, causes 
Impact of initiatives: process measures, and/or economic, clinical and humanistic 
outcome measures (ECHO) 
* Not applicable for the first two review questions. 
6.2 METHODOLOGY  
6.2.1 Search strategy  
A combination of three approaches was used:  
1. Indexed literature search,  
2. Handsearch of specific Belgian medical and pharmaceutical journals AND 
abstract books of national conferences 
3. Grey literature search through a questionnaire survey sent to “experts” in the 
field. 
The details of the search strategy for these three data sources are provided in the 
appendix related to chapter 6. 
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6.2.2 Selection of the studies 
Studies needed to comply with the following criteria to be included: 
Date of project 1995 till present 
Language English OR Dutch OR French OR German 
Setting Transition between ambulatory care (including nursing homes) and hospital 
care. Only studies performed in Belgium 
Sample Patients admitted to hospital AND/OR patients discharged from hospital (no 
age or other limitations regarding the patients) 
Health care professionals caring for these patients in the outpatient and 
inpatient settings 
Intervention No intervention in case of descriptive studies on drug related problems 
OR Seamless care interventions to avoid drug related problems, e.g. admission 
or discharge management 
Outcome 
measures 
Drug related problems due to the transfer of patients between ambulatory care 
and hospital care 
OR Causes of these drug related problems 
OR Costs of drug related problems 
OR Characteristics of seamless care interventions aiming to avoid drug related 
problems and impact of these interventions 
The following exclusion criteria were applied: 
Sample Transition between settings of care, not in the context of admission 
/discharge from the hospital (e.g. transition between ambulatory care 
and nursing home, between an intensive care ward and a cardiology 
ward,...) 
Intervention Seamless care interventions not focusing on medicines 
Outcome measures Drug related problems not associated with transition between settings 
of care  
Details on the inclusion process are in the appendix that relates to chapter 6. 
6.2.3 Data extraction 
The description of the data extraction is in appendix 4 with the items of the data 
extraction forms developed for that purpose.  
A project was called a ‘research project’ when clear measures of evaluation were 
described and results were presented. A project was called ‘initiative’ when it was not a 
research and no results (other than data on the level of implementation of the initiative 
like number of interventions done) were presented.  
6.2.4 Data analysis and interpretation 
The characteristics and the results of the included studies and initiatives are summarized 
in the tables 7 to 10. The textual narrative synthesis of the results is organized around 
the following themes: 
• Research projects describing drug related problems associated with transition 
between settings of care 
• Research projects evaluating interventions to improve seamless care 
• Research projects evaluating opinions or experiences of stakeholders on 
themes related to seamless care 
• Ongoing research projects 
• Initiatives taken to improve continuity of care with regard to medications 
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6.3 RESULTS  
6.3.1 Search results: number of projects identified by source 
The number of projects identified by source is in appendix 4 and summarised in the 
figure below. 
Figure 3: Overview of search strategy 
 
6.3.2 Results: description of the projects 
An overview hereafter describes all projects and initiatives that were identified. The 
numbers used in the text refer to the ID numbers in the summary tables. Financial 
support was considered to be ‘none’ when projects were carried out by students. 
Projects were labelled ‘hospital’ when financed through normal payment of staff (nurses, 
pharmacists,...). 
6.3.2.1 Projects describing drug-related problems associated with transition between 
settings of care.  
Thirteen projects were identified that attempted to describe the type, number and 
characteristics of drug-related problems associated with transition between settings of 
care (1-13). Most of these projects focused on discharge from the hospital.  
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Drug-related problems measured at discharge 
In two projects (1,2), a quantitative and qualitative analysis was made of the 
communication about the discharge treatment in the discharge letter. Both found a lot 
of missing information, either about the treatment that was initiated during hospital stay 
or about the (dis-)continuation of home medication.  
In five projects (3-7) a clinical pharmacist evaluated the content of the discharge package 
(discharge medication, medication scheme, substitution form,...) or the discharge 
medication as such. All found high numbers of packages to be incomplete or containing 
errors. Furthermore, the majority of discharge packages contained more medication 
than is legally allowed, i.e. medication for three consecutive days.  
The study of Leemans (8) investigated the number and type of problems related to 
discharge medication, as evaluated by the community pharmacist. In 33% of cases, 
pharmacists notified at least one problem concerning medications prescribed at hospital 
discharge. Furthermore, 30.9% of patients who consulted a pharmacist with the 
medication scheme received from the hospital, admitted not to have fully understood.  
In a parallel study (9), the number and type of problems related to discharge medication 
was evaluated by GPs. In 35.6% of cases at least one DRP was noticed. About 90% of 
those were system- or HCP-related (e.g. discrepancies between information in the 
medication scheme and the actual discharge medication; lack of information on 
discharge medication,...). Out of 20 GP’s who noticed at least one DRP, 12 evaluated 
the most severe DRP as potentially dangerous for the patient.  
Only one study (10) analysed the follow-up of the discharge process i.e., after return at 
home. The researchers compared the actual drugs taken by the patient 7-17 days post 
discharge with the drug regimen at discharge. A mean of 6 discrepancies per patient was 
reported, with 95% of those system-related and due to incomplete registration of drug 
therapy at admission (68%) or erroneous instruction at discharge (25%). 
Drug-related problems measured at admission 
One study (11) from Leuven found a lot of information missing in drug histories taken 
at admission, with medication records complete for patients being transferred from 
nursing homes only. According to this study, the lack of adequate information in the 
medication record leads to errors in dosage or frequency of administration, or even 
omission of drugs, in 25-44% of cases.  
Another study from Ghent found that there seems to be no major difference in the 
quality of the medication history in the medical files of a university hospital and a 
regional hospital, but patients on geriatric wards seem to be better off than patients on 
surgery wards, for whom the medication history is notified in the medical file in a 
minority of cases only (12).   
Checking referral letters for the information on medication learned that data on chronic 
medication are present in 71% of cases, whereas only 33% of referral letters have 
information on the actual medication profile (13).  A typed referral letter seemed to 
enhance the chance of having information on chronic medication and allergies / 
intolerances (p=0.04; p=0.03). 
Conclusion: drug-related problems associated with transition 
between settings of care 
In conclusion, most projects describing drug-related problems associated with transition 
between settings of care focus on discharge from the hospital. All but one did not 
include any follow-up at home. Several projects have shown large numbers of missing or 
erroneous information in the information and medication at discharge, related or not 
with missing information in the medication record of the patient upon admission. More 
data on the latter type of problems were identified through intervention studies 
described in the following paragraph. 
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Table 7: Research projects describing drug-related problems associated with transition between settings of care 
ID Referenc
e  
Setting / 
Study population 
A/D/A
D 
Study 
design  
Measures  Main results  Financial 
support 
1 Delmée  Cliniques Universitaires Saint-
Luc 
 
50 patients discharged from the 
orthopedic surgery ward 
D Prospective 
observational 
study 
(P) Quantitative and qualitative evaluation 
of discharge treatment communicated in 
the discharge letter (done by a clinical 
pharmacist) 
Pain treatment (added in 46/50 cases): names 
and dosages mentioned in 33% of cases only 
LMWH (added in 29/50 cases): treatment 
duration not mentioned in 17% of cases 
Other medication (added in 21/50 cases): not 
mentioned in 67% of cases 
Overall, lack of information on therapeutic 
modifications in 54%; imprecise or erroneous 
information in 80%. 
Hospital  
2 Deryckere 
132 
University Hospital Gent 
 
62 patients > 60 years 
discharged from surgery ward 
D Prospective 
observational 
study 
(P) Quantitative and qualitative evaluation 
of discharge treatment communicated in 
the discharge letter (done by a clinical 
pharmacist) 
In 6.5% of discharge letters, no discharge 
medication was mentioned 
In 83.9% of discharge letters, discharge 
medication was mentioned but no home 
medication 
FOD projects 
clinical pharmacy 
3 Bouchier 133  Algemeen ziekenhuis Maria 
Middelares Gent 
 
14 patients discharged from 
gastro-enterology ward 
D Prospective 
observational 
study 
(P) Quantitative and qualitative evaluation 
of discharge packagea (done by a clinical 
pharmacist) 
71% of discharge packages were complete. In 
75% of cases where a drug had been 
substituted in the hospital, no written 
information on this substitution was present.  
Only 36% of medication schemes were 
complete and correct. Correct information on 
drug dose was present in 71% of cases. 
In 37% of cases the packages contained more 
medication than legally allowed. 
None 
4 Maenhaut 134 Algemeen ziekenhuis Maria 
Middelares Gent 
 
32 patients discharged from 
geriatric ward 
D Prospective 
observational 
study 
(P) Quantitative and qualitative evaluation 
of discharge packagea (done by a clinical 
pharmacist) 
(P) Patient knowledge about discharge 
medication after discharge counseling by 
ward nurse (done by clinical pharmacist) 
 
75% of discharge packages were complete. In 
53% of cases where a drug had been 
substituted, no written information on this 
substitution was present.  
72% of medication schemes were complete and 
correct. 
In 95% of cases, the packages contained more 
medication than legally allowed. This 
percentage decreased to 23% after reporting to 
the head nurses. 
33% of patients had good knowledge about 
their medicines; in 24% knowledge was 
moderate. 24% of patients had bad knowledge; 
19% had no knowledge at all.  
Of the patients who had one or more drugs 
stopped or substituted, 56% and 38% 
None 
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respectively knew which one(s). 
5 Lazeure 135 UZ Leuven 
 
42 patients discharged from 
traumatology ward 
D Prospective 
observational 
study 
(P) Quantitative and qualitative evaluation 
of discharge medication, i.e. errors in 
drugs given at discharge as compared to 
the discharge prescription (done by a 
clinical pharmacist) 
One or more errors in 54.8% of cases; mean 
3.9 errors/patient. 67% of errors related to 
home medication. 
64% of packages contained more medication 
than legally allowed;  > 50% of packages 
contained medication for at least 8 days. 
Double medication (brand and generic) was 
present in 25% of packages. 
11% of packages contained ‘extra’ medication 
(drugs given during hospital stay but already 
stopped or drugs never meant to be used by 
the patient) 
None 
6 Indevuyst 136 UZ Leuven 
 
24 patients discharged from 
pediatric wards (oncology and 
infectious diseases) 
D Prospective 
observational 
study 
(P) Quantitative and qualitative evaluation 
of discharge medicationb (done by clinical 
pharmacist) 
(P) Patient knowledge about discharge 
medication after discharge counseling by 
ward nurse (done by clinical pharmacist) 
One or more discrepancies between the 
discharge medication and the intended 
medication scheme in 54.2% of cases.  
Most frequent discrepancies: missing drug 
(4.8%), incorrect dose (4%); incorrect 
frequency (1.6%); erroneous advice related to 
intake with or without food (3.2%) 
Overall, patient knowledge about discharge 
medication was satisfactory. Two items 
required extra information from the clinical 
pharmacist: the indication of the drug (3.2 / 
10.3% of respective cases) and whether or not 
to take the drug with food (4.8 / 5.6% of cases 
respectively).  
None 
7 Bink 137 Virga Jesse Ziekenhuis Hasselt 
 
785 patients on an oncology, 
hematology or abdominal ward 
D Prospective 
observational 
study 
(P) Quantitative and qualitative evaluation 
of discharge management (done by a 
clinical pharmacist)  
(P) Acceptance of the medical staff of 
proposed interventions 
The clinical pharmacist has to change the 
discharge management in 63% of cases. 
Correction of discharge medication in 71% for 
oncology, in 22% for hematology and in 6 % for 
abdominal surgery 
Advice by the clinical pharmacist about 
discharge medication is done in 76% for 
oncology, in 20% for hematology and in 4% for 
abdominal surgery. 
90% of interventions accepted by staff 
FOD projects 
clinical pharmacy 
8 Leemans  138 82 Community pharmacies in 
Flanders 
 
261 Patients discharged from 
hospital  
D Prospective, 
observational 
study 
(P) Number and type of problems related 
to discharge medication, evaluated by the 
community pharmacist 
69% of patients had received a medication 
scheme upon discharge 
30.9% of patients who presented in the 
pharmacy with the medication scheme received 
from the hospital, admit not to have fully 
understood this scheme 
In 33% of cases the pharmacist noticed at least 
CDSP 
CM 
Focus 
Farmaceutische 
Zorg vzw 
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1 problem concerning medications prescribed 
at hospital discharge. 
9 Daenen 139 28 Flemish GP’s 
 
87 Patients discharged from 
hospital 
 
D Prospective 
observational 
study  
(P)  Number and type of problems related 
to discharge medication, evaluated by the 
GP 
84/87 patients had to take medicines post 
discharge. 22 of those did receive neither 
discharge medicationb, nor prescriptions from 
the hospital. 6/22 waited more than 2 days 
(mean = 6 days) to contact the GP. 
Medication was changed due to hospitalization 
in 90% of cases; most frequent change was 
addition of a new drug.  
In 35.6% of cases the GP noticed at least one 
DRP. In 90.3% of cases the DRP was system- or 
HCP-related. 12/20 GP’s who noticed at least 
one DRP evaluated the most severe DRP as 
potentially dangerous for the patient.  
Admission on a surgical ward seams to raise 
the chance that neither the GP nor the patient 
receives information on discharge medication 
(p=0.001). 
None 
10 Hens 140 6 French-speaking hospitals 
 
25 patients discharged from 
internal medicine or surgery 
wards 
D Prospective 
observational 
study 
(P) Number, characteristics  and causes of 
discrepancies between discharge 
medication and medication taken by 
patients 7-17 days post discharge (home 
visits by a nurse)  
151 discrepancies; mean 6 / patient. 
Most frequent discrepancies: addition (65%), 
difference in frequency (13%) or dosage (10%).  
95% of discrepancies are system-related, and 
due to incomplete registration of drug therapy 
on admission (68%) or erroneous instruction at 
discharge (25%). 
None 
11 Vermeulen 
141 
 
UZ Leuven 
 
220 patients admitted to 
traumatology ward 
A Prospective 
observational 
study 
(P) % of complete drug histories for 
different sources 
(P) Prescribing errors due to incomplete 
drug histories 
%  complete drug histories for different 
sources: nursing homes, 100%; emergency 
ward, 70%; ward nurse, 63%; 
anesthesiology,53% 
Errors in prescribed home medication: dosage 
errors (44%); omission (38%); frequency of 
administration (25%)  
None 
12 De Sloovere 
142 
Regional Hospital Maria 
Middelares Gent and university 
Hospital Gent 
 
1 x 15 medical records on 
orthopedic surgery, abdominal 
surgery and geriatric surgery  
A Prospective 
observational 
study 
(P) Registration of medication history in 
medical records 
Not many differences in registration of 
medication history in medical records between 
regional and university hospital. 
The medication history is almost always 
present in the medical file of patients on 
geriatric wards; for patients on surgery wards 
medication history is often missing. 
During  hospital stay, home medication is 
prescribed for all patients on geriatric wards; 
for patient on surgery wards prescribing of 
home medication is forgotten in the majority of 
None 
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cases.  
Only 11% of the referral letters can be used as 
information source for medication history 
taking. 
In 54% of cases the GP agrees with the 
medication history as told by the patient. 
13 Lybaert 143 Sint-Jan Brugge 
 
98 patients admitted to 
emergency ward 
A Retrospective 
observational 
study 
(P) Qualitative and quantitative analysis of 
referral letter 
74/98 referral letters were composed during a 
home visit; 68/74 were hand-written. 
70/98 of referral letters contain information on 
chronic medication; 32/98 have information on 
the actual medication. Only 8/98 have data on 
allergies or intolerances.  
Information on chronic medication and 
allergies/intolerances is more present in typed 
letters than in hand-written letters (p=0.04; 
p=0.03). 
 
None 
Abbreviations: A: admission; CDSP: Centre de Developpement Scientifique des Pharmaciens; CM: Christelijke Mutualiteit; D: discharge; DRP: Drug Related Problem; FOD: 
Federale Overheidsdienst; GP: General Practitioner; HCP: Health Care Professional; LMWH: Low Molecular Weight Heparin; P: Process measure; UZ: University Hospital 
adischarge package = a bag, containing the discharge medication + a medication scheme for the patient, information forms about substituted drugs for the patient and a 
discharge letter for the GP; 
bdischarge medication = the medication given at the patient on discharge; meant to take home.  
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6.3.2.2 Projects evaluating interventions to improve seamless care 
Added value of a clinical pharmacist for medication history taking 
Sixteen projects (14-29) were identified that evaluated interventions to improve 
seamless care. Nine projects (14-22) focused on admission, and investigated whether a 
clinical pharmacist is of added value in medication history taking. All studies found high 
numbers of discrepancies between a medication history taken by the clinical pharmacist 
and a medication history done by the nurse or medical doctor. The proportion of 
discrepancies (one or more) varied between 42% to 67.7% of cases, with mean numbers 
of about 2 discrepancies per patient. The most frequently reported discrepancies were 
drug omissions, wrong drugs and dose and frequency errors. In one of these projects 
(18) it was further shown that there is a difference between a medication history 
performed by the clinical pharmacist in collaboration with the patient, and a medication 
history performed through a phone call of the clinical pharmacist with the GP or 
community pharmacist (mean numbers of 2.01 and 1.72 discrepancies per patient 
respectively – data paired for the same patients).  
Impact of patient counselling at discharge 
About 6 projects (22-27) investigated the impact of patient counselling upon discharge, 
either by the ward nurse or by a clinical pharmacist, on different types of outcomes 
such as patient knowledge and satisfaction about the counselling. One study (23) found 
significant impact of discharge counselling by the clinical pharmacist on the number of 
discrepancies between the intended discharge medication and the actual medication 
taken by the patient 2-3 weeks post discharge (0.17 versus 0.32 discrepancies per 
patient). Another study (26) checked whether the recommendations that were made by 
the clinical pharmacist at discharge were followed by the GP or the patient one month 
post-discharge. The results for the patients were encouraging, with 89% of patients 
following lifestyle and dietary advice and even 95% reporting to be fully adherent 
(respecting dosing times and intervals). However, 65% of GP’s did not follow 
recommendations. In two projects (24,25), information leaflets were used to support 
the counselling session. The study by Deryckere (25) was performed on a traumatology 
ward and showed a positive impact of patient counselling on patient knowledge 
(p=0.002) and satisfaction with information (p=0.006). The study by Desplenter (24), 
also mentioned in chapter 4, was performed in different psychiatric hospitals. Although 
no impact of the counselling could be found on clinical or humanistic outcomes, neither 
on compliance, the counselling had a significant effect on loss of productivity (p=0.022) 
as well as on costs for medical consultations (p=0.036). 
Added value of discharge letter 
A pilot program evaluated the usability of a discharge letter, written by the clinical 
pharmacist, for the community pharmacist (27). 10 out of 12 community pharmacists 
who received the discharge letter through the patient thought it facilitated patient care; 
5 of them used the document to counsel their patient.  
Procedures to improve admission / discharge management 
Two before-after studies were identified that evaluated procedural aspects of either 
admission or discharge. The study by Amant (28) found a positive impact of the use of a 
template for referral letters on the experienced quality of this referral letter. The study 
in the General Hospital ‘Zusters van Barmhartigheid’ in Ronse (29) showed an 
improvement in the quality of the discharge package after optimization of the discharge 
procedure and communication of this new procedure towards the people involved. 
KCE  Reports 131 Seamless care 67 
 
Conclusion: interventions to improve admission and discharge 
management 
In conclusion, many interventions to improve seamless care focused on admission, and 
involved medication history taking by a clinical pharmacist. Some of the interventions 
involved patient counselling at discharge either by a nurse or by a clinical pharmacist.  
For all interventions tested, a positive impact on one or more outcome parameters was 
reported. According to several authors, there is an added value of medication history 
taking by a clinical pharmacist. Discharge counselling was shown to have a positive 
impact on patient knowledge and satisfaction, but the impact on clinical outcomes could 
not be demonstrated. Only one of the projects evaluated the impact on economic 
outcomes. 
68  Seamless care KCE Reports 131 
Table 8: Research projects evaluating interventions to improve seamless care 
ID Reference Setting /  
Study population 
A/D/A
D 
Study 
design 
Intervention 
(+ control) 
Measures Main results  Financial 
support 
14 Quennery 144 Cliniques Universitaires Saint-
Luc 
 
50 patients admitted on 
orthopedic surgery ward 
A Prospective 
controlled 
study 
Medication history on 
admission performed 
by a clinical pharmacist 
vs by the admitting 
nurse 
(P) Number and 
characteristics of 
discrepancies  
107 discrepancies, mean 2.1/patient 
Most frequent discrepancies: omission (40%), 
dosage (36%), frequency of administration 
(11%) 
27% of errors concerned OTC drugs 
Hospital  
15 Leysen and De 
Baere 145 
UZ Brussel 
 
110 patients admitted to 
geriatric ward 
A Prospective 
controlled 
study 
Medication history on 
admission performed 
by a clinical pharmacist 
vs by the admitting 
physician / nurse 
(P) Number and 
characteristics of 
discrepancies 
6.6±3.5 drugs/patient registered by admitting 
physician / nurse  vs 7.8±3.8 by clinical 
pharmacist 
53% of discrepancies clinically relevant 
Most frequent discrepancies: 36% incorrect 
dosage; 35% wrong drug; 11% incorrect 
formulation 
FOD projects 
clinical 
pharmacy 
16 Deryckere 132 University hospital Gent 
 
175 patients admitted on 
surgery and emergency ward 
A Prospective 
controlled 
study 
Medication history on 
admission performed 
by a clinical pharmacist 
vs by the admitting 
physician / nurse 
(P) Number and 
characteristics of 
discrepancies 
1007 drugs reported by clinical pharmacist vs 
792 by admitting physician / nurse 
Most frequent discrepancies: 15.9% wrong 
drug; 14.9% incorrect dosage; 7.8% frequency 
missing; 4.8% incorrect frequency 
FOD projects 
clinical 
pharmacy 
17 De Winter 146 UZ Leuven 
 
2656 patients admitted on 
emergency ward 
A Prospective 
controlled 
study 
Medication history on 
admission performed 
by a clinical pharmacist 
/ pharmacy technician 
vs by the admitting 
physician / nurse 
(P) Number and 
characteristics of 
discrepancies 
One or more discrepancies in 61% of cases. 
Most frequent discrepancies: 36% omission; 
11% dose missing; 6% frequency missing 
Mean time needed to fill the document: 16 
minutes. 
In 53.1% information obtained from different 
sources; in 39% GP or community pharmacist 
contacted 
FOD projects 
clinical 
pharmacy 
18 Deliens – 
Vandegaar 147 
Cliniques Universitaires Saint-
Luc 
 
65 patients admitted to internal 
medicine, geriatry, gastro-
enterology and cardiac surgery 
wards 
A Prospective 
controlled trial 
Medication history on 
admission performed 
by clinical pharmacist in 
collaboration with the 
patients vs with GP and 
community pharmacist 
(though a phone call by 
the clinical pharmacist) 
(P) Number and 
characteristics of 
discrepancies 
Comparison patient – GP: mean of 2.01 
discrepancies / patient 
Comparison patient – pharmacy: mean of 
1.72 discrepancies / patient 
11 % of discrepancies are class 3 (causing 
clinical deterioration or severe discomfort).  
None 
19 Sterckx 148 Algemeen Ziekenhuis Sint-
Dympna Geel 
 
78 patients admitted to 
cardiology, orthopedic surgery 
or neurosurgery ward 
A Prospective 
controlled trial 
Medication history on 
admission performed 
by a clinical pharmacist 
vs by the nurse 
(P) Number and 
characteristics of 
discrepancies 
One or more discrepancies in 67.7% of cases. 
Most frequent discrepancies: omission 
(20.5%); time error (12.8%); dose error 
(7.7%). 
None 
20 Mertens 149 UZ Leuven 
 
55 patients admitted to 
A Prospective 
controlled trial 
Medication history on 
admission performed 
by a clinical pharmacist 
(P) Number and 
characteristics of 
discrepancies 
One or more discrepancies in 52% of cases. 
Most frequent discrepancies: omission 
(12.2%); dose error (4.1%); frequency error 
None 
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ID Reference Setting /  
Study population 
A/D/A
D 
Study 
design 
Intervention 
(+ control) 
Measures Main results  Financial 
support 
pediatric wards (oncology and 
infectious diseases) 
vs by the nurse (1.7%). 
21 ASL150  AZ Damiaan Oostende 
 
273 geriatric patients under 
polymedication 
AD Prospective 
controlled 
study 
Medication history on 
admission performed 
by a clinical pharmacist 
vs by the nurse 
 
(P) Number and 
characteristics of 
discrepancies 
(P) Acceptance of 
medical staff of 
proposed interventions  
One or more discrepancies in 42% of cases 
at admission; in 66.7% of cases at discharge.   
Most frequent discrepancies at admission : 
omission(67.29%); addition (16.82%); 
incorrect frequency (7.48%); incorrect dose 
(7.48%). 
67% and 98 % of interventions accepted by 
medical staff at admission and at discharge 
respectively 
FOD projects 
clinical 
pharmacy 
22 Muylkens151  Imeldaziekenhuis Bonheiden 
 
Part 1: 15 patients admitted to 
orthopedic ward 
Part 2: 27 patients discharged 
from orthopedic ward 
AD Part 1: 
prospective 
controlled trial 
Part 2: 
prospective 
uncontrolled 
trial 
Part 1: Medication 
history on admission 
performed by a clinical 
pharmacist vs by the 
nurse 
Part 2: Discharge 
counseling by ward 
nurse 
(P) Number and 
characteristics of 
discrepancies 
(P)Patient knowledge 
on discharge counseling 
(H) Patient satisfaction 
on discharge counseling 
Most frequent discrepancies: omission (53%); 
incorrect dosage (73%); time of 
administration (26%) 
Indication of home medication known by 83% 
of patients;  indication of new medication by 
51%. 74% of patients confirmed they had 
ample opportunity to ask questions about 
their medication; 37% had additional 
questions.  All patients (100%) were satisfied 
with the discharge form and with the extra 
information.   
FOD projects 
clinical 
pharmacy 
23 Remy 152 Cliniques Universitaires Saint-
Luc 
 
37 patients discharged from 
internal medicine and 
orthopedic surgery wards 
D Prospective 
controlled trial 
Information on 
medicines provided to 
patient upon discharge 
by the clinical 
pharmacist vs usual 
care 
(P) inter-rater reliability 
of the MDT to evaluate 
medication 
discrepancies 
(P) Number, 
characteristics  and 
causes of discrepancies 
between discharge 
medication and 
medication taken by 
patients 2-3 weeks post 
discharge (phone call by 
a blinded clinical 
pharmacist)  
Inter-rater reliability satisfactory (0.96; 0.79 
and 0.97) 
Mean number of 0.32 discrepancies in the 
control group vs 0.17 in the intervention 
group  
Reasons for discrepancies:  Intervention 
group: 40% intentional non-compliance, 
33.3% non-intentional non-compliance, 20% 
and 16.7% incomplete or contradictory 
information respectively  
Control group: 47.4% intentional non-
compliance; 21% automedication                      
None  
24 Desplenter 76 11 Flemish psychiatric hospitals 
 
99 patients admitted with 
major depression (DSM IV) 
D Prospective 
controlled trial 
Control group: usual 
care 
Undifferentiated group: 
discharge counseling for 
all patients, using 
information leaflet on 
relevant antidepressant 
Differentiated group: 
(P) Compliance 
(C) HADS, SCL, 
adverse effects 
(H) satisfaction and 
quality of life 
(E) productivity, costs, 
readmissions (see also 
chapter 4) 
No effect on compliance 
No effect on HADS, SCL or adverse 
reactions 
No difference between groups on satisfaction 
or quality of life 
Differentiated approach resulted in a lower 
decrease of productivity (p=0,022), and 
lower costs for medical consultations 
IWT 
Vlaanderen 
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ID Reference Setting /  
Study population 
A/D/A
D 
Study 
design 
Intervention 
(+ control) 
Measures Main results  Financial 
support 
discharge counseling for 
patients with high 
extent of information 
desire only 
 (p=0,036). 
Undifferentiated approach decreased the 
number of re-admissions within 12 months 
post discharge (p = 0.031).  
 
25 Deryckere 153 UZ Leuven 
 
29 patients discharged from 
traumatology ward 
D Prospective 
controlled trial 
Intervention group 
patients received 
information leaflets (3) 
on low molecular 
weight heparine, pain 
medication and 
antibiotics; control 
patients received only 
verbal information 
(P) Knowledge about 
discharge medication  
(H) Satisfaction with 
information on 
discharge medication; 
readability of leaflets 
Increase in patient knowledge about 
discharge medication significantly higher in 
intervention group than in control group 
(p=0.002) 
Satisfaction with information 8.78/10 in 
intervention group vs 7.83 in control group 
(p=0.006) 
Majority of patients scored leaflets as well-
structured, readable and understandable.  
None 
26 Jullion 154 Hopital Erasme Bruxelles 
 
78 patients discharged from 
cardiology ward 
(A)D Prospective 
uncontrolled 
trial 
Medication history on 
admission performed 
by clinical pharmacist, 
analysis of 
pharmacotherapy 
during hospital stay, 
discharge counseling 
(P) Follow-up of 
recommendations by 
patients and GP one 
month after discharge 
 
89% of patients followed lifestyle and dietary 
advice; 95% respected dosing times and 
intervals. 65% of GP’s did not follow 
recommendations of clinical pharmacist. 
 
SPF – clinical 
pharmacy 
projects 
27 Cavrenne 155 Cliniques Universitaires Saint-
Luc and Mont-Godinne 
 
18 patients discharged with 
treatment changes 
D Prospective 
uncontrolled 
pilot study  
Discharge form written 
by the clinical 
pharmacist and given to 
the community 
pharmacist by the 
patient 
(P) Usefulness and 
quality of the discharge 
form (telephone call to 
community pharmacist 
2 weeks after 
discharge) 
(P) time required for 
the clinical pharmacist 
12 pharmacists received the discharge plan. 
10 pharmacists thought the document 
facilitated continuity of patient care; 5 used it 
to counsel their patients. 
Mean time needed to fill the document: 25 
minutes.  
None  
28 Amant 156 1 hospital (not specified) 
 
10 specialised medical doctors 
 
A Before – after 
study 
Classic referral letter vs 
referral letter 
composed by using 
template 
(P) Quality of the 
referral letter (layout, 
brevity, content, 
professionalism, 
usability) 
Overall quality score before intervention: 
8/10; overall quality score after intervention: 
8.78/10 
Improvement on brevity (p=0.028), 
professionalism (p=0.045) and quality in 
relation to ideal referral letter (p=0.008). 
None 
29 Medicatie project  Algemeen Ziekenhuis Zusters 
van Barmhartigheid, Ronse 
D Before – after 
study 
Optimization of 
discharge procedure 
related to medication 
 (P) Quantitative and 
qualitative evaluation of 
discharge management 
Less discrepancies between hospital file and 
discharge form / discharge letter after 
intervention  
Discharge medication conform legal rules 
Improvement in readability of medication 
scheme 
Hospital 
Abbreviations: A: Admission; AZ: Algemeen Ziekenhuis; C: Clinical outcome measure; D: Discharge; FOD: Federale Overheidsdienst; GP: General Practitioner; H: Humanistic 
outcome measure; HADS = Hospital Anxiety and Depressions Scale; IWT: Instituut voor de aanmoediging van Innovatie door Wetenschap en Technologie in Vlaanderen; 
MDT: Medication Discrepancy Tool; OTC: Over-The-Counter; P: Process measure; SCL: Symptom Checklist; UZ: Universitair Ziekenhuis 
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6.3.2.3 Research projects evaluating opinions or experiences of stakeholders on themes 
related to seamless care 
Ten projects (30-40) surveyed the experience of different stakeholders on themes 
related to seamless care. 
Experiences of nurses 
In three studies (30-32) ward nurses were asked about current practice in medication 
history taking. These studies showed that any nurse is allowed to perform a medication 
history taking, and that there is no standard procedure as to obtain information on the 
medication record of the patient. The study by Sterckx (30) further showed that next 
to the patient, the patients’ family is the most important source of information, and that 
only in a minority of cases (6%) the GP or the community pharmacist is contacted. 
The CASOC project (33) (CASuïstic rond Ontslag Coordinatie) shows that there are 
many discrepancies between the ward nurse’s statement and the patient’s experience 
concerning admission and discharge management. Nurses claimed in more than 70% of 
cases that they gave written instructions for the GP to the patient, and that they 
explained these instructions in 90% of cases. However, only 52.9% of patients confirmed 
they had received these instructions, with not yet 25% agreeing that these instructions 
were explained.   
Collaboration between hospital and home care setting 
As part of a large, three-year project on admission and discharge, OVOSIT (Oost 
Vlaams Overleg Samenwerkings Initiatieven Thuiszorg) organized a questionnaire survey 
as well as focus groups to identify the current practice in collaboration between health 
care providers of hospital and home care settings, and showed that there is 1) a need 
for an electronic database to facilitate communication between all partners; 2) a need 
for a clear definition on the roles and responsibilities of all different partners, and 3) no 
consensus as to the ideal person / function to coordinate transition between settings of 
care (34). 
The experience of patients 
In the study by Desplenter (35) semi-structured interviews with patients and health care 
professionals were performed to investigate current practice in information provision 
about antidepressant drugs throughout hospital stay. As for medication history taking, 
information provision is not structured or standardized, is mostly done by the 
psychiatrist or the nurse, and is more usual when starting or changing pharmacotherapy 
than at discharge.  
Patient experience and satisfaction about the discharge process was also questioned in a 
survey performed at Gezondheidszorg Oostkust (36), where a vast majority of patients 
confirmed that they received a medication scheme upon discharge, as well as 
information about this scheme and on the drugs themselves.   
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Opinion of patients and health professionals on the information 
process 
Three studies were identified that asked the opinion of patients and/or health care 
professionals on information processes.  
The patient forum ‘Vlaams patiëntenplatform’ found that 53% of chronically ill patients 
who participated in the survey find it’s the task of the GP to inform the hospital about 
his/her medication record. 67% are opposed to direct exchange of information on 
discharge medication between the hospital and the community pharmacy, while 91% 
agree with direct information between hospital an GP (37). 
Clinical pharmacists would favour a secured on-line system to exchange data between 
community pharmacy and hospital (38). Also GP’s and medical doctors working on 
emergency wards are in favour of an electronic health record, to be used in acute 
situations, given that it minimally contains information on all the medication chronically 
used by a patient, including dose and frequency of administration, allergies, the medical 
history of the patient and the vaccination status (39).  
In a project aiming to improve seamless care for oncology patients, the community 
pharmacist would first contact the GP (39.1%) then the oncologist (33.8%) in case of 
need for information (40). Only a minority of pharmacists would contact the clinical 
pharmacist. This might change however, as a meeting between clinical pharmacists and 
community pharmacists, and leaflets written by the clinical pharmacists were evaluated 
very positively.   
Conclusion: perception of stakeholders 
In conclusion, medication history taking, information provision and discharge counselling 
are in most hospitals not structured or standardized. Many health care professionals are 
involved in these processes, without any clear definition on the roles and responsibilities 
of all different partners. Patients usually remind and appreciate the information they 
received although their perception differs from the perception of the caregiver who 
gave it. Clinical pharmacists, GP’s and other specialists involved in projects are in favour 
of an electronic health record to enhance the performance of medication history taking, 
the medical decision making and the communication between health care professionals. 
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Table 9: Research projects evaluating opinions or experiences of stakeholders on themes related to seamless care 
ID Reference  Setting /  
Study population 
A/D/A
D 
Study design Measures Main results  Financial 
support 
30 Sterckx 148 Algemeen ziekenhuis Sint-
Dympna Geel 
 
48 ward nurses (8 different 
wards) 
A Questionnaire 
survey 
(P) Admission procedure with regard 
to medication history taking  
Sources of information: 35.4% patient;  18.8% 
previous admission; 16.7% patient; 8.3% other 
hospital; 6.3% nursing home;  4.2% GP 
In case of unclear or missing information, family 
(59%), GP (6%), community pharmacist (6%) or 
nursing home (6%) is contacted. In 23% of cases, the 
specialist is informed.    
All nurses are allowed to perform medication history 
taking and to transfer the data into the electronic 
medication record of the patient.  
None 
31 De Sloovere 
142 
Algmeen ziekenhuis Maria 
Middelares Gent and UZ Gent 
 
6 head nurses 
A Questionnaire 
survey 
(P) Admission procedure with regard 
to medication history taking  
 On an abdominal, orthopedic and geriatric wards of 
both hospitals medication history is taken by a nurse. 
Exception is the emergency department of university 
hospital Gent, where medication history is only 
taken on demand of the doctor. 
Patients on a geriatric wards do often bring their 
home medication, including pill boxes, to the 
hospital. However, there is no general rule as to 
bring home medication upon admission. 
None 
32 Saelen 157 4 Flemish hospitals (600-1000 
beds each) 
 
300 ward nurses 
A Questionnaire 
survey 
(P) Medication history taking According to 84,4% of the respondents, medication 
history taking is a task for the nurse.  
Their opinions on background in pharmacotherapy 
are divided, but all confirm that they have no 
standardized procedure to perform a medication 
history. 
Information on home medication is written in the 
nursing file in 95.9% of cases, and in the medical file 
in 52.1% of cases.  
None 
33 CASOC  Ziekenhuis Overleg Gent (4 
hospitals) 
 
Patients > 65 discharged from 
hospital and followed-up by SIT 
+ ward nurses 
AD Questionnaire 
survey  
(P) Admission and discharge procedure 
according to the ward nurse  
(P) Admission and discharge procedure 
experienced by the patient 
In 10.8% of cases, ward nurses claimed that they 
actively informed the GP about the admission of 
their patient; patients thought in 68.4% of cases that 
their GP was informed about their admission. 
In 13.2% of cases, GP’s were actively informed about 
discharge of their patients; patients thought this was 
done in 26.8% of cases. 
Nurses claimed in 88.2% of cases that prescriptions 
for discharge medication were given to the patients 
or their family; 67.9% of patients said they received 
prescriptions. In 80.90% of cases, nurses said they 
None 
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provided medicines for the first days; 70.6% of 
patients said they received medication. 
In 70.6% of cases, written instructions for the GP 
were given to the patient; only 52.9% of patients said 
they received this type of instructions. Nurses said 
they explained these instructions in 89.78% of cases; 
only 24.5% of patients agreed this was done. 
34 OVOSIT 158 Ziekenhuizen en thuiszorg 
Oost-Vlaanderen 
 
320 health care professionals 
for the questionnaire survey 
 
Health care professionals and 
policy makers for the focus 
groups 
AD Questionnaire 
survey 
 
 
Focus groups 
(P) Communication between different 
partners about admission and discharge 
(who? when? how?) (P) Optimization of 
transfer documents? 
(P) Optimization of collaboration 
between all partners? 
(P) How to answer the need for a 
seamless care coordinator settings? 
On the long term, an electronic database is required. 
On the short term, the written home care file is 
preferred as transfer document.  
There is a need for a clear definition of the roles and 
responsibilities of the different partners in order to 
optimize collaboration. 
No conclusions could be made as to the ideal person 
to coordinate transition between settings 
Provincie-
bestuur Oost-
Vlaanderen 
35 Desplenter 
159 
11 Flemish psychiatric hospitals 
 
17 patients; 48 health care 
providers 
AD Semi-structured 
interviews 
(P) Information provision about 
antidepressant drugs throughout 
hospital stay 
Information is mostly given by the psychiatrist and 
the nurse. 
 Information provision is not structured or 
standardized.  
While information provision when starting or 
changing pharmacotherapy is usual, interventions at 
discharge are very limited.  
IWT 
Vlaanderen 
36 Ontslag 
medicatie  
Gezondheidszorg Oostkust 
 
113 patients discharged from 
D, C and Sp wards 
D Questionnaire (H) Patient experience and satisfaction 
about discharge process 
97% of patients received a medication scheme upon 
discharge; 96% received information about this 
scheme, while 91% received information about the 
drugs. 97% of patients claim to have understood the 
information.  
None 
37 Vlaams 
Patiënten 
Platform 160 
Chronically ill patients, member 
of patient association 
AD Questionnaire 
survey 
(H) Role and responsibility of different 
HCP in sharing information on 
medication record upon admission and 
discharge 
53% of respondents find it the task of the GP to 
inform the hospital about his/her medication record 
upon admission. 17% think it is the task of someone 
else (patient, family or specialist).  
45% agree that the name of the pharmacist should be 
kept in the hospital file; 38% disagrees. 
67% are opposed to direct exchange of information 
on discharge medication between the hospital and 
the community pharmacy. 91% agree with direct 
information between the hospital and the GP. 58% of 
patients prefer to inform the community pharmacy 
themselves.  
None 
38 Leemans 161 All Flemish hospitals with FOD 
project clinical pharmacy 
(Clinical) pharmacists, 
responsible for admission and 
AD Questionnaire 
survey, focus 
groups and semi-
structured 
(P) Problems related to transfer of 
information between community 
pharmacy and hospital 
(P) Essential elements of a shared 
Respondents confirmed that information on home 
medication of patients upon admission is often 
unclear 
Identification of family pharmacy and availability of 
APB 
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discharge + software 
developers 
interviews pharmaceutical record? 
(P) Current status of development of 
pharmacy software related to these 
issues?  
complete drug history are of major importance for 
clinical pharmacist.  
Respondents would favor a secured on-line system 
to exchange data between community pharmacy and 
hospital.  
39 De Nys 162 404 GP’s (82% Dutch-speaking; 
17% French-speaking) 
 
21 medical doctors working at 
emergency wards (80% Dutch-
speaking; 19% French-speaking) 
A Questionnaire 
survey (electronic) 
(P) Essential elements of an Electronic 
Health Record (EHR) for use in acute 
situations 
(P) Attitude towards and confidence in 
an EHR 
According to the respondents, the EHR should at 
least contain information on 1) allergies; 2) all 
medication chronically used by the patient, including 
information on dose and frequency of administration; 
3) medical history of the patient, including 
information on surgeries; 4)vaccination status and 5) 
reanimation code 
The survey shows that respondents have some 
doubts about the safety of an EHR, but think that 
using an EHR is efficient and is beneficial in making a 
correct diagnosis.  
None 
40 Duvivier  Centre Hospitalier Peltzer la 
Tourelle (oncology) 
 
Clinical pharmacist + 
community pharmacists 
D Questionnaire 
Survey  
Meetings for 
information 
(P)Information needed by the 
community pharmacists for counselling 
oncologic patients discharged from 
hospital 
(H) Satisfaction vs meetings and leaflet 
given (and written) by the clinical 
pharmacist 
(P) 45% of respondents reported that patients often 
ask questions over their oncologic treatment: side 
effects (15,5%), pain (14,2%), associated treatments 
(12,5%), medicines (11,2%), interactions (10,5%), 
treatment length (10,3%), intervention of the mutual 
insurance company (9,8%), home care services 
(8,8%) 
(P) the first person contacted by the pharmacist in 
case of need of information is: the GP (39,1%), the 
oncologist (33,8%), the service of oncology (17,7%), 
the clinical pharmacist (9,4%) 
(H) Evaluation of the meeting: 87,5% satisfaction , 
evaluation of the leaflet written by the clinical 
pharmacist for the community pharmacists: 100% 
satisfaction 
FOD Clinical 
Pharmacy 
projects 
Abbreviations: A: Admission; APB = Algemene Pharmaceutische Bond / Association Pharmaceutique Belge; D: Discharge; EHR: Electronic Health Record; FOD: Federale 
Overheidsdienst; GP: General Practitioner; HCP: Health Care Professional; IWT: Instituut voor de aanmoediging van Innovatie door Wetenschap en Technologie in 
Vlaanderen; P: Process measure; UZ : Universitair Ziekenhuis
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6.3.2.4 Ongoing research projects 
A few ongoing research projects were identified, that aim to encompass the gaps in the 
existing evidence, or that aim to investigate the impact of interventions on a larger 
scale.  
One research project will evaluate, in a cluster controlled trial, the impact of discharge 
medication scheme and information (composed by the clinical pharmacist) for the 
patient, the GP and the community pharmacist versus usual care (41). Outcome 
measures are 1) the number and characteristics of discrepancies between discharge 
medication and medication taken by the patient 2 weeks post-discharge (through phone 
call with patient/carer and GP), using the validated MDT (Medication Discrepancy Tool); 
2) satisfaction of patients, GP’s and community pharmacists and 3) readmission and care 
consumption 1 month after discharge. The results are expected by the end of 2010. 
The aim of two other research projects, one in Flanders and one in Wallonia, is to 
develop an electronic platform to share health-care related data between health care 
professionals (42,43). Both projects should result in a proof of concept, tested and 
evaluated by different stakeholders. As part of the Share4Health project (42), a pre-
study was performed to investigate the legal as well as practical possibilities of this type 
of platform, and the expectations and opinions of different stakeholders (results 
expected in 2010). Two other projects (44,45) focus on the use of existing medication 
schemes, and aim at developing a uniform document. The project of Leemans (45) will 
use qualitative interviews, while the study of the SIT Brugge-Oostkust (44) starts from 
document analysis. The results from these projects might inform others, as the 
developers of electronic platforms, on the expectations and usability of tools to 
enhance seamless care.  
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Table 10: Ongoing research projects 
ID Referenc
e 
Setting /  
Study population 
A/D/A
D 
Study design Intervention (+ control) Measures Financial 
support 
41 Claeys  Cliniques Universitaires Mont 
Godinne, Centre Hospitalier de 
Jolimont-Lobbes 
Geriatric and orthopedic wards 
(A)D Cluster controlled 
trial 
Discharge medication scheme and 
information (composed by the clinical 
pharmacist) for the patient, the GP and 
the community pharmacist vs usual 
care 
(P) Number and characteristics of discrepancies 
between discharge medication and medication 
taken by the patient 2 weeks post-discharge 
(through phone call with patient/carer and GP), 
using the validated MDT 
(H): Satisfaction of patients, GP’s and 
community pharmacists 
(C-E): readmission and care consumption 1 
month after discharge 
FNRS 
42 Share4 Health  Virga Jesse Ziekenhuis Hasselt / 
AZ Groeninge Kortrijk 
GP’s and community 
pharmacists from both regions 
AD Proof of concept Development of an inter-professional 
patient-centered IT platform that 
enables sharing of health-related data. 
WP4 focuses on the exchange of the 
medication record between hospital, 
GP and community pharmacy 
(H) Usablility IBBT 
43 Réseau santé 
Wallon  
38 French speaking hospitals AD Proof of concept Development of an electronic platform 
to share patient information between 
doctors (i.c. the specialist and the GP)  
(H) Usablility SPF Santé Publique, 
Région Wallonne, 
DELL 
44 SIT Brugge – 
Oostkust  
Different hospitals in the region 
of Brugge - Oostkust 
SIT Brugge – SIT Oostkust 
AD Document analysis 
Development of a 
universal 
medication scheme, 
to be used in the 
different settings 
NA (H) Layout, readability and use of existing 
medication schemes 
None 
45 Leemans  UZ Brussel 
Patients and nurses on different 
wards 
AD Qualitative 
interviews 
NA (H) Layout, readability and use of existing 
medication schemes 
None 
Abbreviations: A: admission; AZ: algemeen ziekenhuis; C: Clinical outcome measure; D: discharge; E: Economic outcome measure; FNRS: Fonds National de la Recherche 
Scientifique; IBBT: Interdisciplinair instituut voor BreedBand Technologie; IT: Information Technology; MDT: medication discrepancy tool; NA: not applicable; P: Process 
measure; SIT: Samenwerkingsinitiatieven Inzake Thuisverzorging; UZ: Universitair Ziekenhuis 
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6.3.2.5 Initiatives to improve the continuity of care with regard to medications, without 
any outcome measurement 
Searching for evidence through contacts with experts in the field resulted in a list of 
initiatives aimed to improve continuity of care with regard to medications, but without 
measurement of the impact on any outcome parameter (46-62). Many initiatives are 
clinical pharmacy based, either oriented on the admission process or on the admission 
and discharge processes. Some initiatives have an IT focus, while in others the use of a 
medication scheme or treatment plan was implemented. Two initiatives were identified 
that focused on the active follow-up of patients. In three hospitals, a brown bag was 
introduced. This kind of bag is to be used by patients upon admission, and should 
contain all the medication a patient is currently taking. In two other settings, transfer 
documents are developed that should enable transition between settings of care. 
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Table 11: Initiatives to improve seamless care, without outcome measurement 
ID Reference  Setting  A/D/A
D 
Type of 
initiative  
Brief description HCP 
involved   
Comments  Financial 
support 
46 Mediweb  AZ Groeninge, Kortrijk D IT Creation of a ‘mediweb’, which enables 
electronic access for GP’s to the medical files 
of their patients in the hospital 
For general 
practitioners 
One-way system. 
Information on medicines 
might be limited and 
distributed over different 
files and reports.  
AZ Groeninge 
47 Verhelle AZ  Groeninge AD IT 
Information and 
standardiza- 
tion 
Analysis of current admission and discharge 
procedures; standardization; participation in 
Share4Health.  
For general 
practitioners, 
hospital and 
community 
pharmacists  
 AZ Groeninge 
AVK 
IBBT 
48 My UZ  UZ Leuven A IT Personal and medical data, needed for 
anesthesiology, can be filled in by patients at 
home in an on-line application. Information is 
stored in a patient-specific file accessible for 
anesthesiologists.  
For specialists Not exclusively focusing 
on medicines 
UZ Leuven 
49 GLS  Services et soins à domicile, 
Liège 
AD Medication 
scheme + 
Information and 
coordination 
between 
stakeholders 
Development of a patient-specific medication 
scheme to be used upon transfer of patients 
between settings of care 
Development of a coordination book for 
stakeholders  
By nurses, in 
collaboration 
with pharmacists 
and GPs 
For GP’s, 
pharmacists, 
nurses, 
physiotherapists, 
patients 
 SPF Santé 
Publique 
50 Medicatie 
schema BOA  
Community pharmacies, region 
of Brugge – Oostende 
AD Medication 
scheme 
Development of a medication scheme to be 
filled in by the community pharmacist in order 
to clarify the established drug regimen after 
discharge and/or to be used upon transfer 
between settings of care 
By community 
pharmacists 
 BOA 
51 Meert 163 Algemeen Ziekenhuis Maria 
Middelares Gent – gatro-
enterology ward 
D Medication 
scheme 
Development of a simplified medication 
scheme, to be used upon discharge  
By clinical 
pharmacist 
Follow-up of project by 
Bouchier (49) 
None 
52 Ziekenhuis 
project WGK 
Limburg  
Hospitals and Wit-Geel Kruis, 
Limburg 
D Treatment plan, 
including 
medication 
scheme  
Preparation of discharge of patients previously 
cared for by WGK and organization of care by 
‘continuity’ nurse 
By nurses  Not exclusively focusing 
on medicines 
WGK 
Limburg 
53 Project Puente  43 psychiatric hospitals Vzw 
Remissie 
D Patient follow-
up 
Assertive 
Follow-up of patients with schizophrenia, with 
focus on compliance to drug regimen and with 
attention for communication between HCP’s. 
By nurses Not exclusively focusing 
on medicines 
Koning 
Boudewijn  
stichting 
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ID Reference  Setting  A/D/A
D 
Type of 
initiative  
Brief description HCP 
involved   
Comments  Financial 
support 
outreach CSR Johnson 
& Johnson, 
Janssen - Cilag 
54 APPI 164 UZ Antwerpen – policlinic 
surgery 
D Treament plan 
+ patient 
follow-up 
Elaboration of a patient-specific pain treatment 
plan + telephonic follow-up of patients post 
discharge 
By clinical 
pharmacist 
 FOD projects 
clinical 
pharmacy 
55 Van Hove 165 Algemeen Ziekenhuis Sint-
Nikolaas 
AD Medication 
scheme + 
Information and 
coordination 
between 
stakeholders 
Development of a uniform medication scheme, 
to be used upon discharge 
Implementation of brown bag 
By clinical 
pharmacist, in 
collaboration 
with nurses and 
GP’s 
 
 FOD projects 
clinical 
pharmacy 
56 Verhaeghe 166 AZ Groeninge – emergency 
ward 
A Clinical 
pharmacy 
Drug history taking, including drug-disease and 
drug-drug interaction checking 
By clinical 
pharmacist 
 FOD projects 
clinical 
pharmacy 
57 Clinical 
pharmacy 
admission and 
discharge 167 , 
168 , 169 , 170 
, 171 , 172 , 
173 174;; 
Different hospitals (see list 
below)a 
AD Clinical 
pharmacy 
Drug history on admission, and informing 
patient/GP/community pharmacist upon 
discharge 
By clinical 
pharmacist, in 
collaboration 
with other HCP 
Not all wards covered at 
the same time; dependent 
on availability of clinical 
pharmacists. 
FOD projects 
clinical 
pharmacy + 
hospital (in 
limited cases 
only) + 
external (in 
limited cases 
only) 
58 Inventarisatie 
thuis-
medicatie  
Algemeen Ziekenhuis Sint-
Jozef Turnhout 
A Brown bag Patients receive a ‘brown bag’ upon pre-
operative consultation or when admitted to the 
emergency ward. Patients are asked to bring all 
the medicines they use at home in the brown 
bag upon admission. The ward nurse discusses 
the content of the brown bag with the patient 
and uses this information to build the drug 
history. Upon discharge, the brown bag is given 
back to the patient, and any change or 
discontinuation is explained.  
By ward nurses  Hospital + 
Vlaams 
Ziekenhuis 
netwerk 
59 Zakje voor 
persoonlijke 
geneesmid-
delen  
Algemeen ziekenhuis Sint-
Blasius Dendermonde 
A Brown bag Patients receive a ‘brown bag’ upon pre-
hospitalization consultation. Patients are asked 
to bring all the medicines they use at home in 
the brown bag upon admission.  
By ward nurses  Pilot phase Hospital 
60 Medicatie-
zakje  
UZ Leuven A Brown bag Patients receive a ‘brown bag’ + information 
leaflet upon pre-hospitalization consultation or 
when admitted to one of the participating 
By ward nurses, 
specialized 
doctors (e.g. 
Started in November 2008 
as part of the ‘Week van 
de patiëntveiligheid’. 
UZ Leuven 
Vlaams 
Ziekenhuis 
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ID Reference  Setting  A/D/A
D 
Type of 
initiative  
Brief description HCP 
involved   
Comments  Financial 
support 
wards. Patients are asked to bring all the 
medicines they use at home in the brown bag.  
anesthesiology) 
and clinical 
pharmacists 
Netwerk 
61 Samen-
werking 
MZNL WGK 
Limburg 
Maria Ziekenhuis Noord 
Limburg 
WGK Peer, Bree, Neerpelt, 
Lommel 
AD Discharge 
protocol  
Transfer 
document, 
including 
medication 
scheme 
Development of a uniform discharge protocol 
and discharge document for patients cared for 
by WGK.  
Ward nurses 
WGK nurses 
Not exclusively focusing 
on medicines 
 
62 TransFert 
Document  
AZ Sint-Maarten Duffel D Transfer 
document 
Development of a standardized drug therapy 
chart, to be used upon discharge of patients 
 
 Concept phase  
63 Van farmac. 
anamnese tot 
elektronsiche 
ontslagbrief 
AZ Groeninge Kortrijk AD Clinical 
pharmacy + IT 
Drug history taking, including drug-disease and 
drug-drug interaction checking. 
Storage of data in electronic record.  
Electronic discharge letter, composed of 
information in the electronic record.  
 
By clinical 
pharmacists 
 None 
Abbreviations: A: Admission; AVK: Apothekers Vereniging Kortrijk; AZ: Algemeen Ziekenhuis; BOA: Brugse en Oostendse Apothekersvereniging; CSR: Corporate Social 
Responsibility; D: Discharge; FOD: Federale Overheidsdienst; GP: General Practitioner; HCP: Health Care Professional; IBBT: Interdisciplinair Instituut voor Breedband 
Technologie; IT: information technology; SPF: Service Public Fédéral; UZ: Universitair Ziekenhuis; WGK: Wit-Gele Kruis  
a Hospitals with clinical pharmacy initiatives on seamless care (admission and discharge): 
AZ Damiaan Oostende – geriatric ward (42); AZ Groeninge Kortrijk – emergency department (22); AZ Sint-Blasius Dendermonde – geriatric ward (44); AZ Sint-Lucas Gent – 
geriatric ward (23); AZ Sint-Lucas Gent – geriatric ward (23); AZ Sint-Nikolaas Sint-Niklaas – geriatric ward (43); CH du Bois de l’Abbaye et de Hesbaye – geriatric ward 
(10D); CH Peltzer La Tourelle – Oncology (59); CHU Liège – geriatric ward (10E); CHU Tivoli – geriatric ward (10B); CHU Tubize Nivelles – geriatric ward (10E); Clinique du 
Sud du Luxembourg – Orthopedic ward (10E); Cliniques Universitaires Saint-Luc Bruxelles – internal medicine, revalidation, dialysis, intensive care, pediatrics, orthopedics* 
(10C)(38)(36)(37); Erasme – cardiology (19); Hôpital Vésale CHU de Charleroi – geriatric ward (1OE); Imelda ziekenhuis Bonheiden – orthopedic surgery (6); Intercommunale 
CHP de Liège – psychiatric ward (10E); Onze-Lieve-Vrouw ziekenhuis Aalst – oncology (7); UCL Mont-Godinne – geriatry, orthopedic surgery, digestive surgery, internal 
medicine, cardiology, pneumology* (10A)(35)(32); UZ Antwerp – surgery day-hospital; UZ Brussel – geriatric ward (30); UZ Gent – surgery (27); UZ Leuven – emergency 
department (28); Virga Jesse Ziekenhuis Hasselt – oncology ward, hematology ward, abdominal surgery (29); Ziekenhuis Oost-Limburg Genk – cardiology – gastro-enterology 
– abdominal surgery – urology – oncology – pneumology – neurology- geriatric ward – thoracal surgery – orthopedics surgery – neurosurgery
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6.3.3 Results: Barriers and difficulties reported by the experts 
Some of the barriers identified by the experts who filled the questionnaires are patient-
related, while other are linked with the health-care professional performing the 
intervention. However, most barriers, are system-related. 
6.3.3.1 Patient-related barriers 
• Patients don’t always know the name of the community pharmacist or do not 
have a fixed pharmacy where they collect their medicines. This has an impact 
on the possibility to perform medication history taking in collaboration with 
the community pharmacist (18).  
• Patients often have difficulties to use an on-line tool as developed to 
inventory personal and medical data needed for anaesthesiology (48). Some 
patients don’t know how the e-ID reader works, don’t know the codes or 
don’t fill in the files properly. 
• Patients might need help to complete the medication scheme provided on the 
brown bag and need to be counselled to take the bag with them upon 
admission and discharge (58-60). 
• Patients may not want the direct exchange of information between the 
hospital and the community pharmacy (37) 
• Language and health literacy may be barriers when counselling patients upon 
discharge (26). 
• Leaving the patient with a transfer document for the community pharmacist 
might weaken the power of this type of intervention. Some patients might 
forget or not give the information letter to the pharmacist (27). 
6.3.3.2 Barriers related to the health care professional performing the intervention 
• Specific education and training is needed to perform clinical pharmacy (21). 
• Nurses and discharge managers often lack adequate knowledge on 
medication (36). 
• Community pharmacists might feel uncomfortable to contact clinical 
pharmacists (40) 
6.3.3.3 System related barriers 
• Access to patient files is often difficult and electronic data insufficient 
(7,56,57). 
• It is often difficult to reach the GP or community pharmacist when 
attempting to get into contact when performing medication history  (18).  
• Discharge planning is often very variable, which makes it difficult to plan 
interventions by clinical pharmacists (24). 
• Many of the interventions are time consuming. Health care professionals 
struggle with a lack of economic and human resources (7,21,53,54,56,57). 
• The “Forfaitarisation”5 of medication in hospitals makes it difficult to find a 
balance between adequate service and budget (36). 
• In some settings, there is a lack of interest of doctors and other HCP’s for 
the medication problem and more specifically for the development of clinical 
pharmacy. 
                                                     
5  Forfaitarisation means that the hospital receives a fixed amount of money per patient and per indication 
that should be sufficient to pay all costs, including drug expenditure. In order to reduce costs, hospitals 
may limit the amount of discharge medication. 
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6.3.4 Results: Driving forces reported by the experts 
The experts also identified facilitators, i.e. elements that sustain or even stimulate the 
development of new services. Quite a lot of experts reported that the most motivating 
factor is that patients as well as other health care professionals welcome the initiative, 
and that they confirm the added value of the intervention. Also the positive results or 
improvements following initiatives seem to be motivating for further development of 
interventions. An overview of specific facilitators mentioned by experts involved in the 
inventoried projects, is given below. 
6.3.4.1 Patient-related facilitators 
• When visiting patients at home (10), or when counselling patients at 
discharge (24), health care professionals experience the appreciation of 
patients for having a meeting with someone who is really interested in their 
difficulties, without judgement. 
• Patients report to find added value in being counselled by a clinical pharmacist 
upon discharge (24,26), and appreciate the personalized approach (26).  
• Patients seem to appreciate receiving an appropriate medication scheme as it 
meets their need for more information about their treatment 
(49,50,51,52,61,62). 
6.3.4.2 Facilitators related to the interaction with other health care professionals 
• GP’s and community pharmacists do react in a positive way when contacted 
by the clinical pharmacist to collaborate in medication history taking (18). 
• Community pharmacists express their appreciation for receiving an 
information document, written by the clinical pharmacist upon discharge (27). 
• Medical doctors and nurses confirm the added value of services such as the 
Apotheek Service Loket (21). 
• Nurses express their satisfaction with the fact that composing a medication 
scheme is taken over by the pharmacist, because they lack time and 
knowledge to perform this task (49,50,51,52,61,62). 
• Doctors and other health care professionals are enthusiastic about clinical 
pharmacy initiatives (7,56,57), and confirm that these initiatives result in time 
saving. Nurses do find the presence of a clinical pharmacist supportive, and 
report gaining knowledge about drugs.  
6.3.4.3 Results or improvements perceived by health care professionals 
• Discrepancies observed when comparing drug histories taken by medical 
doctors / nurses and clinical pharmacists, are often clinically relevant and have 
an impact on clinical judgement (17). 
• Electronic access for GP’s and specialists to medical files of patients does 
improve the communication between health care professionals (43,46). 
• Personal and medical data filled in by patients at home (on-line) is 
comfortable for patients, decreases the rate of medication errors at 
admission and saves time for doctor and patient (48). 
• Clinical pharmacy initiatives upon discharge result in an improved follow-up 
of therapy, e.g. notification of drug interactions, and in a decreased number of 
phone calls from GP’s to specialists after discharge (7,56,57).  
• Patient counselling upon discharge results in better compliance and 
understanding of the therapy by the patient (7,56,57). 
• Implementation of a brown bag decreases the number of phone calls from 
GP’s to specialists after discharge (58,59). 
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• Projects do result in integration of the clinical pharmacist in the health care 
team (26) (21) an enhance the appreciation for the clinical pharmacist as a 
reference person to be contacted for all questions related to medication 
(7,56,57). 
6.4 DISCUSSION  
This work gives an extensive overview of initiatives on seamless care for medication in 
Belgium. There is a growing awareness of the problems around seamless care as most 
projects or initiatives identified started over the last three years. 
6.4.1 Setting: outnumber of hospital based initiatives 
Most projects were initiated by health care professionals working in the hospital setting. 
Very few studies were set up as collaboration between primary and secondary care.  
The majority of projects were single-centre, with only a few multi-centre studies.  
Projects were developed in both teaching and non teaching environments. There does 
not seem to be any clear-cut difference in the problems encountered or other results 
found, which enhances generalisation of the results. 
6.4.2 Sources of funding 
From the list of projects, it is clear that the pilot projects in clinical pharmacy, 
sponsored by the Ministry of Health, have ‘boosted’ this research domain. Without this 
support, half of the projects reported in this study would not have been performed. The 
yearly budget for these projects, started in 2007, was estimated to be 1.248.983 €.   
Other projects have been funded by the hospital, through employment of the people 
involved, or didn’t require extra funding because they were performed by students as 
part of their master thesis. For PhD projects, funding was searched at organisations as 
IWT or FWO/FNRS. 
Some projects, initiated by health care professionals in ambulatory care, were 
supported by home care organisations as Wit-Gele Kruis. One project was sponsored 
by the province of Oost-Vlaanderen, another by IBBT.  
6.4.3 Design: controlled interventions with small sample sizes  
Studies that evaluated DRP were all, except one, prospective in nature. This enhances 
the validity of the data collected.  
When looking at the design of intervention studies, there was no randomised controlled 
trial, but most studies were controlled. Three studies evaluating the impact of discharge 
counselling were uncontrolled (22,26,27), and therefore their validity and usefulness is 
questionable.  
An important weakness of the evidence collected refers to the sample size. About half 
of the studies included less than 50 patients, and only one-third of them included more 
than 100 patients. This has important consequences in terms of generalisation  and 
power. If future studies are designed, they should include enough patients to be able to 
show an impact on important patient outcomes, and preferably be multicentre.  
Most projects that investigated drug-related problems at discharge yielded information 
on the numbers of problems only, not on the causes of these problems.  Only one 
study (10) investigated possible factors contributing to these problems. 
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6.4.4 Stakeholders involved  
The initiatives reported were taken by different stakeholders (e.g., pharmacists, GPs, 
nurses, SIT (Samenwerkings Initiatieven Thuiszorg)) with an important proportion of 
initiatives taken by clinical pharmacists. Overall, there is a need for interdisciplinary 
projects, with a focus on the community setting and what can be done there. 
Despite the heterogeneity in outcome measures, the results show discrepancies 
between drug histories performed by a doctor/nurse versus by a clinical pharmacist. 
This concurs with results from studies performed in other countries 20 , 21 and with the 
international consensus that medication history taking by a clinical pharmacist should be 
considered as ‘golden standard’, under the condition that it is performed in a structured 
and comprehensive way, combining different sources of information. 
So far, the evaluation of the role of the community pharmacists is limited, but 
interesting. The fact that only a small number of answers were received from discharge 
managers might show the limited attention paid to medication in the process of case 
management or when developing discharge procedures.  
6.4.5 Population of interest: at risk for DRP 
The patients mostly targeted were patients admitted on surgery and geriatric wards as 
well as on the emergency department. This is not surprising as these patients are at high 
risk of adverse drug events. Consequently, many seamless care studies conducted in 
other countries have targeted the same groups of patients 21, 27 , 40, 41. One could expect 
that the impact of the interventions tested may be different when performed at 
different wards or when focusing on different patient groups.  
Studies evaluating DRPs upon discharge evaluated both the perspective of GPs (by 
looking at missing or erroneous information in the discharge letter) and of patients (by 
looking at the information they received, as well as errors in the drugs given at 
discharge). In contrast, in the majority of intervention studies focusing on discharge, the 
focus was on the patient (by measuring knowledge of medications, for example) and not 
on the GP or the community pharmacist. This is an area for further research. 
6.4.6 Type of intervention  
Most projects that analyzed the problems at the transition between settings focused on 
the errors at discharge. The interventions that aimed to improve seamless care mostly 
focused on admission. Many initiatives focused on changing the role of HCP’s, and more 
specifically on the role of the clinical pharmacist. This was also the case in the 
international literature review.  
Several projects and initiatives on clinical pharmacy were repeated in different settings 
(hospital or ward). The amount of ‘new’ or ‘original’ research projects is rather limited. 
However, the fact that some of the results were shown in different settings and at 
different wards, enhances the generalisation of the main findings.  
Development of IT tools is still in concept phase. In the projects or initiatives reporting 
on electronic access to data, this access is limited to doctors (GP’s, specialists). So far, 
there is no involvement of pharmacists or home care nurses, except for the 
Share4Health project (42) where the electronic exchange of information between 
hospital, GP and community pharmacy will be tested. However, there is a real interest 
from pharmacists, as could be seen in the studies by Leemans (38). Furthermore, the 
impact of the proposed IT tools has not yet been evaluated. Also in other countries 
there is a lack of studies reporting the impact of IT initiatives.  
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6.4.7 Evaluation: heterogeneous outcome measures and limited data 
6.4.7.1 Lack of clinical and economical outcome measures 
An important weakness of the studies is that none but one of them evaluated the 
impact on clinical outcome measures (such as adverse drug events or readmission) or 
on economic outcome measures. The vast majority of research studies used process 
measures as primary and secondary endpoint.  
6.4.7.2 Short term effects 
Most interventions focused on short term effects at discharge. One study planned a 
home visit post discharge to evaluate discrepancies between the intended medication 
and the medication actually taken by the patient. Only one other study looked at ADEs 
or readmissions that could occur in consequence. Therefore, future studies should be 
designed in order to collect follow-up data and to focus on long-term effects of the 
interventions.  
6.4.7.3 Heterogeneous outcome measures 
Another weakness in the identified projects is that there is a lack of homogeneity in the 
measures used and that only a few studies used or reported using validated process 
measures. In studies comparing drug histories performed by a doctor/nurse vs by a 
clinical pharmacist (10 studies in total), the categories used to report discrepancies 
varied from one study to another, which makes comparison of the results more difficult. 
There is therefore a need to develop and validate a national form (similarly to the form 
to report clinical pharmacy interventions), or to use a validated form from the 
literature. Despite these differences, the results clearly show that discrepancies 
between drug histories performed by a doctor/nurse vs by a clinical pharmacist are 
extremely frequent. This concurs with results from studies performed in other 
countries 20 , 21 and with the international consensus that medication history taking by a 
clinical pharmacist should be considered as ‘golden standard’, under the condition that it 
is performed in a structured and comprehensive way, combining different sources of 
information. 
A few studies evaluated humanistic outcome measures, mainly satisfaction of patients on 
the counselling process. For projects evaluating opinions or experiences of 
stakeholders, the transferability of the results is questionable. The information conveyed 
by these studies is limited and the data obtained might be valid in specific settings only. 
However, most of these projects confirm the existence of the problems identified by 
other studies, and point towards the need to improve the continuity of care with regard 
to medicines. 
6.4.7.4 Limited data on causes of drug related problems 
One of the objectives of this study was to identify the possible causes of drug related 
problems related to transition of care. Although many studies investigated the frequency 
and nature of DRP’s on admission as well as discharge, data on the causes of these 
problems were not identified as such and can only be extrapolated from the studies. 
Determining factors in the hospital setting seem to be: 1) the fact that medication 
history taking, information provision and discharge counselling is in most cases not 
structured or standardized, and 2) the fact that many health care professionals are 
involved in these processes, without any clear definition on the roles and responsibilities 
of all different partners. This lack of standardisation also seems to apply to ambulatory 
care, as was shown in studies investigating referral letters of GP’s.  
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6.4.8 Barriers and facilitators: multilevel data 
The barriers and facilitators for developing seamless care interventions, as reported by 
experts in the field, could be categorized at three levels: the patient level, the health 
care professional level, and the system level. This is in full agreement with the findings of 
Coleman 48, describing barriers to effective care transition for persons with continuous 
complex care needs. The lack of formal relationships between care settings, hence 
influencing the communication and collaboration between health care professionals, is 
probably the most important barrier to target.  
A frequently reported motivating factor to improve seamless care is the fact that 
patients as well as health care professionals welcome this kind of initiatives and that 
they confirm the added value of the interventions. Moreover, the health care 
professionals involved, seem to perceive a positive impact of the interventions tested. 
From these reports, we feel that facilitators overweigh barriers and that there is, at 
least at an individual or local level, enthusiasm for the development of new services. 
Whether this enthusiasm is also present at other levels (e.g. health care professionals 
who have not been involved yet in projects; policy makers), will be explored in the 
qualitative study (see chapter 8).  
6.5 SUMMARY 
The main objective of this review was to obtain an exhaustive overview of the past and 
ongoing seamless care projects in Belgium. The results show a high number of recently 
initiated heterogeneous projects, mostly initiated in the hospital setting. Many 
interventions focus on admission, and involve medication history taking by a clinical 
pharmacist. Patient counselling at discharge, either by a nurse or a clinical pharmacist, is 
part of many other projects. All interventions with record of outcome measures 
reported a positive impact on one or more outcome parameters (process measures; 
economic or humanistic outcomes). However, we cannot discount the fact that there is 
enthusiasm with any new initiative which gives better results regardless of intervention. 
The impact on clinical outcomes could not be demonstrated.  
Overall, the quality of the evidence obtained is low. The weaknesses observed apply to 
sample size, design (including lack of randomisation and blinding), evaluation measures 
used, and generalisation. One cause for this might be that many initiatives were only 
recently set up, mainly as part of pilot programs. Other projects were part of students’ 
master theses. This situation might explain the limited scope of projects, with small 
numbers of included patients, in only one ward and over a short period of time.  
Ongoing research projects hold great interest, because they will fill gaps in existing 
research (through evaluation of the impact of IT initiatives (42,43), and evaluation of the 
impact of discharge management from the perspective of three different HCPs, within a 
multicenter design, and with clinical outcome measures in addition to process measures 
(41). 
In spite of efforts to inventory all possible initiatives, it is still possible that this review 
missed some interesting projects. However, this inventory gives a good overview of the 
current situation in Belgium and can be used to further analyze possibilities or strategies 
to enhance seamless care. 
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Key points 
• This chapter reviews the initiatives taken in Belgium to improve seamless 
care. Data were retrieved using a combination of strategies: indexed 
literature search, handsearch of Belgian journals, and a questionnaire survey. 
• A variety of types of interventions has been found, mostly in the hospital 
setting, with an important proportion of initiatives taken by clinical 
pharmacists.  
• For most studies a positive impact was reported on one or more process 
measures. The impact on clinical outcomes was evaluated in a few cases 
only, and could not be demonstrated. 
• Overall, the quality of the evidence is low. 
• Ongoing research projects hold great interest, because they will fill gaps in 
existing research. 
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7 PILOT STUDY: DRUG SUBSTITUTION 
ASSOCIATED WITH A HOSPITAL STAY 
7.1 INTRODUCTION 
Transitions between settings of care are often accompanied by changes in medication. 
Many types of changes may occur i.e. changes of specialty name for the same chemical 
substance as defined by the Anatomical Therapeutic Chemical Classification System 
(ATC) level 5(for example Simvafour versus Simvastatin EG), changes of dosages (for 
example 20 mg once daily versus 10 mg twice daily), changes within the same chemical 
subgroup (ATC level 4) (for example atorvastatin versus simvastatin),...  
One particular type of change associated with transition between settings of care is the 
change between generic and originator drugs due to different prescription rules in 
hospital and in ambulatory care (cf. qualitative study, chapter 8).  
Pressure to sustain health care provision whilst curtailing pharmaceutical expenditure 
and price competition among pharmaceutical manufacturers are fuelling the 
development of generic drug markets in European countries 175. In Belgium, the market 
for generic drugs is relatively under-developed as compared to other countries 176. As 
compared with other European countries, Belgian physicians face few incentives to 
prescribe generic drugs and existing incentives tend to be weak. The size of generic 
drug markets therefore varies within Belgium according to the settings. On the one 
hand, generic drugs are increasingly being prescribed and dispensed in ambulatory care. 
For instance, the market share of generic drugs by volume (as measured by the number 
of defined daily dosages) in the Belgian retail market rose from 0.6% in 1997 to 24.0% in 
2008177. On the other hand, the use of generic drugs in hospitals is restricted due to, 
amongst other things, the existence of hospital-specific drug formularies that list one 
commercial preparation of a specific chemical substance/dosage available for 
prescription. The limited availability of generic drugs with a suitable pharmaceutical form 
(e.g. for intravenous injection or perfusion, for intramuscular injection, etc.) might 
explain why so few generic drugs are on drug formularies, and hence why generic drugs 
are prescribed to a lesser extent in hospitals. Differences in the amount of generic drug 
use between hospital and ambulatory care may lead to drug substitution associated with 
a hospital stay: a generic drug prior to hospitalisation may be replaced by an originator 
drug during (and potentially following), hospitalisation, or vice versa. 
Finally, financial aspects associated with drug substitution need to be considered: several 
studies have demonstrated that substantial savings could be gained from substituting 
generic drugs for originator drugs in Belgium 175 , 178. 
7.2 RESEARCH QUESTIONS 
The aim of this chapter is to conduct a pilot study on drug substitution associated with 
a hospital stay in Belgium. The research question is the following: To what extent does 
drug substitution associated with a hospital stay take place in Belgium?  
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7.3 METHODOLOGY 
7.3.1 Study setting 
The study focused on drug use in ambulatory care of patients who have been admitted 
and discharged from Belgian acute hospitals. 
7.3.2 Data source 
Data were extracted from the 2006-2007 permanent sample dataset of IMA/AIM, the 
Belgian Agency of Health Insurance Funds. The permanent sample dataset is an 
anonymous sample of the Belgian population that includes data on demographic 
characteristics and health care claims. The permanent sample consists of a 1:40 sample 
of patients aged below 65 years and a 1/20 sample of patients aged 65 years or older. As 
older patients are over-represented in the permanent sample, the analysis weighted 
data so that the results presented in this section becomes representative of the Belgian 
population.  Data cleaning conventions and rules applied to the data are described in the 
appendix 5 that relates to chapter 7.  
No ethical approval was needed for this study. 
7.3.3 Data  
The study database extracted information about demographic characteristics, drug 
claims and hospitalisations from the IMA/AIM permanent sample dataset.  
The demographic characteristics of patients related to gender; age of birth; and time of 
death, if applicable.  
Data on reimbursed drugs dispensed in ambulatory care were extracted for the three-
month period prior to hospitalisation and for the three-month period following 
hospitalisation. For each three-month period, variables included the drug code 
according to the Anatomical Therapeutic Chemical Classification System 179; the number 
of packages and the number of defined daily doses 6  (DDD) of generic drugs; the 
reimbursement tariff, patient co-payment and supplement of generic drugs; the number 
of packages and the number of defined daily doses of originator drugs; the 
reimbursement tariff, patient co-payment and supplement of originator drugs; and 
dispensing dates. Two additional variables allowed identification of generic drugs and 
cheap drugs (i.e. generic drugs and originator drugs that have dropped their price to the 
level of the reference price or a lower level). The label ‘generic drug’ referred to 
generic drugs and copies, while the label ‘originator drug’ related to originator drugs, 
parallel imported drugs, reference specialities, and orphan drugs. Cases where a patient 
took more than 25 packages of a specific drug during a three-month period were 
considered to be outliers and, hence, excluded from the dataset. 
Also, data were gathered on start and end dates of patient hospitalisations. The study 
focused on hospitalisations in an acute hospital: day hospitalisation, palliative care and 
stays in a psychiatric hospital were not considered. As only those hospitalisations could 
be included that had a three-month period prior to and following the hospital stay 
during 2006-2007, hospitalisations needed to start on 1st April 2006 at the earliest and 
needed to end on 30th September 2007 at the latest. Patients may have experienced 
multiple hospitalisations during 2006-2007. Two hospital stays, for which there was a 
gap of three days at the most between two stays, were considered as one 
hospitalisation. In order to have data on drug use in ambulatory care during a three-
month time period, no other hospitalisation could occur in the three months prior to 
or following a hospitalisation. 
                                                     
6  The defined daily dose refers to the assumed average daily dose of a drug needed to treat its main 
indication in an adult person weighing 70 kg. 
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7.3.4 Medications under study 
7.3.4.1 Selection of medications 
The study was limited to all compounds in drug classes that answered to different 
criteria, i.e.: 
• With the highest public expenditure in 2008 180;  
• That were included in the physician-health insurance convention;  
• That may lead to transition-related problems between ambulatory care and 
hospital 181;  
• That are administered for chronic indications;  
• That included generic drugs.  
The project team agreed to include the following drug classes in the analysis (see Table 
12): 
Table12: Medications under study 
Note: ATC = Anatomical Therapeutic Chemical Classification System. 
7.3.4.2 Drug substitution 
Substitution between generic and originator drugs 
In the first analyses drug substitution was identified as a switch from a generic drug to 
an originator drug or vice versa between pre- and post-hospitalization periods. A switch 
had to involve the same active substance as defined at level 5 of the Anatomical 
Therapeutic Chemical Classification System (for example Simvastatine EG® versus 
Cholemed®). When the same active substance was used prior to and following 
hospitalisation, a descriptive analysis quantified the extent of drug substitution by 
calculating the percentage of generic drug – originator drug switches, the percentage of 
originator drug – generic drug switches, the percentage of generic drug – generic drug 
cases, and the percentage of originator drug – originator drug cases between pre- and 
post-hospitalization periods. 
ATC code Description 
A02B Drugs for peptic ulcer and gastro-oesophageal reflux disease  
A10B Blood glucose lowering drugs, excl. insulins 
C03B Low-ceiling diuretics, excl. thiazides 
C03C High-ceiling diuretics 
C03D Potassium-sparing agents 
C07A Beta blocking agents 
C08C Selective calcium channel blockers with mainly vascular effects 
C09A Ace inhibitors, plain 
C10A Lipid modifying agents, plain 
M01A Anti-inflammatory and anti-rheumatic products, non-steroids 
M05B Drugs affecting bone structure and mineralization 
N02A Opioids 
N05A Antipsychotics 
N06A Antidepressants 
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Substitution within the same chemical subgroup or with the same 
chemical substance 
Given the low substitution rate between generic and originator drugs it has been 
decided in a further step to analyse more in depth all changes in therapy that could be 
the cause of medication errors after hospitalisation. Drug substitution was defined much 
larger i.e. as any change that occurred within the same chemical subgroup (at level ATC 
4) or any changes in dosage or names of the specialty within the same chemical 
substance subgroup (at level ATC 5), i.e.: 
1. Changes between chemical substances within the same chemical subgroup (as 
defined at the level 4 of the ATC system) (e.g. switch from simvastatin to 
atorvastatin); cases of patients who had several drugs within the same chemical 
subgroup before and/or after hospitalization were added to this category of 
change (for example Simvastatine EG® switched to Simvastatine EG® and 
Crestor®); 
2.  Changes in specialty name of the product with the same composition (e.g. 
switch from Cholemed® to Docsimvastatine®) including the changes already 
analysed above (same chemical substance with a generic or originator label) 
3.  Changes of tablet dosage but no change in the specialty name of the product 
(e.g. switch from a tablet of 20mg to a tablet of 40mg of simvastatin) 
4. Both changes (specialty name and tablet dosage for the same chemical substance) 
The initial database had no separate fields for specialty name and dosages. All marketed 
drugs had, therefore, first to be manually coded according to specialty names and 
dosages separately to identify any possible change for the patient. There were 87 
possibilities for the statins group and 117 different possibilities for the proton pump 
inhibitors group. The analyses were therefore restricted those two medications. 
5. ATC level 4 = C10AA: HMG CoA Reductase Inhibitors (Statins)  
6. ATC level 4 = A02BC: Proton Pump Inhibitors (IPP group) 
7.3.5 Data analysis 
A descriptive analysis was carried out of the demographic characteristics of the patient 
sample. Characteristics were reported as relative frequencies for categorical data; mean 
and standard deviation for continuous data. The age was calculated as the difference 
between the year in which the most recent hospitalisation took place and the year of 
birth.  
The analysis focused on the use of the same active substance during the three-month 
period prior to hospitalisation and during the three-month period following 
hospitalisation. A patient may buy a medication of the same chemical subgroup or 
chemical substance group at multiple points in time during the pre- and post-
hospitalization periods. When investigating the occurrence of drug substitution, the 
medication bought at the time point closest to the hospitalisation was considered. In 
other words, the last purchase of a drug prior to the hospitalisation was compared with 
the first purchase following the hospitalisation.  
The reader should note that patients who died or stopped taking a drug at some point 
during the three months following hospitalisation were not excluded from the analysis. 
This is because such patients still provided relevant data about possible drug 
substitution for our analyses as only cases with available medication information prior 
and following the hospitalization were taken into account in the analyses. 
All analyses were conducted in SAS Enterprise Guide 4. 
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7.4 RESULTS 
7.4.1 General information 
The database used in the analysis related to 17,764 patients: the mean age of patients 
was 65.9 years (standard deviation: 16.72 years) and 60% of patients were female. As a 
result of the data selection procedure as described above, patients had a minimum of 1 
and a maximum of 4 hospitalisations during 2006 and 2007. 
7.4.2 Drug substitution between generic and originator drugs 
The study database included 41,633 records where the patient purchased the same 
active substance prior to and following a hospitalisation. As explained before (see 
section 7.3.2.), the data were weighted and extrapolated to the Belgian population. 
Table 13 reports absolute and relative frequencies of generic drugs and originator drugs 
purchased during the three-month periods prior to and following a hospitalisation in 
2006-2007.  
The extent of drug substitution was limited. In 71% of cases, an originator drug was 
purchased prior to and following hospitalisation. Similarly, a generic drug was purchased 
prior to and following hospitalisation in 25% of cases.  
Some form of drug substitution occurred in 3.9% of cases: a generic drug was replaced 
by an originator drug in 2.4% of cases and an originator drug was replaced by a generic 
drug in 1.5% of cases. Focusing on those cases where a generic drug was purchased 
prior to hospitalisation, the generic drug was substituted with an originator drug in 8.7% 
of cases. Focusing on those cases where an originator drug was purchased prior to 
hospitalisation, the originator drug was substituted with a generic drug in 2.0% of cases.  
With respect to individual drug classes, drug substitution was most likely to occur for 
M01A anti-inflammatory and anti-rheumatic products (11% of cases); N02A opioids (5% 
of cases); C03D potassium-sparing agents (6% of cases); C03B low-ceiling diuretics (5% 
of cases); C03C high-ceiling diuretics (5% of cases); C08C selective calcium channel 
blockers with mainly vascular effects (5% of cases); and N06A antidepressants (4% of 
cases). 
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Table 13: Weighted Frequencies of generic and originator drugs prior to and 
following hospitalisation  
 
ATC code and name 
Generic – 
generic drug 
Generic – 
originator 
drug 
Originator – 
generic drug 
Originator – 
originator 
drug 
A02B Drugs for peptic ulcer 
and gastro-oesophageal reflux 
disease 
69,260 (56%) 2,160 (2%) 1,140 (1%) 51,900 (42%) 
A10B Blood glucose lowering 
drugs, excl. insulins 
7,880 (10%) 1,580 (2%) 680 (1%) 69,520 (87%) 
C03B Low-ceiling diuretics, 
excl. thiazides 
5,960 (48%) 360 (3%) 220 (2%) 5,760 (47%) 
C03C High-ceiling diuretics 10,300 (23%) 1,200 (3%) 1,020 (2%) 32,420 (72%) 
C03D Potassium-sparing agents 6,380 (28%) 740 (3%) 520 (2%) 15,000 (66%) 
C07A Beta blocking agents 42,960 (28%) 4,700 (3%) 1,820 (1%) 101,700 (67%) 
C08C Selective calcium channel 
blockers with mainly vascular 
effects 
10,020 (17%) 1,680 (3%) 1,100 (2%) 46,880 (78%) 
C09A Ace inhibitors, plain 15,680 (19%) 1,320 (2%) 840 (1%) 66,620 (78%) 
C10A Lipid modifying agents, 
plain 
32,960 (28%) 1,960 (2%) 920 (1%) 79,800 (69%) 
M01A Anti-inflammatory and 
anti-rheumatic products, non-
steroids 
12,460 (24%) 3,200 (6%) 2,540 (5%) 34,660 (65%) 
M05B Drugs affecting bone 
structure and mineralization 
40 (0%) 0 (0%) 60 (1%) 17,820 (99%) 
N02A Opioids 6,800 (12%) 1,420 (3%) 1,500 (3%) 46,920 (83%) 
N05A Antipsychotics 3,280 (7%) 120 (0%) 100 (0%) 40,300 (93%) 
N06A Antidepressants 34,260 (22%) 4,020 (3%) 2,440 (2%) 111,980 (73%) 
 
Total 
258,240 (25%) 24,460 (2%) 14,900 (1%) 721,280 (71%) 
7.4.3 Additional analyses : any change after hospital stay 
7.4.3.1 Proton Pump Inhibitor Drugs 
Table 14 presents the estimated frequency and percentage of the possible changes by 
type (originator or generic) of the drug delivered prior the hospitalization for the 
Proton Pump Inhibitors drugs. 
Considering all the possible changes mentioned previously: 
• 71% of the cases did not change , neither of dosage of the tablets nor of 
name on the package  within the same chemical substance group) 
• 18% of the cases changed of name and/or tablet dosage with the chemical 
substance group 
• 11% of the cases changed of chemical substance group (ATC level 5) 
The results by drug type purchased prior the hospitalisation shows that: 
No change group: 
• 65% of the cases when a generic was purchased prior the hospitalization  
• 79% of the cases when an originator was purchased prior the hospitalization. 
Major Changes: 
• Cases when a generic was purchased prior the hospitalization: 24% of the 
cases changed within the same chemical substance group (within the same 
ATC level 5) 
• Cases when an originator was purchased prior the hospitalization:11% of the 
cases changed for another chemical substance group 
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Table 14: Estimated frequency and percentage of Changes by type of the drug delivered before the hospitalization in Proton Pump 
Inhibitor Drugs class (estimated total number of cases = 105 600) 
Type of the drug delivered prior 
the Hospitalization 
Type of change after the Hospitalization 
Weighted Frequency 
Row percent 
 
Change of 
ATC level 5 
Change only in 
dosage 
Change only in 
specialty name 
Both change ( 
specialty name & 
dosage) 
No change 
Generic & Copie 
n=62380 
6720 2280 9100 3640 40640 
11% 4% 15% 6% 65% 
Originator 
n=43220 
5120 3100 480 280 34240 
12% 7% 1% 1% 79% 
Total 
N = 105600 
11840 5380 9580 3920 74880 
11% 5% 9% 4% 71% 
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7.4.3.2 HMG CoA Reductase Inhibitors (statins) 
Table 15 presents the estimated frequency and percentage of the possible changes by 
type (originator or generic) of the drug delivered prior the hospitalization for the HMG 
CoA Reductase inhibitors (statins) drugs group  
Considering all the possible changes mentioned previously: 
• 83% of the cases did not change , neither of dosage of the tablets nor of 
name on the package  within the same chemical substance group) 
• 13% of the cases changed of name and/or tablet dosage with the chemical 
substance group 
• 4% of the cases changed of chemical substance group (ATC level 5) 
The results by drug type purchased prior the hospitalisation shows that: 
No change group: 
• 70% of the cases when a generic was purchased prior the hospitalization  
• 90% of the cases when an originator was purchased prior the hospitalization. 
Major Changes: 
• Cases when a generic was purchased prior the hospitalization: 25% of the 
cases changed within the same chemical substance group (within the same 
ATC level 5) 
• Cases when an originator was purchased prior the hospitalization:5% of the 
cases changed only or dosage and 4% changed for another chemical substance 
group 
 
 
KCE  Reports 131 Seamless care 97 
 
Table 15: Estimated frequency and percentage of Changes by type of the drug delivered before the hospitalization in HMG CoA 
Reductase inhibitors Drugs class (estimated total number of cases = 103720) 
Type of the drug delivered 
prior the Hospitalization 
Type of change after the Hospitalization 
Estimated Frequency 
Row Percent 
Change in ATC 
level 5 
Change only in 
dosage 
Change only in 
specialty name 
Both change 
(specialty name & 
dosage) 
No change 
Generic & Copie 
n=34480 
1600 1080 5740 1860 24200 
5% 3% 17% 5% 70% 
Originator 
n= 69240 
2440 3760 840 180 62020 
4% 5% 1% 0% 90% 
Total 
n = 103720 
4040 4840 6580 2040 86220 
4% 5% 6% 2% 83% 
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7.5 DISCUSSION 
This pilot study has addressed seamless care by focusing on the issue of drug 
substitution associated with a stay in a Belgian acute hospital during 2006 and 2007.  
This study has shown that hospitalisation is not a trigger for drug substitution for the 
switches between generic and originator drugs. When the same active substance was 
purchased prior to and following hospitalisation, the extent to which drug substitution 
took place was limited: in around three-quarters of cases, the patient continued to use 
an originator drug following hospitalisation (see Table 13). Drug substitution from 
originator to generic drug (or vice versa) within the chemical substance (ATC level 5) 
occurred in 3.9% of cases only, with substitution of an originator drug for a generic drug 
more likely to occur than vice versa. This may reflect the limited use of generic drugs in 
Belgian hospitals. 
More detailed analyses for statins and IPP medications show that the changes of any 
type (dosage, composition and/or specialty name) within a chemical subgroup (ATC 
level 4) was 17 % for the statins and 29% for the IPP subgroup. Unfortunately the 
reason for changes (medical versus other reasons) could not be retrieved from the 
administrative data. However, if those changes occur for one medication that belongs to 
a much larger patient medication list, the possibilities for medication errors following 
hospital discharge are a reality for many patients.  
Schemes have been developed abroad to enhance seamless care with a focus on the 
substitution with generic drugs. For instance, the Safe Therapeutic Economic 
Pharmaceutical Selection method (STEPS) was implemented in Northern Ireland. This 
scheme reached agreement among specialist physicians, general practitioners, hospital 
and community pharmacists and prescribing advisers with regard to the use of seven 
generic drugs that had equivalent clinical efficacy as the originator drugs.  
Our dataset was restricted to drugs that are reimbursed by INAMI-RIZIV. Therefore, 
our results apply to substitution of reimbursed drugs only. Data on substitution of for 
example over-the-counter drugs and non-reimbursed prescription drugs associated with 
a hospital stay were not available. However, the issue of substitution of generic and 
originator drugs is primarily relevant to reimbursed drugs, as few generic over-the-
counter drugs are available in Belgium. Another limitation of this study is that it only 
gives information on changes between drugs purchased in ambulatory care, i.e. between 
the drugs prescribed before and after hospitalisation. Intramural substitutions have not 
been studied. Finally, this study quantified the extent of drug substitution, but was not 
able to explore the possible health impact of drug substitution between settings. 
Key points 
• This chapter addressed seamless care by focusing on the issue of drug 
substitution associated with a stay in a Belgian acute hospital during 2006 
and 2007. 
• Substitutions between generic and originator drugs were limited after a stay 
in hospital. 
• When medications of the same chemical subgroup was purchased prior to 
and following hospitalization, changes occurred (dosage, composition, 
specialty name) in 29% of the cases for Proton pump inhibitor subgroup and 
in 17% of the cases for the Statins subgroup). 
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8 IDENTIFICATION OF PROBLEMS AND 
SOLUTIONS IN SEAMESS CARE FOCUSING 
ON MEDICATION: QUALITATIVE STUDY 
8.1 RESEARCH QUESTIONS 
The objectives of the qualitative part of this project are to answer the following 
questions: 
1. According to the experience of health care professionals, what are the most 
important drug related problems that can occur due to admission and discharge? 
2. Which solutions are proposed by health care professionals to improve the safety 
of patients at transition across care settings? 
3. Which barriers and facilitators do health care professionals identify for the 
implementation of the proposed strategies?  
4. From a policy perspective, which actions need priority? 
5. Aiming at implementation of the selected strategies, what are the prerequisites 
and preferred target groups? 
8.2 METHODOLOGY 
Given the research questions and the benefit of interactions between participants, a 
combination of nominal and focus techniques were selected as qualitative research 
method [Kitzinger, 1995, 8915 ; Flick, 2002, 6935]. This type of research stimulates 
interaction among participants, which has the potential for greater insights to be 
developed (Hancock B. Trent focus for research and development in primary health 
care: an introduction to qualitative research. 
http://www.trentrdsu.org.uk/cms/uploads/Health%20Needs%20Assessment.pdf 
(Accessed 5 July 2009)).   
8.2.1 Organisation of the groups 
Between mid-December 2009 and the beginning of February 2010, eleven groups were 
organised: 9 with health care professionals (HCPs) and patient representatives and 2 
with stakeholders. The focus groups with health care professionals were organised at 
different locations, geographically spread all over the country. In each selected region 
(see table 16), a hospital was the starting point for participant sampling for the focus 
groups with HCPs. 
Details on the locations, sampling methods, process, topic guides of the groups are in 
appendix 6. 
8.2.2 Data analysis 
Data analysis started from the notes taken during the focus groups. Verbatim 
transcription of the focus groups and in-depth text-based analysis was not feasible. A 
framework analysis approach was applied. Details are in appendix 6. 
8.3 RESULTS 
8.3.1 Description of the groups 
The table below gives an overview of the eleven focus groups (9 with health care 
professionals, 2 with stakeholders).  
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Table 16: Overview of focus groups  
N° Date Location Language Participants 
FG1 16/12/2009 Charleroi French HCPs 
FG2 16/12/2009 Ieper Dutch HCPs 
FG3 05/01/2010 Duffel Dutch HCPs 
FG4 07/01/2010 Eeklo Dutch HCPs 
FG5 08/01/2010 Ottignies French HCPs 
FG6 14/01/2010 Liège French HCPs 
FG7 15/01/2010 Genk Dutch HCPs 
FG8 21/01/2010 Libramont French HCPs 
FG9 28/01/2010 Brussels Dutch/French HCPs 
FG10 02/02/2010 Brussels Dutch/French Stakeholders 
FG11 04/02/2010 Brussels Dutch/French Stakeholders 
In total 100 persons were involved in 11 groups:  
• 47 women (47.0%) and 53 men (53.0%); 
• 40.0% participants were French speaking, 60 (60.0%) were Dutch speaking.  
For the exact composition of the focus groups with HCPs and stakeholders see the 
tables in appendix 6.  
8.3.2 Identified Problems  
When asked about the problems they experience related to (dis-)continuity of care, all 
HCPs mentioned a number of items. The answers on this question, mainly asked as an 
icebreaker, are listed in appendix 6. According to the phase in the transition process or 
the people involved, the problems were further clustered in five themes: problems on 
admission to hospital, problems at discharge, problems as to professions, problems as 
to patients and their carers, and problems as to processes. 
8.3.2.1 Problems on the admission to hospital 
The main issue raised by participants is the lack of a complete overview of all the 
medications used by a patient, including information about over the counter products 
and self medication. When information is present, information seems often incomplete: 
participants mentioned the absence of the dosage, the galenic form, the indication or 
the moment of intake.  
Generic products cause confusion due to frequent changes from supplier (having 
consequences, e.g. for colour of the boxes). Information on generics is lacking.  
Due to the lack of information, it requires quite some time and energy for health care 
professionals to collect the right information on the medications of a patient, even when 
they bring their (written list of) medications to the hospital.  
8.3.2.2 Problems at discharge 
Participants mentioned a lack of information at discharge for patients as well as for 
primary care providers. Sometimes discordance between different pieces of information 
is present, causing errors and inconsistencies. The process of chapter 4 drugs7 causes 
major problems due to the fact that it is often unclear for primary care providers 
whether or not the procedure was started or is ongoing.  
Discharge on Friday afternoon is mentioned as a cause of problems related to 
medications, because it doesn’t always leave time for a visit to/from the GP, or to get 
the right drugs from the pharmacy. This is especially a problem if the contact between 
hospital and primary care providers is absent or limited.  
Problems with medications given to the patient upon discharge were also often cited 
(no medications given, or discrepancies between the medications given and the list of 
discharge medications). 
                                                     
7  Chapter 4 drugs are drugs that need a special procedure for reimbursement.  
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8.3.2.3 Problems as to professions 
HCPs admit not to succeed in keeping an up to date medication list of their patients. 
This is especially a problem when they visit patients at home, and fail to update the 
information on medication in the (electronic) patient file. 
The fact that assistance in medication management is not reimbursed for home care 
nurses, is seen as another problem related to professions. 
8.3.2.4 Problems as to patients and their carers 
The lack of knowledge and information on medications and on their correct use by 
patients and their families was mentioned in almost all focus groups. An hidden problem 
in some patients is the inability to handle medications due to cognitive dysfunction, 
vision problems or problems of praxis and illiteracy, which may influence patient 
compliance.  
8.3.2.5 Problems as to processes 
Laws and regulations seem to aggravate some of the aforementioned problems. For 
example, GPs are called upon to prescribe generics, while prescribing by specialists in 
hospital care is driven by the hospital formulary. This causes frequent changes and 
substitution of the medications prescribed to a patient. Home nurses and GPs asked 
that larger quantities of medications be supplied to patients upon discharge (e.g. a 3-day 
supply), but hospital pharmacists were reluctant due to the “forfait”8 rule. 
8.3.3 Identified Solutions 
An overview of all solutions highlighted by HCPs is in table 17. The solutions were 
clustered into 5 groups, depending on the level and type of resources needed in order 
to implement them: 1) Sensitisation and/or regulation; 2) Small technology and 
regulation; 3) Technical Support; 4) Nomenclature; 5) Transition processes and 6) 
Support for general processes. 
8.3.3.1 Sensitisation and /or regulation 
The need for a national campaign on the role of patients and health care professionals 
to improve continuity of care in medication management was mentioned in two groups. 
Participants referred to campaigns on antibiotics and benzodiazepines as successful 
examples.  
Regarding regulation, participants suggested to impose the delivery of discharge 
medications for a period of three days. Although this is allowed by law, some hospitals 
do not so because they consider this as an extra cost on the fixed budget for 
medications delivered during hospital stay.  Very few participants knew that the 
medications delivered at discharge, for at maximum 3 days, can be billed for separately 
as an outpatient bill.  
8.3.3.2 Technology and standardisation of medication lists and schemes 
Up to date medication scheme 
Nearly all groups mentioned that (at least a paper based) up to date medication scheme 
should be available at all time and for all HCPs i.e. names of the medications, when the 
patient has to take it and for how long. Some proposed a kind of log book that allows 
indicating the changes and reason for change. In some groups, it was stressed that it 
should be possible to have a national standardized form. 
 
 
                                                     
8  “Forfaitarisation”: the hospital receives a fixed amount of money per patient and per indication that 
should be sufficient to pay all costs, including drug expenditure. In order to reduce costs, hospitals may 
limit the amount of discharge medication. 
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FG3/HN: ‘At home you don’t have anything. I should already be pleased when it is on paper.’ 
FG4/HP: ‘When substitution is performed, give a clear message about conversions.’ 
    FG7/CC: ‘It would be easier if all schemes would be the same (any hospital, any 
department)’  
Accurate list of medications across settings: role of the patient and 
format  
An accurate list of medications, to be carried (and if possible managed) by the patient is 
a universal request in al groups. Discussion arises whether the list should be paper 
based, available through the sis-card, ID-card or other means. Most participants 
stressed that the patient, if capable, has to be an active partner in medication 
management, i.e. in dissemination of information on the medications used.  
FG4/GP: ‘Make the patient also responsible to bring an up-to-date medication list.’ 
FG4/P: ‘For me it is logic to give my SIS card, it is like your bank card.’ 
FG9/CC: ‘The patient’s role in the management is underestimated. The patient as the 
information carrier is a pragmatic alternative while waiting for an electronic platform.’ 
A standardized referral letter to be used from primary to secondary care, including an 
adequate and up to date medication list, was proposed as a solution with major impact 
on the accuracy of information upon admission. 
FG4/HN: ‘We need up-to-date information from home to hospital, including who is involved as 
HCP’s.’ 
  FG6/ GP: ‘GPs should use a standardized referral letter’. 
Another solution is one complete discharge file with all relevant documents, on all 
medications and related products, as well as on care procedures: a document from 
specialized physician to GP, from hospital pharmacist to community pharmacist, from 
ward nurse to home nurse, etc. All documents should be gathered in one main file to 
limit the risk of discrepancies between the different files.  
FG8/SP: ‘So really a report from the hospital pharmacist, for the community pharmacist, 
documents for the patient and for the physician. The home nurse and others need access to 
the medical information.’ 
FG1/GP: ’We want that the specialized physician specifies what must be followed up, especially 
in oncology’ 
    FG1/NM: “We need the dosage, when it has to be taken and when they got it the last time 
in the hospital” 
One group proposed to use a regional drug formulary in order to limit the changes in 
medication therapy due to transition of care. 
8.3.3.3 Technical Support 
Suggestion of centralized electronic file 
 In this section, solutions on the use of digital tools and instruments are described. Most 
proposals point towards the implementation of centralized data files, either on 
medications, medical data, social information or a combination of those. ‘Centralized’ 
was used in the meaning of having the possibility to obtain all relevant data on a certain 
topic in one single operation. ‘Centralized’ did not mean the creation of one big file or 
document to be kept on a central server.  
A centralized electronic file with information on all medications delivered to a patient 
was proposed in half of the focus groups. This file should be accessible by different 
health care professionals, upon patient consent. Participants further suggested the 
implementation of a centralized electronic medical file, standardized, protected, and 
accessible (with patient consent) by different health care professionals, whatever the 
setting of care.  
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There was also a suggestion of a larger centralized electronic patient file, including 
medical, pharmaceutical and social information, accessible (with patient consent) by 
different health care professionals, whatever the setting of care. Overall, there was a 
major interest for the latter solution that offers more information.  
FG3/DM: ‘We need an extramural electronic file so we don’t need to be a detective.’ 
FG4/GP: ‘We need good electronic systems with the use of KMEHR (Kind Message Electronic 
health Record). ’ 
 FG3/HP: ‘Data should be collected somewhere. There are so many details, which can simply 
be joined together’ 
Electronic prescribing 
In addition to the introduction of centralized electronic files, participants were also 
waiting for the implementation of electronic prescribing in hospitals and primary care. A 
distinction was made between prescriptions written with the use of software and 
prescriptions sent and shared between different HCPs through an electronic platform. 
This latter one was expected to facilitate appropriate prescribing and administration 
procedures.  
FG5/SP: “Pending clinical pharmacists, we should have electronic prescription with tools to 
check for drug interactions.” 
Connected with it is the request in three groups for electronic procedures to facilitate 
the administration process for chapter IV medications. 
FG4/SP: (about procedures for chapter 4 drugs) ‘if we now simply could do it electronically...’ 
Finally, participants were waiting for a database with all contact details of involved 
HCPs, in order to avoid detective work when attempting to contact a colleague. 
8.3.3.4 Reimbursement of healthcare services 
All focus groups stressed that it is crucial that patients would be well informed on their 
medications, by all care professionals. 
FG2/SP: ‘ICT provides correctness of the information but not necessary transmission of this 
information to the patient.’ 
FG5/P: ‘Information of the patient is the most important: you can automate everything you 
want, if you do not convince me of the relevance of the medication I do not take the 
medication.’ 
Most groups supported the introduction of a reimbursement for home care nurses to 
assist patients in the management of their medications at home.  
FG8/SS: ‘For patients, whose cognitive functions are impaired, someone has to prepare 
medications at home but this is not included in the nomenclature of nurses.’ 
FG9/HN: ‘There is no nomenclature9 for nurses to manage medication: we have to do 
something else, for example wash the patient.’ 
There was a suggestion to a lesser extent to facilitate a GP visit directly after discharge, 
by taking away financial barriers (either third payer system and/or fully reimbursed).  
FG5/GP: ’ 
‘I feel responsible when a patient is discharged home, that he got the information and that he 
has understood his condition. So, I always ask them [my patients] to call me after 
hospitalization. That’s the responsibility of the GP’.  
FG7/SP: ‘… That’s the reason why we don’t give prescriptions, but just a scheme and a short 
supply. That’s the idea behind it, that they first see their GP. Although some people don’t like 
this.’ 
                                                     
9  ‘Nomenclature’ refers to a billing code that is used by HCPs to indicate which activities they have 
performed for a patient, and on which calculations for remuneration and reimbursement are based 
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8.3.3.5 Transition process 
Participants proposed different types of processes to optimise transition, but none of 
them reached an agreement in all groups. 
• Introduction of clinical pharmacy in the hospital to standardize medication 
history taking and to prepare patient discharge in relation to medication. 
•  FG8/SP: ‘We need the expertise of a clinical pharmacist.’ 
• Contact between hospital and primary care HCPs before discharge (i.e. 
exchange of information, proposed changes and their value/usefulness).  
•  FG2/ GP: ‘I want to discuss on beforehand with the specialist why some 
medications are prescribed.’   
•  FG4/SP: ‘It should be necessary to consult with the specialist who has 
prescribed.’ 
• To send the medication discharge plan to the community pharmacist, the GP 
and the home care nurse. 
• To discourage discharge on Friday afternoon or, if difficult to implement, to 
prepare discharge well in advance:  
•  FG8/HN: ‘When patients return home on Friday or Saturday, and need 
medications that are not necessarily available in pharmacies, it might be 
difficult for these people to continue their treatment.’ 
8.3.3.6 Support for general processes 
In two of the nine focus groups, it was suggested to reduce the administrative workload, 
to use substitution rights and to reduce the range of generic products available on the 
market, as to reduce frequent changes in medication therapy. 
 An important measure supported in nearly all groups was the local/regional 
concertation to enhance cooperation between settings of care and between HCPs at 
the micro- and the meso-level. 
FG8/WN: ‘ICT can regulate many things but not all: each HCP has to explain his approach (to 
the other HCPs).’ 
FG5/SP: ‘We need to know the professional needs of the others.’  
FG7/P: ‘The GP should be a central and also an intermediary person. Much more 
communication is needed.’ 
FG4/SP: ‘It would be good to involve the specialist, GP, and pharmacist to discuss what to do 
with incompatibilities.’ 
8.3.3.7 “Extra”: other solutions mentioned 
In addition to the solutions described above, some solutions were mentioned only once 
or twice e.g. presence in the hospital of a physician with a training focused on 
coordination and integration of medical problems, all generic products in the same size 
and colour, readable information leaflets,...  
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Table 17: Overview of solutions  
A SENSITISATION AND/OR REGULATION 
A1 National campaign: inform the public on the problems (cfr overuse of antibiotics and sleep medication), and 
encourage people to take their role in order to minimize these problems 
A2 Encourage patients to bring their medications on admission, in order to improve and to ease medication history 
taking 
A3 Oblige hospitals to deliver medications at discharge and to apply existing regulations 
B  TECHNOLOGY AND STANDARDISATION OF MEDICATION LISTS AND SCHEMES 
B1 Up to date (paper-based or electronic) medication list / plan, including a logbook of changes and reasons for 
modifications, contact details of HCPs,... If possible, (national) standardised form. 
B2 Accurate list of medications, to be carried and managed by the patient (paper-based or electronic, e.g. on SIS card or 
ID card) 
B3 Standardized referral letter to be used from primary care to secondary care 
B4 Discharge file with all relevant documents for patients and HCPs (from specialist to GP, from hospital pharmacist to 
community pharmacist, from ward nurse to home care nurse,….) 
B5 Uniform regional drug formulary 
C TECHNICAL SUPPORT (IT) 
C1 Centralised national electronic database with all information on all medications (+related products) delivered to 
patients, whatever the setting of care – if patient consents 
C2 Centralised electronic medical file (standardised, protected),  accessible by different HCPs, whatever the setting of 
care – if patient consents 
C3 Centralized national electronic patient file, including medical, pharmaceutical, care and social information, 
whatever the setting of care – if patient consents 
C4 Electronic prescribing in hospitals, facilitating appropriate prescribing  and administration procedures for 
reimbursement of medications 
C5 Database with contact details for HCPs in primary and secondary care 
C6 On-line and real-time available procedures for chapter 4 drugs  
D REIMBURSEMENT OF HEALTHCARE SERVICES 
D1 Assistance of patients in their medication management (e.g. for home care nurses) 
D2 Fully reimbursed visit by the GP for patients post-discharge (2-3 days) in the third payer system 
D3 Therapeutic education for patients  
E TRANSITION PROCESS  
E1 Clinical pharmacy (e.g. standardized medication history taking).  
E2 Contact between the hospital and primary care HCPs shortly before discharge to discuss relevant information  
E3 Discourage discharges later than 3pm on Fridays as well as over the week-end, unless this was planned in advance 
and/or follow-up care is organized 
E4 Medication discharge plan sent to community pharmacist, GP and home care nurse, upon discharge 
F GENERAL PROCESSES 
F1 Reduction of administrative workload (e.g. attestation,...) 
F2 Reduction of range of generic products on Belgian market 
F3 Use substance names for drug prescribing  
F4 Local consultation to enhance cooperation between settings of care and between  HCPs (micro- and meso-level).  
G EXTRA 
 Clinical pharmacist in  general 
 Readable information leaflets 
 Medication review every year 
 Digital information databases 
 Hospital practitioners 
 Obligatory visit of GP at discharge 
 Perform discharge management 
 Fixed ‘chaperon’ for patient during  hospitalisation 
 Coordination of care at home and  in  the hospital 
 Taking social factors in mind 
 Substitution 
 Medical specialist should also prescribe generic products  
 Enhance the communication processes 
 Cahier de liaison 
106 Seamless care KCE Reports 131 
8.3.4 Barriers, facilitators and prerequisites 
Table 18 gives an overview of the barriers, facilitators and prerequisites that were 
identified for the top-3 solutions identified in each of the focus groups. As there was a 
high level of concordance between the solutions mentioned as the most important ones 
in the different focus groups, the final list of solutions could be limited to a set of ten 
items. Therefore barriers, facilitators and prerequisites are only listed for this set of 
solutions. 
Overall, the most important barriers are money, time availability, and willingness to 
implement and use the same system/software. IT tools are seen as an important 
facilitator. Prerequisites that were mentioned are patient informed consent, privacy, a 
good implementation plan, finances, availability and motivation of professionals, 
standardisation and adequate support. 
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Table 18: Overview of barriers, facilitators and prerequisites  
B TECHNOLOGY AND STANDARDISATION BARRIERS FACILITATORS PREREQUISITES 
B1 Up-to-date (paper-based or electronic) medication scheme including a 
logbook of changes and reasons for modifications, contact details of 
HCPs,... 
- Risk of loss by patient 
- Transfer delay  
- Patient privacy 
- Standardization 
 
- Patient consent 
- Transfer should be in time 
B2 Accurate list of medications, to be carried and managed by the patient 
(paper-based or electronic, e.g. on SIS card or ID card) 
- No standardisation  
- Electronic prescription 
- Own routine 
- Cost 
- Lack of updating 
- More than one card 
- Perception lack of added 
value 
- Time 
- Willingness to do  
- Cost hardware  
- Patient privacy (e.g. 
psychiatric patients) 
- Adapted rules 
- Electronic prescription 
- Peer review 
- Project based 
implementation 
- Ownership 
- Mass distribution 
- Quick access to 
information 
- Card readers do exist 
- Integrated 
- Well designed 
- Added value for patient 
- flexibility (acute versus 
chronic use) 
- Usable in different settings 
- Accountability 
- Adequate implementation 
plan (preparing in small 
regional groups) 
- Willingness 
C TECHNICAL SUPPORT (IT) BARRIERS FACILITATORS PREREQUISITES 
 General topics applicable to solutions C1-C4 - Cost  
- Limited sharing 
(pharmacists) 
- Patient information remains 
needed  
- No emails allowed 
- Existing SIS or ID card 
 
 
- Reserved and payed time 
- Protection and privacy 
- Need for IT support 
 
C1 Centralised national electronic database with all information on all 
medications (+related products) delivered to patients, whatever 
the setting of care – if patient consents 
- Patient refusal - Legal issues (2009) 
- Communication 
prescribers 
- Accessibility for hospital 
pharmacist with writing 
permission 
C2 Centralised electronic medical file (standardised, protected),  
accessible by different HCPs, whatever the setting of care – if 
patient consents 
- No sufficient logistic 
materials (PC etc.) 
- Individualism of health care 
workers 
- Doctors don’t trust 
communication of data 
- Time 
- No planning at 
governmental level 
- Professionals not enough IT 
knowledge 
- Lack of knowledge patient 
- Securisation 
- Feasibility 
- Technical progress 
- High participation of health 
care workers in dialogue 
- It is readable 
- ‘Subvention’ of hospital 
informatisation 
- Frustrated professionals 
 
 
- Cost 
- Education 
- Concertation needed 
- Patient access 
- Need to preserve the 
human relationship 
- Planning by national 
working group 
- Securisation 
- System should be general 
(whole country, all settings) 
C3 Centralized national electronic patient file, including medical, 
pharmaceutical, care and social information, whatever the setting of 
care – if patient consents 
- Authorisation (reading, 
writing) 
- ICT mindedness 
- Cost 
- Financial incentives 
- Databases with good links 
- Standardisation as far as 
possible 
- e health 
- Willingness for 
cooperation 
- availability of staff 
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- Divergence of programs 
- Overkill of information 
- Sis card needs readers 
everywhere 
- expertise - ICT mindedness 
- Step by step 
implementation 
- Expertise 
- Stability of the system 
- Privacy matters (patient) 
C4 Electronic prescribing, facilitating appropriate prescribing  and 
administration procedures for reimbursement of medications 
- Treating pharmacist not 
known 
- Resistance of physicians 
 
- Existing file at community 
pharmacy 
- Digital progress 
 
- Informed consent of 
patient  
-  Pharmacists all need to use 
IT 
D REIMBURSEMENT OF HEALTHCARE SERVICES BARRIERS FACILITATORS PREREQUISITES 
D3 Therapeutic education for patients  
 
- Competition between 
hospital and community 
care  
- Lack of time 
- Short hospital stays 
- Corporatism of 
professionals (nurse, 
occupational therapists) 
- Cognitive problems 
- Motivation  
- Cost 
- Decrease readmission  
- Decrease accidental falls 
- Personal motivation 
 
E TRANSITION PROCESS  BARRIERS FACILITATORS PREREQUISITES 
E1 Clinical pharmacy, e.g. standardised medication history taking on 
admission  
- Lack availability 
- Recruitment 
- Cost 
- implementation process 
- Acceptation by physicians 
- Expertise 
- Time available 
- Is done everywhere 
- Teamwork 
- Formation/ education 
- Availability staff 
F GENERAL PROCESSES BARRIERS FACILITATORS PREREQUISITES 
F4 Local consultation to enhance cooperation between settings of care and 
HCPs (e.g. to compose a uniform regional drug formulary) 
- Availability of pharmacists 
- Time 
- Anonymity 
- Accessibility 
 
- Videoconferencing,  
- Financial support  
- Clinical benefits: avoiding 
medication errors 
- Time gain 
- Personal availability 
- Willingness for 
cooperation 
- Time 
- Established indications 
- Mutual respect 
- Follow up of the  results 
- Correct and complete 
composition of the group 
 
G Extra      BARRIERS              FACILITATORS PREREQUISITES 
 Coordination - Fragmentation is dangerous 
 
- New honorary system for 
pharmacists 
- Financial incentives in – and 
extra-mural 
 
- Personal available 
- Willingness for 
cooperation 
- Nomenclature (nurses, 
clinical pharmacists) 
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8.3.5 Additional themes  
In addition to the main research questions the participants were asked about their ideas 
on the Australian guiding principles for medication management, the most appropriate 
health care professional to coordinate medication management, and the patient groups 
that need priority when developing seamless care initiatives. 
8.3.5.1 Concordance with the Australian guiding principles  
All participants confirmed the importance of the six key elements in medication 
management, as defined in the Australian guiding principles to achieve continuity in 
medication management 
(http://www.health.gov.au/internet/main/publishing.nsf/Content/4182D79CFCB23CA2C
A25738E001B94C2/$File/guiding.pdf): 
accurate medication history, assessment of current medication management, medication 
action plan, supply of medications information to patients, ongoing access to medication 
and communicating medications information. It is stressed however that a good 
description of the items is important and that the interaction between the elements 
should be continuous.  
8.3.5.2 Appropriate HCP to coordinate medication management at transition moments 
Seven out of the 9 focus groups mentioned the GP as the most important person for 
coordination. Nurses, community pharmacists and hospital pharmacists were also 
thought to play an important role. However, there was a general consensus on the fact 
that each type of HCP has specific responsibilities in the process of ensuring continuity 
of care, and that approaches for optimisation MUST be multidisciplinary in nature. The 
participants also stressed that it is important to check if coordination is really needed 
and in a second step to see which professional is the most efficient in the current 
situation.  
In nearly all groups the clinical pharmacist was mentioned as an important person in the 
coordination of medication management as well. The experiences with this function 
were variable, mainly positive. The lack of similar experiences resulted in an absence of 
consensus between the different focus groups regarding the introduction of this 
function.  
8.3.5.3 Priority patient groups 
There is a general consensus that strategies to enhance seamless care should focus on 
patients with a geriatric profile, psychiatric patients, patients with polymedication and 
the combination of polymedication (i.e. more than 5 medications) and polypathology. 
Other target patient groups were isolated patients, patients with anticoagulation drugs, 
patients with dementia and patients being cared for within care pathways 
(‘zorgtrajecten/trajets de soins’). Many participants acknowledged that these groups 
represented an important proportion of patients. 
Given this agreement on the priority groups, it was also mentioned that solutions 
should be designed to be applicable for every patient.  
8.3.6 Additional input from stakeholders  
The aim of the focus groups with stakeholders (and two additional interviews) was to 
get input on the proposed problems and solutions from a policy perspective. Additional 
ideas and comments that resulted from these focus groups and interviews are described 
here. 
8.3.6.1 Identified problems 
 The stakeholders confirmed the listed problems and did not notice any major missing 
elements. One added that the problems encountered differ depending on the social 
situation of patients, and that the proposed solutions should take these differences into 
account. 
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8.3.6.2 Solutions 
At all levels and in all disciplines projects are going on as to the issue of medication 
management at transitions. The most elaborate work at this moment is done by the 
pharmacists (hospital as well as community). Important examples are the pilot programs 
on clinical pharmacy in hospitals and the implementation of a pharmaceutical file in 
community pharmacies, which allows the storage of data on all prescribed medications, 
along with ( a limited number of) patient data. 
The following items in the list of solutions were most frequently mentioned by 
stakeholders as being of major importance, although not everyone agreed with all of 
them: 1) a national information campaign; 2) an up to date medication scheme; 3) a 
centralized electronic patient file, including medical, pharmaceutical, care and social 
information 4) assistance for patients in the management of their medications; 5) clinical 
pharmacy and 6) a medication discharge plan. Three out of these six solutions (numbers 
2, 3 and 5) were also selected in one or more focus groups with HCPs as top-3 
initiatives. 
As for an information campaign, stakeholders mentioned that the topic is far more 
complex than e.g. antibiotics. A campaign should therefore be tailored to the aged 
population with simple messages (i.e. “show medications to all consulted doctors, bring 
them to hospital”). 
The idea of a centralized electronic patient file, triggered major reactions linked to 
privacy and ownership. For some stakeholders this solution is clearly going too far. 
Not all stakeholders welcomed the idea of implementation of clinical pharmacy. The 
presence of a clinical pharmacist was considered to be useful on some wards, but 
redundant and even confusing on others. 
A medication discharge plan was considered to be very important, but a direct 
transmission to the community pharmacist triggered some reluctance, as it 
encompasses the coordination role of the GP and the correct identification of the right 
pharmacist might be difficult. 
8.3.6.3 How to proceed? 
Stakeholders were in favour of a national policy plan in order to guide future 
developments in medication management and e-Health, as well as of a bottom-up 
approach to enhance local initiative and implementation. It is not clear however what 
level ‘local’ exactly is. The stakeholders stressed that we need hard endpoints to 
measure the effect of what is being done, sustaining the development of a structural 
financing system. 
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8.4 DISCUSSION  
8.4.1 Important results and observations  
8.4.1.1 Question 1: According to the experience of health care professionals, what are 
the most important drug related problems that can occur due to admission and 
discharge? 
Problems at different levels 
The focus groups provided a long list of problems that could be summarized in five 
different clusters, according to the phase in the transition process or the people 
involved:  
1. problems at admission (mainly lack of information on the medication used by a 
patient);  
2. problems at discharge (predominantly lack of information for patients as well as 
HCPs);  
3. problems as to professions (e.g. not succeeding in keeping an up to date 
medication file of all patients; no reimbursement for patient assistance in 
medication management);  
4. problems as to patients (mainly lack of knowledge and information on medication 
taken); 
5. problems as to processes (e.g. loyalty to laws and regulations aggravating some 
of the aforementioned problems). 
All problems were identified in more than one group, by different health care 
professionals and the stakeholders confirmed the existence of these problems.  
Few information about the rules in other settings 
It was remarkable that a lot of participants had little or no information about the rules 
and regulations that are applied in other health care settings. There is certainly a 
problem of correct perception of the real situation. For example, primary care HCPs 
did not know much about the “forfeit” financing system in hospitals and people working 
in the hospital did not realize the pressure for generic prescribing in primary care.  
Perspective on problems and solutions limited to settings and 
professional groups 
Moreover, HCPs in primary care and hospital settings expect more from other HCPs 
and from the government than they are able to give themselves. For example, GPs 
complained about the lack of information and clear documents from the hospital, while 
failing to write good referral letters. 
Even at the stakeholders’ meetings, problems were regarded from a limited perspective, 
i.e. from a professionals’ group rather than from a system point of view. Furthermore, 
some representatives were not very confident as to the ideas and perceptions of their 
members, and in some cases representatives of the same professional group had 
differing views.  
Importance of law and regulations 
 Another important observation was that problems seem to arise in consequence to 
adherence to existing rules and regulations. Although the main regulations are 
developed and supervised at the federal level, some gaps between regulations in primary 
care versus secondary care settings may lead to inconsistencies in practice. For 
example, GPs are supposed to prescribe a great proportion of generic drugs, while 
hospital physicians have to stick to the drugs in the local formulary for which good 
price-quality arrangements have been obtained.  
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The latter is in turns important in order not to exceed the lump sums that were agreed 
for each type of hospitalisation and care procedure.   
8.4.1.2 Question 2: Which solutions are proposed by health care professionals to 
improve the safety of patients at transition across care settings? 
There is overall agreement about the need for a comprehensive package of solutions. 
Most participants agreed with the different elements of this package, although there 
were some barriers mentioned for specific points.  
Proposals of concrete solutions 
Important parts for a comprehensive package of solutions, are: 1) a national information 
campaign; 2) an up-to-date (paper-based or electronic) medication list / plan;  3) a 
comprehensive discharge file (understood as a main file with all relevant documents for 
different HCPs, without discrepancies); 4) a centralised national electronic patient file 
including medical, pharmaceutical, care and social information; 5) electronic prescribing; 
6) reimbursement for assisting patients in their medication management; 7) therapeutic 
education for patients; 8) clinical pharmacy, 9) local consultation to enhance 
cooperation between settings of care and HCPs, and 10) coordination of medication 
management. All solutions were highlighted in more than one group and by different 
health care professionals. 
The potential role of a clinical pharmacist was systematically discussed in all focus 
groups (see Key Question 5.2 of the topic guide). Not all participants did agree on the 
necessity for implementation of clinical pharmacy, or even had firm objections to the 
involvement of clinical pharmacists in medication history taking or discharge counselling, 
which was mostly due to variable and limited experiences with this concept.  
Ongoing initiatives and future implementation 
So far, initiatives taken by stakeholders are limited in number and content. Most 
important initiatives are taken by pharmacists (hospital as well as community based), 
which is likely due to the “medication” focus. The federal government FOD/SPE 
prepares, based on the positive results of the pilot projects on clinical pharmacy, a 
broader implementation of this concept. The number of hospitals being funded for 
developing clinical pharmacy will be doubled. APB mentioned to be working on different 
solutions: a pharmaceutical file, which is obliged by law since 01/01/2010; a quality 
standard for pharmacists, describing all kinds of procedures, development of a position 
paper on a medication file in nursing homes; implementation of an electronic care-plan, 
including a medication plan; development of an information database concerning generic 
products; introduction of medico-pharmaceutical “concertation-overleg”; and testing 
pilot programs on electronic prescribing. Other professional groups invest in training, 
education and “concertation-overleg”. 
The development and availability of IT tools generated great expectations among 
participants. At the same time, however, HCPs acknowledged that IT is not the only or 
final solution, but they rather considered it as a support tool. Taking responsibility and 
using and optimising the already existent systems were considered to have a major 
impact on seamless care. 
Some solutions that were mentioned are currently worked out in ongoing projects of 
the Ministry of Public Health or the National Institute for Health and Disability 
Insurance (NIHDI-RIZIV/INAMI). For example the Chapter 4 procedure will be 
facilitated by on-line procedures, and the problems with electronic prescribing in 
hospitals should be tackled by the end of 2010. HCPs and even some stakeholders were 
not aware of these projects, but they indicated that these types of solutions would 
make a big difference and that this is the right moment to further invest in and 
implement these projects. 
Overall, participants stressed that there is no more need for pilot projects; sustainable 
initiatives are terribly wanted. By stressing this, participants gave way to their frustration 
of not being able to continue pilot programs that were perceived as effective, although 
scientific evidence is often limited.  
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8.4.1.3 Question 3: Which barriers and facilitators do health care professionals identify 
to the implementation of the proposed strategies?  
The main barriers can be summarized as issues of privacy, lack of standardization, lack 
of the willingness to change, lack of time to proceed with the solutions, (professional) 
resistance at all levels and accessibility of the solutions (standardised, supported and 
adequately implemented technical solutions). Ongoing projects, the fast development of 
IT solutions and the supposed added clinical value of the proposed interventions seem 
to be important facilitators. Furthermore, these solutions can be facilitated by changing 
some rules, and e.g. using the e-health methodology.  
8.4.1.4 Question 4: From a policy perspective, which actions need priority? 
As mentioned above, participants (both HCPs and stakeholders) stressed that not one 
solution on its own will solve the problem. There is a need for a multi-level, multiphase 
and multidisciplinary strategy. Everybody has to take up his own responsibility. This idea 
of shared responsibility also arose from the discussion on the most appropriate HCP to 
coordinate continuity in medication management.  Moreover, participants stressed that 
coordination is not always necessary, and one should avoid designing complex 
interventions like useless team meetings or when feasibility is compromised. 
Therefore, the priority is a balanced and long term vision on the bottlenecks and the 
solutions, along with the design of an implementation plan, involving all actors. Hard 
endpoints (e.g. the number of drug related problems following discharge; the number of 
hospital re-admissions) should be used to measure the effects of the actions taken. A 
sensitisation campaign for patients as well as HCPs, well established and prepared, could 
be a starting point. 
8.4.1.5 Question 5: Aiming at the implementation of the selected strategies, what are 
the prerequisites and preferred target groups?  
Participants stated that important prerequisites for the implementation of the selected 
strategies are a well balanced implementation plan, finances, staff members, 
accountability and ownership, and patient involvement, consent and education. Efforts 
for optimal seamless care should focus on every patient but some groups of patients 
deserve particular attention e.g. patients with a geriatric profile, psychiatric patients, 
patients with polymedication (n>5) and/or polypathology, and low SES (socio economic 
status) groups.  
8.4.2 Strengths of the study  
This large qualitative study involved 100 participants, with different professional 
backgrounds, from all over the country. HCP’s statements have been confirmed and 
completed by the stakeholders’ ones who are more involved in decision making and 
implementation. The overall concordance within the groups and between the groups, as 
well as the concordance with the ideas of the stakeholders, favours the generalisation of 
the results and conclusions. A discussion of the findings, in light with the literature and 
international data on this topic, is part of chapter 9. 
The focus groups further had a balanced input from all HCPs, who presented their 
opinion with respect for each others’ ideas. The discussions were very constructive and 
solution-oriented.  
The participants very often did not know the rules, regulations, problems and situations 
of other settings and health care providers. For example, people working in the hospital 
didn’t realize the pressure for generic prescribing in primary care while the latter didn’t 
know that in hospital care a formulary is obligatory. With regard to this point, the 
process of the focus groups created unexpected output: groups were formed and 
(local) interaction between participants, an important argument for local consultation, 
was induced following the focus groups. This underlines the importance of local 
concertation at the mesolevel. 
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The encounter with some participants in the groups pointed towards very concrete 
solutions for the Belgian situation. Some of them were not mentioned in previous parts 
of this project, and are still very relevant to the topic (cf. NIHDI-RIZIV/INAMI – 
Chapter 4 drugs). These additional solutions will be checked in interviews in a next part 
of the project. 
8.4.3 Limitations of the study 
Problems and solutions were identified at each level and step of the transition care 
process. However, little information was gathered concerning the transition process 
from and to the nursing home. One explanation can be that few GP-coordinators in 
nursing homes were present. A second reason can be that in nursing homes the 
problems are less prominent as medication is managed in a more structured way, and at 
each transition information can be obtained from the nurses.  
As to the composition of the focus groups, some bias may have occurred during the 
sampling procedure. The recruitment was partly done by coordinators at the hospital 
and they may have invited HCPs that knew better or who were a priori interested in 
the theme. Generally, the researchers went on inviting until all predefined disciplines 
were present. Overall, the presence of specialists could have been more broadly divided 
over different disciplines. The researchers did not succeed including specialists from 
surgical or emergency wards, even if those specialists also received an invitation. Also 
the presence of specialists in internal medicine, other than geriatricians, was limited. 
This issue was addressed and partly resolved through two additional one-to-one 
interviews with internists. However, other specialists such as surgeons could still have 
views that are totally different from the internists’ or geriatrician ones, in particular for 
the role of a clinical pharmacist at discharge (e.g. in counselling patients receiving a 
combination of anticoagulation with a treatment for other conditions).  
In five out of nine focus groups a patient was present, in four of them a carer / family 
member. Although the patients often gave valid personal comments, carers / family 
members gave more specific information on problems and solutions concerning 
seamless care.  
There seems to be some overlap between the functions of care coordinator, discharge 
manager and social worker although specific accents exist and the functions may be 
filled in differently in different settings. This caused some confusion on the background 
and working experience of some participants, which might have hampered the 
interpretation of some of the findings. 
 There are strong arguments in favour of the validity of the results. However, focus 
groups can never give certainty about the acceptability of the proposed interventions by 
all involved HCPs in daily practice. Enthusiasm during a meeting with participants, who 
have in principle an interest in the topic, does not necessarily reflect the reactions of 
any HCP when implementing solutions into practice. Especially the issues of privacy and 
informed consent of the patient, besides other legal, deontological and practical 
prerequisites warrants attention.  
8.5 CONCLUSIONS 
Important problems exist as to medications at transition moments, especially for 
vulnerable and at risk patients. 
The involved healthcare professionals identified feasible and desirable solutions. These 
should be multifaceted and multileveled, incorporating the input of many professionals 
and organisations. Important issues have to be solved for an adequate implementation 
of solutions for people most at risk.  
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Key points 
• This chapter discusses the problems and solutions that were analysed in 
focus group discussions with Belgian HCPs and stakeholders to optimize 
seamless care. 
• Problems have been identified in different settings and at different points of 
the transition process. 
• Concrete solutions, including barriers and facilitators for their 
implementation, were highlighted in more than one group and by different 
health care professionals i.e.:  
- a national information campaign;  
- an up-to-date (paper-based or electronic) medication list / plan;  
- an accurate list of medications, to be carried and (if possible) managed by the 
patient; 
- a comprehensive discharge file;  
- a centralised national electronic patient file including medical, pharmaceutical, 
care and social information;  
- electronic prescribing;  
- reimbursement schemes for assisting patients in their medication 
management; 
- therapeutic education for patients;  
- clinical pharmacy; 
- local consultation to enhance cooperation between HCPs and between care 
settings; 
- coordination of medication management.  
• The development and availability of IT tools (e.g. a centralized electronic 
patient file containing medical, pharmaceutical, care and social information) 
generates great expectations.  
• Participants stressed the need for shared responsibility in medication 
management. When coordination is needed, the GP was often mentioned as 
the most appropriate HCP. 
• Priority patient groups were identified (e.g. geriatric profile, psychiatric 
patients, patients with polymedication) but there was agreement on the fact 
that efforts for optimal seamless care should focus on every patient. 
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9 SUMMARY OF FINDINGS: BUILDING 
BLOCKS TO OPTIMIZE SEAMLESS CARE 
FOCUSING ON MEDICATIONS 
9.1 OBJECTIVE OF THIS PART 
The aim of this part is to summarize the findings of this research in order to identify 
building blocks for the development of a quality improvement system to optimize 
seamless care focusing on medications. Some practical considerations are mentioned in 
relation to the implementation in Belgium. 
9.2 METHODOLOGY 
The main findings of the research were summarised, compared, and tabulated. 
Additional stakeholders were consulted to obtain up-to-date information on various 
initiatives with potential implications for seamless care (i.e. eHealth, Recip-e, Prorec, E-
prescribe and RIZIV/INAMI – see list in appendix 7). Common findings were extracted 
from the summary of the international and Belgian data, and lessons to learn were 
subsequently discussed within the research group.  
9.3 SUMMARY OF FINDINGS AND BUILDING BLOCKS 
9.3.1 Summary of findings 
The table below summarizes the main findings of this research project, with regard to 
solutions identified. For clarity and coherence with the lessons proposed in 9.3.2, the 
findings were classified according to the level of care at which the initiative should be 
taken/developed: policy, professionals, and patient levels 182 
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Table 19: Overview of the main findings, obtained from international and Belgian data 
Description Evidence from international data Evidence from Belgian data Building 
block nra 
 Systematic reviewb 
(chapter3) 
Grey literature 
(chapter 5) 
Existing projects  
(chapter 6) 
Qualitative study  
(chapter 8) 
 
Policy level      
National guidelines No data Well described and developed 
in several countries (A, C, NL, 
UK) 
No data Not described or requested as 
such, but some participants 
mentioned the need for a long 
term vision 
1 
National campaign No data Occurred in several countries 
(C,NL), in combination with 
other initiatives 
No data Requested by several 
participants. Considered by 
stakeholders as an initiative of 
major importance.  
2 
Regulatory and/or financial 
incentives to apply 
recommendations 
No data financial penalty if 
recommendations not applied ( 
recommendations linked to 
accreditation (C) 
No data Not addressed 3 
Reimbursement of health 
care services  
No data Pharmacist-based activities in 
acute care and ambulatory care 
(A,C,) 
 
No data Requested for: post-discharge 
consultation with GP; patient 
education and medication 
management by home care 
nurse. The latter was 
considered by stakeholders as 
an initiative of major 
importance.  
4 
IT support to facilitate the 
exchange of information on 
medications 
Very limited data on impact as 
such 
Described in most countries – 
limited data on impact (D) 
Share4Health Seen as important by HCPs 
and stakeholders. 
5 
IT support to facilitate the 
exchange of information on 
health (including medical 
and pharmaceutical data) 
Very limited data on impact as 
such 
Developed as a supportive tool 
in all countries; local and 
national levels involved; very 
limited data on impact 
Different local or regional 
initiatives mentioned to allow 
GPs to access  the hospital file 
or to share information 
between prescribers  
Seen as very important by 
HCPs and stakeholders. 
5 
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Health care professionals 
level 
    
 
Local concertation to 
enhance cooperation 
between settings of care 
 
Described in several countries 
(N, UK) 
Pilot project on oncology   
Requested several times (joint 
formularies, use of standard 
documents, GP-pharmacist 
concertation, concertation 
between hospital and home 
care …) 
9,10 
Development and use of a 
standardised medication 
scheme 
Standardised schemes used in 
RCTs, but effect evaluated as 
such in one study  
Yes, either national scheme 
(Australia), or local/regional 
schemes  
Described in some local 
projects (but no evaluation for 
most) 
Requested, with additional 
details on the content  
9, 11, 12, 
14 
Development and use of transfer 
documents c 
Standardised documents used 
in RCTs, but effect evaluated 
together with patient 
counselling  
Local/regional standardised 
documents available in most 
countries  
Described in some local 
projects (but no evaluation for 
most) 
Requested, with additional 
details on the content  
9, 11, 12, 
14 
Patient level      
Medication reconciliation 
(at each transition between 
settings of care) 
Medication history by clinical 
pharmacists on admission 
improves the quality of the 
medication list and decreases 
discrepancies 
Widely developed in several 
countries in different settings of 
care 
Mainly through clinical pharmacy 
projects 
Requested by several types of 
HCPs, although the term 
“reconciliation” was not used  
11,12,14 
Medication bag brought by 
patients on admission 
No data Described in UK guidelines  Several pilot projects Suggested 
11 
Patient education at and/or 
after discharge 
10 RCTs have evaluated its 
impact; more likely to be 
effective when provided 
before and after discharge  
Described in guidelines, 
standard care in some 
countries, mostly involving 
pharmacists 
Mainly through clinical pharmacy 
projects; reinforcement after 
discharge nowhere implemented 
Seen as very important; 
mentioned by different HCPs 
in different settings 
 
12,14 
Informing HCPs at 
discharge about medication 
plan 
5 RCTs available on informing 
GPs and/or community 
pharmacists 
Described in guidelines, 
informing GPs implemented in 
all 6 countries; informing 
community pharmacists 
performed but not 
systematically in most countries 
Evaluated in pilot projects: structured 
and comprehensive information to the 
GP, and information for community 
pharmacist Nr 41, 27 
Requested, with additional 
details on the information to 
be provided. Considered by 
stakeholders as an initiative of 
major importance. 
12 
Availability of accurate list 
of medications to be 
 
Described in guidelines (UK); 
systems or initiatives available 
 
Need for an accurate list of 
medications to be carried by 
15 
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carried by the patient, 
supported by (IT) tools  
(US, C, Australia)    the patient repeatedly 
mentioned, although need for 
support tools or interventions 
was not mentioned. 
Considered by stakeholders as 
an initiative of major 
importance. 
Medicine review and 
adherence support after 
discharge 
 
Described in several countries 
(A, UK); some data on impact 
  
14 
[Table annotations] a Number of the lesson to learn made in link with this finding, see 6.3.2, b only controlled trials were considered for inclusion in the review, c This type of 
document can contain diverse administrative, medical and pharmaceutical data, eg reason for admission, past medical history, drug history or medication changes after 
discharge, biological data, clinical data,... 
Abbreviations: A: Australia, C: Canada; D: Denmark; HCP: health care professional; IT: information technology; NL: The Netherlands; RCT: randomised controlled trial; UK: 
United Kingdom; US: United States (Vista and Geisinger systems) 
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9.3.2 Lessons learned to optimise continuity of care focusing on medications 
The lessons learned are described as “building blocks“ that can be used to re-design a 
health care system that allows a more effective management of transitions between 
settings of care. The first group of building blocks depends upon the policy level. The 
second one refers to the professionals at a regional and/or local level, with a focus on 
communication. The last group describes initiatives that are needed at the individual 
patient level. 
For each building block, the authors first summarise its rationale based on the results of 
the research and then briefly elaborate on practical considerations about 
implementation. 
9.3.2.1 Initiatives at policy level  
The Belgian findings have shown that many local projects have been (and are being) run, 
for example in individual hospitals, because HCPs themselves experienced the need for 
improvement in continuity of care focusing on medications. To move forward, initiatives 
taken at policy level are now essential. Their objectives will be to provide clear 
recommendations on the kind of interventions that should be implemented and how 
these interventions should be implemented, and to centralize and to share the initiatives 
taken at local levels. 
Building block nr 1: National guidelines on optimizing continuity of 
care focusing on medications 
The international experiences show that national guidelines are often an initial and 
important step to optimize the continuity of care. It gives professional groups and HCPs 
clear directives on what should be done and how. Participants from focus groups also 
called for a standardization of procedures and practices, and for a long-term vision on 
the best procedures and practices. 
National guidelines from five countries (Australia, Canada, The Netherlands and United 
Kingdom) 3 , 91, 92, 93 , 94, 95, 108-112, 113 , 114, 115 have a similar content that addresses the 
following points:  
• standards of care (see building blocks 11 to 14);  
• role, responsibility and accountability of the different HCPs;  
• proposal of a pre-tested standard medication scheme and transfer form;  
• technology requirements;  
• training for HCPs involved (at all levels i.e. undergraduate, postgraduate and 
continuous education);  
• definition of key performance indicators;  
• steps for implementing seamless care initiatives; 
• clues to overcome barriers;  
• patient privacy and confidentiality issues.  
The guidelines in most countries were written by national working groups with e.g. 
representatives of health authorities, patient and professional representatives, practicing 
HCPs from all disciplines, academics and researchers with relevant expertise. These 
guidelines are designed to allow local adaptations, as seamless care cannot be achieved 
using a single specific model. 
Building block nr 2: National campaign on continuity of care 
focusing on medications  
The grey literature shows that, in parallel to the development of national guidelines, 
running a national campaign is important to increase the awareness of HCPs and 
patients to the problem of seamless care focusing on medications and to insist that their 
involvement is needed for optimization3. (http://www.saferhealthcarenow.ca). 
www.medicatieoverdracht.nl108.  
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Foreign countries developed different types of support tools for HCPs and patients e.g. 
books, websites, e-learning methods in order to reinforce the message of the campaign. 
Quantitative data on the clinical impact of such campaigns at the national level are, 
however, lacking. Several participants of the focus groups (chapter 8) also mentioned 
the need for a national campaign (similar to the positive example of the hand washing 
campaign). Other participants were more skeptical due to experienced limitations of 
such initiatives (e.g. campaign on the use of benzodiazepines).  
The set-up of a campaign on the topic of seamless care has therefore to consider 
success factors and barriers identified in other national campaigns. This campaign would 
be based on the national guidelines (see building block nr 1) but also refer to results and 
learning points from local pilot projects on seamless care in Belgium (see chapter 6). 
Target groups for such a campaign are both HCPs and patients.  
Building block nr 3: Financial and/or regulatory incentives to 
promote optimization of continuity of care 
The international experience clearly shows that financial and regulatory incentives are 
perceived as major success factors (see chapter 5). However, no evidence from good 
quality studies of the specific impact of such incentives was found. 
Incentives can be linked to accreditation or registration systems, to local contracts 
signed by primary and secondary health care providers, or to assessment of compliance 
to national standards of care. The review of the grey literature also describes an 
accreditation procedure for taking part in local consultation teams. 
The development of an incentive-based system requires different steps i.e.: 
• the development of measurable validated indicators of seamless care focusing 
on medications, 
• if available, an automatic extraction of indicators from electronic health 
records, 
• the evaluation of the impact of such incentives on the quality of continuity of 
care.  
Building block nr 4: Financing specific services to improve seamless 
care 
The participants from the qualitative study (chapter 8) suggested three measures to 
improve seamless care i.e. (1) a fully reimbursed (thus “free”) visit by/to the GP within 3 
days after discharge, (2) financing patient education on medication management, and (3) 
financing the assistance of ambulatory patients in their medication management.  
The full reimbursement of a visit by/to the GP within 3 days after discharge could 
facilitate coordination and medication reconciliation by the GP and promote 
compliance, in particular for vulnerable groups (e.g. polymedicated elderly patients, 
patients discharged from surgery wards, psychiatric patients…). Many participants 
perceived the patient co-payment (after a stay in hospital) as a barrier to seamless care. 
The key elements of an early post-discharge visit by/to the GP are detailed in building 
block nr 14. 
Patient education on medication management applies to patients who manage 
themselves their medication after discharge. As explained above, some form of financing 
was requested by the participants of the focus groups, because this education takes time 
and is perceived as beneficial. This is in line with the international situation. First, the 
systematic review concluded that patient education that is provided at and after 
discharge is the initiative that has shown the best evidence of impact. Second, funding is 
available for such services in several countries. Education can be performed by different 
HCPs (but most of the literature refers to pharmacists-based activities), in ambulatory 
as well as in hospital settings.  
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Assistance of ambulatory patients in their medication management applies to vulnerable 
patients (see block 7) who have difficulties (or who are unable) with the management of 
their medicines. This assistance is particularly relevant at transition moments (i.e. when 
the patient comes back from hospital) but might be needed on a regular basis for some 
patients in the home care setting. Participants of the focus groups proposed that the 
latter form of assistance could be performed by home care nurses (as it is already the 
case for psychiatric patients), or by pharmacists who could help patients in preparing 
dosing aids.  
Building block nr 5: Electronic health care infrastructure that 
facilitates seamless care across settings 
The grey literature showed that IT tools facilitate the sharing of information on 
medications across settings of care: they are an important component of the 
optimization procedure in foreign countries, but few solid research data are available to 
demonstrate their impact. The potential benefit of IT support was also raised in all focus 
groups, often with questions on the type of data to be shared and privacy issues. 
Additional discussions were conducted with stakeholders involved in ongoing initiatives 
around “electronic health care” in Belgium (e.g. RECIP-e, ePrescribe, BeScript, 
Share4Healh, electronic prescribing in hospitals, the pharmaceutical record, facilitation 
tools for the prescription and approval of chapter IV drugs). The conclusions are that:  
• their operationality and/or applicability is still very limited, 
• most of them are designed and developed within one specific setting (i.e. the 
ambulatory setting or the hospital setting), with very limited consideration of 
bridging the gap with other settings of care. One exception is Share4Health, a 
project that focuses on the development of a healthcare platform for 
collaboration between GPs, pharmacists and hospitals, while designing 
solutions for patient consent management, federated identity management 
and access management. 
This research highlighted some requirements to set up an IT system related to 
medications and seamless care:  
• Processes have to be well defined and agreed upon by all HCPs as well as by 
patients (see building blocks nr 1 and 11 to 14).  
• Privacy issues have to be targeted: exchange of information requires a 
secured central platform. 
• Coordination and decisions relative e.g. to the processes, access rights and 
privacy issues must occur at the policy level, as in other countries. The need 
for such coordination is reinforced by the observation that most Belgian pilot 
projects are now developed at local level, with very limited sharing of 
experiences at a higher level.  
• Existing tools are a basis for the development of IT systems. For example, in 
Flanders, there are some experiences with the ‘Electronic Home Health 
Record’, whose access is regulated by a token or E-health technology. 
Multidisciplinary collaboration is possible through protected e-mail, 
regulations on access rules and writing/reading permissions. This home health 
record has a functionality to share information on the medication scheme of 
the patient, although this functionality is not yet fully developed and / or used. 
Another example is the proof of concept of the Share4Health portal that also 
uses e-health technology for authentication, has an integrated patient consent 
management tool, and allows the sharing of KMEHR data between HCPs 
(KMEHR is a proposed Belgian medical data standard that enables the 
exchange of structured clinical information). 
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• HCPs and patients should agree on what kind and level of information can or 
must be communicated to whom and how. Research shows that the 
perception of GPs, pharmacists and patients actually differs when speaking 
about sharing medical information183. It is out of the scope of this project to 
define in detail what data should be shared and how (even though a part of 
this has already been defined in relation to the KMEHR-bis message 
“pharmaceutical prescription”). Most participants from the qualitative study 
suggested that at least a pharmaceutical file (which could be part of a global 
medical file, or a separate file) should be available for access and modification 
by HCPs (prescribers, pharmacists, nurses) upon patient consent. The 
question of sharing more information than about medications (e.g. 
indication(s) for the prescribed medication, other issues that may have an 
impact on medication management capacities of the patient) is not clear from 
this research.  
• While designing an electronic pharmaceutical file, the role of patients in 
updating the list of current medicines must be considered. This was 
requested by several participants of the focus groups and has been addressed 
in other countries as well.  
• Electronic prescribing facilitates the generation of an accurate pharmaceutical 
file. Therefore, electronic prescribing (including information on dosing and 
duration of treatment) should be promoted not only within one setting but 
also across settings, e.g. at discharge from hospital, for ambulatory patients 
visiting a specialized physician in the hospital. 
Building block nr 6: Tuned regulations that support continuity in 
medication management  
From the focus groups it was obvious that several problems in seamless care focusing 
on medications arise from existing contradictions in current regulations. For example, 
GPs are encouraged to prescribe generic drugs while hospital doctors must prescribe 
drugs from the “therapeutic formulary” (where generic drugs are not the most 
common). This often leads to medication shifts on admission or at discharge, potential 
risks of double use of medications or altered efficacy. The fact that the generic and 
original drugs do not have the same aspect (form, colour) and carry different names, are 
additional barriers. Finally, the procedures for Chapter IV drugs differ between hospital 
and ambulatory setting: this discrepancy triggers mistakes, frustration and conflicts.  
These data therefore suggests that there is a need for tuned regulations that better 
support the continuity of medication management. 
Building block nr 7: Agreement on the categories of patients that 
would benefit most from optimisation procedures 
National guidelines, processes of care, IT and some other initiatives that can be 
considered as “standard care” apply to all patients. However, the literature shows that 
several categories of patients or situations carry a higher risk of medication problems 
related to transitions 184 , 185  and would benefit most from optimization procedures.  The 
systematic review concluded that most studies did not sufficiently focus on vulnerable 
patients, which might have diluted the effect of the interventions tested.  
New interventions that require additional financial and human resources such as 
involvement of clinical pharmacists and reimbursement for patient education, for 
example, have to be applied in priority to these vulnerable patients in order to 
maximize the cost-effectiveness of the interventions. Categories of high risk patients 
have to be agreed upon at the national level with possible adaptation at the local level, 
depending on the characteristics of the population and available resources. 
There is no international consensus on a specific list of risk factors but there was a 
good agreement within the focus groups on the patients to target i.e. frail elderly 
patients, psychiatric patients, polypharmacy patients, patients with cognitive impairment.  
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Building block nr 8: Research assessing the economic, clinical, and 
humanistic impact of the initiatives 
The systematic review and the analysis of Belgian findings highlighted many areas for 
further research. The two main research questions in relation to interventions that aim 
to optimise seamless care can be summarised as follows: 
• What is – using strong designs with large samples - their relative impact on 
clinical (e.g. prevalence of hospital readmissions) and humanistic measures 
(patient satisfaction, quality of life)?  
• What is their cost-effectiveness from a societal perspective?  
9.3.2.2 Initiatives in relation to health care professionals  
Building block nr 9: Intermediate level of coordination 
The qualitative study clearly showed that HCPs working in one specific setting do not 
know (a) the regulation and difficulties encountered by HCPs working in a different 
setting and (b) the work and difficulties of other HCPs working in the same setting. This 
is an important barrier to seamless care. The international experience also reveals that 
the implementation of national guidelines in local settings requires some level of 
coordination between the national and local levels. 
An intermediate level of coordination creates the frame to achieve clear goals and 
measurable outcomes, to support and alienate clinical and administrative systems, to 
organize structures for communication and data handling and to provide 
multidisciplinary training. Recommendations provided at the national level (see building 
block nr 1) should be used to develop processes of care at the intermediate level. 
Furthermore, a framework for local concertation should be developed at the same 
level. In Flanders, the discussion on the organization of this intermediate level is ongoing 
in preparation of a conference on public health (December 2010). 
Building block nr 10: Involvement, responsibility and accountability 
of GPs and specialist doctors, home and hospital nurses, community 
and hospital pharmacists 
During the focus groups, the idea of shared responsibility was stressed by many HCPs. 
This is in line with the findings from international research projects: the majority of 
them involved multidisciplinary teams. Also international guidelines usually contain a 
section on responsibility and accountability of HCPs. In the focus groups, the GP was 
frequently mentioned as an appropriate HCP to coordinate medication management, 
when a coordination is required. 
Clinical pharmacists played a key role in the implementation of initiatives described in 
other countries as well as in most Belgian pilot projects. The experiences and views of 
focus group participants on clinical pharmacy differed. Availability and funding were 
often cited as barriers for the implementation of clinical pharmacy on a large scale.  
The focus groups also showed that community pharmacists are ready to take up new 
roles as defined in the new legal framework on community pharmacy issued in 2009 and 
that professional organisations are developing tools to support this practice change.  
9.3.2.3 Initiatives to be implemented at patient level  
The international experience (see chapter 5) has shown that a bottom-up approach in 
optimizing seamless care is a critical factor for success. The local implementation of 
optimization procedures is driven by the recommendations and initiatives taken at a 
higher level and by personal or small group initiatives taken by different HCPs. 
Building blocks nr 11 to 15 are derived from international guidelines (chapter 5), were 
applied in most controlled trials (chapter 3), some were successfully developed in 
Belgian pilot projects (chapter 6) and suggested by participants of focus groups (chapter 
8). 
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Building block nr 11: On admission to hospital: use of different 
sources of information and standardized procedures to perform 
medication history and medication reconciliation 
Several elements found in different parts of the study facilitate medication history taking. 
A combination of these elements will enhance the quality of the information on the 
actual medication list of the patient at admission:  
• GP referral letter with a list of medications taken by the patient, including 
dosages, frequency of administration, indication, recent changes and allergies. 
This information might be part of the electronic medical record, and be 
compatible with the SUMEHR structurej. 
• Patients who bring their usual medications upon hospital admission. This 
facilitates the medication history taking and avoids duplication at discharge. 
This has been successfully tested in a Belgian pilot project and in the UK 108.  
• Standardized procedures and questionnaires to perform medication history 
taking and medication reconciliation at admission. This has been set up in 
Belgian projects and abroad with the expertise of clinical pharmacists.  
There is also specific international literature on the method for conducting medication 
histories on admission, and on the respective roles of different HCPs (including clinical 
pharmacists)186. One Belgian paper is also in press 187. This question has however not 
been addressed in details in this research. 
Building block nr 12: At discharge from hospital: timely, structured, 
and comprehensive information for patients and health care 
professionals 
• A standardized procedure is needed to inform patients (or the person caring 
for the medications after discharge) and HCPs on the discharge medication 
plan, 
•  Medication reconciliation is also necessary at discharge, especially if changes 
to the home medication were made in hospital, 
• The following elements need to be present in each discharge letter,  
o list of medications including DCI name, dosage, frequency and time of 
administration, other modalities of administration, day and time of last 
administration,  
o medication changes during hospital stay (with reasons for change), 
o recommendations for follow-up: especially for new drugs, drugs with 
restricted use and highly specialized drugs (e.g. chemotherapy, biological 
agents),  
o administrative steps taken for chapter IV drugs (e.g. results of tests),  
o summary of efficacy and side-effects of new medications prescribed during 
hospital stay,  
o if applicable, arrangements taken for medication management after 
discharge  or proposals to improve compliance.  
• Each discharge letter is transmitted on the day of discharge (ideally 
electronically) to the GP. The international literature and the qualitative study 
also suggested the possibility to transmit medication information to the 
community pharmacy and to the nurse (when applicable) with the patient’s 
consent.  
• Finally, the participants of the focus groups also mentioned that discharge on 
Friday afternoon triggers problems when not well prepared e.g. GP informed, 
planned consultation, drugs ordered by the community pharmacist.  
                                                     
j  SUMEHR is a KMEHR message, used for the exchange of medical information. This summarizes the 
minimal set of data that a physician needs in order to understand the medical status of the patient in a 
few minutes and to ensure the continuity of care. 
126 Seamless care KCE Reports 131 
Building block nr 13: At discharge from hospital: appropriate 
medication supply for patients 
Participants from the qualitative study insisted that patients should be given a sufficient 
amount of medication to cover the period between discharge and medication purchase 
(and therefore the whole week-end for patients discharged on Friday afternoon) in the 
community pharmacy. It seemed that this was often not the case, due to reluctance 
from hospitals (see building block nr 6). 
Building block nr 14: After discharge from hospital: reinforcement of 
information and medication reconciliation 
After discharge, information on medication as well as medication reconciliation and/or 
proactive medication review contributes to detect/prevent medication related 
problems. The participants to the qualitative study confirmed that the GP has an 
important role in that respect, but in other countries part of this is frequently 
performed by a hospital HCP (phone call reinforcement) or by the community 
pharmacist. 
Building block nr 15: Availability of an accurate medication plan for 
each patient, accessible for each HCP involved  
A medication plan carried by the patient gives each HCP the possibility to consult it 
when needed. The importance of the availability of this type of information was stressed 
by participants of the focus groups and was clear from the grey literature. The 
availability in an electronic record raises privacy issues (see above, building block 5). An 
interesting initiative mentioned in this context is the development of the Mobile Patient 
Support that allows the storage of the actual medication plan on the patient’s 
Smartphone. Physicians as well as pharmacists are able to add and check medication 
information on this Smartphone upon patient consent. Another initiative identified in 
the research is “www.followweb.eu”: an internet platform used to create an electronic 
database with the current list of medications prescribed to a patient. It is available at any 
point of care to the patient, to authorized doctors and (in a further step) authorized 
community pharmacists, through a personal account.  
Building block nr 16: local consultation to enhance cooperation 
between HCPs within and across settings of care 
The need for local consultation between HCPs and between settings of care was 
repeatedly worded in the focus groups. The scope of this type of consultation at the 
local level is a (group of) patient(s) with the aim to organize care and / or to agree on 
the medication plan. The way to implement this consultation depends on the local HCPs 
involved.  
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Essential elements for a quality improvement system on seamless care 
focusing on medications 
• National guidelines on optimizing continuity of care focusing on medications 
• National campaign on continuity of care focusing on medications 
• Financial and/or regulatory incentives to promote optimization of continuity 
of care 
• Reimbursement of specific services to improve seamless care: consultation 
with GP within 3 days after discharge, assistance of patients in medication 
management, and patient education on medication therapy 
• Electronic health care infrastructure that facilitates continuity of care across 
settings 
• Tuned regulations that support continuity in medication management 
• Agreement on the categories of patients that would most benefit from 
optimisation procedures 
• Research assessing the economic,  clinical, and humanistic impact of the 
initiatives 
• Set up of an intermediate level to coordinate actions for improvement 
• Involvement, responsibility and accountability of GPs and specialist doctors, 
home and hospital nurses, community and hospital pharmacists 
• On admission to hospital: use of different sources of information and 
standardized procedures to perform medication history and medication 
reconciliation 
• At discharge from hospital: timely, structured, and comprehensive 
information for patients and health care professionals 
• At discharge from hospital: appropriate medication supply for patients 
• After discharge from hospital: reinforcement of information and medication 
reconciliation 
• Availability of an accurate medication plan for each patient, accessible for 
each HCP involved 
• Involvement, responsibility and accountability of GPs and specialist doctors, 
home and hospital nurses, community and hospital pharmacists 
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